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ABSTRACT 
Monoamine oxidase (MAO) is an oxidative enzyme that deaminates a variety of amine 
substrates, including the neurotransmitter dopamine. The enzymatic reaction requires 
molecular oxygen and produces hydrogen peroxide as a by-product. MAO is localised in 
the outer mitochondrial membrane and exists as two isoforms, MAO-A and MAO-B, 
which are differentially expressed in the body and differ in their substrate and inhibitor 
specificities. Previous studies have suggested that MAO-generated reactive oxygen species 
(ROS) contribute to oxidative stress in the cell and can directly inhibit electron transport, 
cause damage to mitochondrial DNA and enhance cell death signalling. In this study the 
role of MAO in cell death was investigated in dopaminergic neuroblastoma (SH-SY5Y) 
cells, in three diverse models of mitochondrially-mediated apoptosis. The relevance of 
MAO in cell death signalling was confirmed with the use of two unrelated MAO inhibitors 
and the creation of stable SH-SY5Y cell lines that either over express MAO-A or have 
reduced levels of MAO-A.  The study is the first to over express MAO-A using 
recombinant technology and to use miRNA to stably knock-down MAO-A expression in 
human neuronal cells. 
Results confirm that MAO-A is involved in modulating cell death but the mechanism and 
extent of the involvement depends on the apoptotic inducer. In classical apoptosis induced 
by staurosporine (STS), cells undergo rapid morphological and biochemical changes 
indicative of mitochondrially-mediated apoptosis, which is partly dependent on ROS 
production by MAO-A and induction of mitogen-activated protein kinase (MAPK) 
signalling cascades. MAO-A protein and catalytic activity are increased in this model, 
however the mechanism by which this occurs is unknown and is not a result of increased 
gene transcription. In death induced by growth factor withdrawal, the MAO-A gene is up 
regulated via p38 and JNK MAPK pathways, which occurs downstream of caspase 
activation. In both the STS and growth factor withdrawal models, MAO inhibition reduced 
apoptosis. Most significantly reduced levels of MAO-A expression in ‘knock down’ cells 
protected against cell death induced by the complex I inhibitor rotenone, suggesting that 
MAO has an important role in mitochondrial function. Over expression of MAO-A 
resulted in stress and apoptosis, followed by a period of cellular senescence and eventually 
death by necrosis. These data compliment the effects of chronic exposure to oxidative 
stress in ageing and neurodegeneration. 
 V
For the first time this work has shown that the MAO-A isoform is an important regulator of 
STS-induced apoptosis, that MAO-A gene expression is regulated by JNK signalling, and 
that MAO-A is significantly involved in mitochondrial dysfunction induced by complex I 
inhibition. These data raise important questions regarding predisposition to the 
development of neurodegenerative diseases such as Parkinson’s disease and to approaches 
used for their treatment.   
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GENERAL INTRODUCTION 
1.1. MONOAMINE OXIDASE 
Monoamine oxidase (amine: Oxygen oxidoreductase [deaminating] [flavin containing] EC 
1. 4. 3. 4 [MAO]) is an enzyme that catalyses the oxidative deamination of a wide range of 
biogenic and dietary amines to their corresponding aldehydes. The enzymatic reaction 
requires molecular oxygen (O2) and produces hydrogen peroxide (H2O2) as a by-product, a 
simplified schematic of which is shown below. 
 
In addition, MAO requires a flavin-adenosine-dinucleotide (FAD) co-factor and insertion 
into the outer mitochondrial membrane (OMM) for its activity. The primary substrates of 
MAO in the brain are neurotransmitters such as adrenaline, noradrenaline (NA), dopamine 
(DA), serotonin (5-HT) and β-phenylethylamine (PEA). There are two isoforms of MAO, 
coded for by two separate genes, termed MAO-A and MAO-B, which are characterised by 
their substrate and inhibitor specificities. MAO plays a central role in neurotransmitter 
metabolism and has been implicated in a range of human conditions including Parkinson’s 
disease (PD).  
1.1.1 A brief history Blashko et al. 1937 
• 1928-Mary Hare termed the amine deaminating enzyme she discovered in rabbit 
liver, tyramine oxidase. The name was later modified to monoamine oxidase to 
reflect its substrate specificity following related studies in neurotransmitter 
metabolism (Blashko et al. 1937). Hare 1928, Gorkin 1966, Youdim and Sourkes 1966 
• 1966-Gorkin proposed that there were two different MAO variants and MAO was 
solubilised and purified from rat liver (Youdim and Sourkes).  
• 1968-Johnston characterised two MAO isoforms (MAO-A and –B) by their substrate 
and inhibitor specificities. Johnston 1968, Knoll and Magyar 1972 
• 1972-Knoll and Magyar developed the MAO-B inhibitor Deprenyl. This inhibitor 
was later to become a mainstay treatment for Parkinson’s disease (PD).  
• 1977-Achee and Gabay found that MAO was attached to the OMM. 
• 1983- Cohen proposed that the production of hydrogen peroxide by MAO could 
damage dopaminergic neurons. Savov proposed that this damage was caused by the 
lipid peroxidation of mitochondrial membranes.  
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• 1983-Langston and co-workers showed that the synthetic compound, 1-methyl-4-
phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) produced PD-like symptoms in man and 
the conversion of MPTP to its active form in vivo was found to occur via MAO-B 
(Markey, 1984).  
• 1988-Bach and others confirmed the presence of two MAO isoforms, coded for by 
two separate genes by cloning human cDNA from liver. The organisation of the 
genes was described by Grimsby et al in 1991. 
• 1995-Cases and colleagues engineered the first MAO knockout mouse.  
• 1996-Hauptmann and colleagues found that MAO generated H2O2 caused oxidative 
damage to mitochondrial DNA.Cases et al. 1995, DeColibus et al. 2005 
• 2001-DeZutter and Davis described the MAO-A gene as a target for pro-apoptotic 
signalling. 
• 2002-The crystal structure of MAO-B was published by Binda et al.Binda et al. 2002 
• 2005- The crystal structure of MAO-A was published by Colibus et al.  
1.1.2 Structure and catalytic mechanism 
1.1.2.1 Structure 
The translated protein sequences of MAO-A and MAO-B cDNA show that the two 
enzymes differ in size, with MAO-A consisting of 527 amino acid residues (Mr 59700 Da) 
and MAO-B comprising 520 amino acid residues (Mr 58800 Da; Brown et al. 1980). 
Three-dimensional modelling of MAO-A and –B suggested that the overall tertiary 
structures and active sites are similar, both isoforms sharing 70 % amino acid homology 
(Geha et al. 2002). The overall structure of the monomers of human MAO-A is similar to 
that of human MAO-B and rat MAO-A, with the only significant structural difference 
being the conformation of the cavity shaping loop (DeColibus et al. 2005). Differences in 
quaternary structure were shown by elucidation of both MAO-A and –B crystal structures. 
Human MAO-B and rat MAO-A crystallise as a dimers (Binda et al. 2002, Ma et al. 2004), 
whereas human MAO-A crystallises as a monomer (DeColibus et al. 2005). The main 
difference between rat MAO-A and human MAO-B is in the structure of their active site 
cavities in the area opposite to the flavin coenzyme, which is responsible for their differing 
substrate and inhibitor affinities (Youdim et al. 2006).Cruz and Edmondson 2007 
A flavin co-factor, covalently linked to the enzyme by a cysteinyl thioester is required for 
both MAO-A and –B activities (Erwin and Hellerman 1967). Glu34 and Tyr44 are required 
for the initial binding of FAD and Gly226 and Asp227 are required for catalytic activity of 
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MAO-B (Zhou 1998). In MAO-A, Cys406 is important in FAD binding and Phe208 and 
Ile335 are crucial at the active site for substrate binding (DeColibus et al. 2005). Tyr444 and 
Tyr407 in MAO-A and Tyr398 and Tyr435 in MAO-B may form an aromatic sandwich that 
stabilises substrate binding (Geha et al. 2002). Both MAO-A and –B both contain a redox-
active disulfide at the catalytic centre in addition to the flavin redox-active group (Sablin 
and Ramsay 1998) and both enzymes follow the same catalytic mechanisms. Significant 
differences in structure are attributed to differences in active sites that govern substrate 
specificity (Edmondson et al. 2007). 
MAO is tightly bound to the outer mitochondrial membrane (Achee and Gabay 1977). In 
MAO-B amino acid residues 489-515 in the C-terminal form a transmembrane helix, 27 
amino acids long (Binda et al. 2002) and in MAO-A amino acid residues 463-506 form the 
C-terminal membrane region which is 43 amino acids long (DeColibus et al. 2005). The 
insertion of MAO into the outer mitochondrial membrane has been suggested to occur via 
the recruitment of ubiquitin and energy generated by ATP (Zhaung and McCauley 1989, 
Zhaung et al. 1992). Recent work by Cruz and Edmondson (2007) showed that the 
entrance to the active site of MAO-A is situated at the mitochondrial surface. They 
suggested that the negatively charged surface may act to attract the protonated amine 
substrates towards the cavity and aid in deprotonation upon entering the active site. 
 
Figure 1. 1 Ribbon diagrams of the crystal structures of human MAO-A and –B elucidated by Binda et 
al. 2002, DeColibus et al. 2005. 
MAO-A monomer, showing FAD binding domain (blue), substrate binding domain (red), C-terminal tail 
(green), clorgyline (cyan) and FAD (yellow, DeColibus et al. 2005). MAO-B dimer showing FAD (yellow) 
and C-terminal tail (green, Binda et al. 2002). 
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1.1.2.2 Catalytic mechanism Ramsey 1991, Ramsay 1998 
The oxidative deamination of amines by MAO is a two step catalytic reaction, which 
involves the formation of a intermediate imine, which quickly dissociates to form an 
aldehyde product (Berry et al. 1994). Step by step; the amine substrate in the presence of 
oxidised MAO, forms the intermediate imine and MAO is reduced. In the presence of 
oxygen, MAO is re-oxidised; hydrogen peroxide is produced (via the oxidation of reduced 
FAD (FADH2) to the FAD cofactor). Finally, in the presence of water, the imine is 
converted to aldehyde and ammonia products. The mechanism has been simplified 
somewhat since other complex events occur during the reaction, described further by 
Ramsay and co-workers (1991 and 1998). The production of H2O2 by MAO and the 
ensuing biochemical effects were a primary concern in this work and therefore the 
characterised reaction of MAO shown below is adequate for the scope of this thesis.  
 
Figure 1. 2 Catalytic mechanism of amine oxidation by MAO 
MAO catalysis is undertaken at the mitochondria where the enzyme is transported 
following its release from the polysomes. Following studies on MAO-A synthesised from 
reticulocytes and rat liver mitochondrial extracts, MAO-A was suggested to exist in a 
soluble but inactive form when it is released from the polysomes, but then binds to the 
OMM in the presence of ubiquitin and ATP and becomes active (Zhaung et al. 1992). 
However, the involvement of ubiquitin has never been confirmed and the question 
regarding whether MAO is active outside the OMM in vivo remains unanswered. 
1.1.3 Isoenzyme classification 
MAO specificity is relatively low compared to some enzymes, and substrates include all 
primary, secondary and tertiary monoamines attached to a free carbon chain (Berry et al, 
1994). The existence of two forms of MAO was proposed on the foundation that there 
were different substrate and inhibitor affinities in in vitro enzyme assays (Johnston 1968). 
MAO-A preferentially deaminates 5-HT and NA and is inhibited by low concentrations of 
clorgyline, whilst MAO-B prefers benzylamine (BA) and β-PEA and is inhibited by low 
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concentrations of L-deprenyl (Gerlach and Riederer 1993). The substrates DA, tryptamine, 
octopamine and tyramine can be deaminated by both isoforms, although in human brain 
DA has a higher affinity for MAO-B (Riederer and Youdim 1986). Substrates described as 
being specific for one form or another however, can still be metabolised by either isoform 
in vivo and this depends on three parameters: concentration, affinity and turnover. Cellular 
compartmentation of MAO may also be responsible for determining substrate specificity 
(Waldmeier 1987). For example, in neurons where there is very little if any MAO-B, the 
metabolism of DA will be undertaken largely by MAO-A. Yet in extra-neuronal cells such 
as astrocytes (which are MAO-B rich) the proportion of DA deaminated by MAO-A 
decreases. 
 
Figure 1. 3 Chemical structures of some substrates of MAO-A and –B 
Top-some preferred substrates of MAO-A. Middle-some preferred substrates of MAO-B and Bottom-some 
substrates of both MAO isoforms.  
1.1.4 MAO inhibitors 
As previously described, MAO-A and -B are commonly characterised by their specific and 
irreversible inhibition by low concentrations of the inhibitors clorgyline and deprenyl 
respectively. The therapeutic use of deprenyl in PD and the anti-apoptotic properties of 
propargylamines are discussed further in sections 1.2.2.2 and 3.3. The MAO inhibitors 
clorgyline and tranylcypromine (TCP) were used in this work and some preliminary 
studies were undertaken using moclobemide (Figure 1. 4). These MAO inhibitors are used 
clinically for the treatment of depression and the anti-depressant properties of MAO 
Chapter 1                                                                                                                              General introduction 
 7
inhibitors result from the selective inhibition of MAO-A in the central nervous system 
(CNS), which leads to increased levels of DA, NA and serotonin 5-HT (Youdim et al. 
2006). Clorgyline is a highly specific and irreversible inhibitor of MAO-A and belongs to a 
group of MAO inhibitors known as the propargylamines because they contain a propargyl 
moiety.  This inhibitor initially binds MAO-A reversibly, but then becomes oxidised by the 
enzyme to become active, covalently binding to the active site via the FAD cofactor, thus 
rendering it permanently unavailable for amine metabolism (Foley et al. 2000). Clorgyline 
has previously been shown to protect against apoptosis (DeZutter and Davis 2001) and 
serum withdrawal-induced loss of cell viability (Ou et al. 2006). However, irreversible 
MAO-A inhibitors are not often used clinically because of the “cheese effect”, so called 
because of potentiation of the sympathomimetic action of dietary tyramine (Youdim and 
Finberg 1987) and cheese contains lots of tyramine. The Inhibitors TCP and moclobemide 
are still in clinical use. Moclobemide does not contain a propargyl group and is a reversible 
and competitive inhibitor of MAO-A (Ramsay 1998). TCP is a non-selective MAO 
inhibitor that does not contain the propargyl moiety, but interacts irreversibly with the 
flavin group. TCP is effective in the treatment of phobic anxiety and atypical depressions 
such as hysteria and bulimia for which they are superior to amine re-uptake inhibitors 
(Youdim et al. 2006).  
 
Figure 1. 4 Chemical structure and specificity of some MAO inhibitors 
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1.1.5  Distribution and physiological significance of MAO 
The physiological functions of MAO are primarily the metabolism of amines and secondly, 
the regulation of neurotransmitter levels and intracellular amine stores (Billett 2004). MAO 
enzymes are widely distributed in various peripheral organs and the expression of the 
isoenzymes depends on distribution, development, ageing and hormonal environment 
(Bompart et al. 2001). MAO-B mainly acts on small exogenous amines, whereas MAO-A 
carries out the degradation of bulkier endogenous amine neurotransmitters (Binda et al. 
2002). In mammals, MAO has been identified in all cell types excluding erythrocytes 
(Berry et al. 1994). In the majority of tissues MAO-A and –B isoforms seem to co-exist 
(Westlund 1988). However, some tissues only express single forms of MAO, namely 
platelets and lymphocytes (Bond and Cundall 1977), which only express MAO-B and 
placenta, which only expresses MAO-A (Sivasubramaniam et al. 2002). The highest levels 
of MAO-A activity in humans are found in the liver, lung and intestines (Tipton 1973) 
whereas the highest levels of MAO-B are found in brain and liver (Glover and Sandler 
1986, Tipton 1973). The ratio of MAO-A/MAO-B in the human brain depend on age 
(Fowler et al. 1980a).Saura et al. 1996 
The distribution of MAO in human brain has been examined by means of 
immunohistochemistry (Westlund 1988, Finch et al. 1995), which revealed that MAO-A is 
found predominantly in adrenergic and noradrenergic neurons and MAO-B in serotonergic 
and histaminergic neurons as well as astrocytes. In 1996, Saura and others used 
quantitative enzyme radiography and in situ hybridisation to study the cellular distribution 
of MAO-A and –B in tissue sections of human brain. They concluded that sites of 
synthesis are the noradrenergic neurons of the locus coeruleus for MAO-A and the 
serotonergic neurons of the raphe and histaminergic neurons of the posterior hypothalamus 
for MAO-B. Neurons of the substantia nigra pars compacta (SNpc) contain small amounts 
of MAO-A and no MAO-B (Westlund 1988). Cawthon and Breakefield 1979 
Within neurons, MAO regulates the levels of neurotransmitters released upon synaptic 
firing (Holschneider et al. 1998). Termination of a neurotransmitter’s action depends on 
their reuptake into the nerve terminals, their dilution by diffusion out of the synaptic 
junction and their metabolic transformation. Uptake of neurotransmitters by glial cells and 
their metabolism via MAO-B also serves to regulate neurotransmitter action.  In the 
gastrointestinal system, the circulatory system and the liver, MAO also serves a protective 
function to oxidise ingested amines and prevent them acting as false neurotransmitters. 
MAO has a similar function at the blood-brain barrier (Holschneider and Shih 2000). It has 
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been hypothesised that the existence of two MAO isoforms may be important in 
maintaining the specificity of function of catecholaminergic and serotonergic neurons, for 
example, MAO-A may help eliminate serotonin in dopaminergic and noradrenergic 
neurons whilst MAO-B may eliminate dopamine and phenylethylamine from serotonergic 
neurons (Westlund 1988). A secondary function of limiting these neurotransmitters may be 
the resulting altered release of hormones; hence MAO may function indirectly as a 
regulator of neuroendocrine function (Holschneider and Shih 2000).  
1.1.6 MAO Genetics  
In 1979, Cawthon and Breakefield suggested that MAO-A and MAO-B were coded for by 
two separate genes, following peptide mapping studies. Their functional differences 
became more apparent when it was shown that the two isoforms had conformational 
differences in their active site (Chen et al. 1985). Successful MAO-A and MAO-B cDNA 
clones from human liver showed that molecular attributes were positively allocated to two 
different genes and the amino acid sequence of both MAO isoforms were published (Bach 
et al. 1988). The primary amino acid sequences for MAO-A and –B show approximately 
70% homology and similar hydrophobicity indices (Bach et al. 1988). The FAD binding 
site was revealed to be in the same position for both MAO-A and –B (Bach et al. 1988).  
Both MAO genes are located on the X chromosome (Breakefield et al. 1980, 
Kochersperger et al. 1986). Later, by utilising full length MAO-A and –B cDNA clones 
and data from mapping studies in humans with Norrie’s disease, the MAO-A and –B genes 
were found to be close to each other and close to the DXS7 locus on the X chromosome at 
position Xp11.23 (Lan et al. 1989). The genes span at least 60 kb and have 15 exons with 
identical intron-exon organisation. Exon 12 codes for the covalent FAD binding site in 
both isoforms and is the most conserved exon, with MAO-A and –B sharing 93.9 % 
peptide identity (Grimsby 1991), suggesting a common ancestral gene. The two genes were 
shown to be arranged in a tail-to-tail configuration with CpG islands at the 5’ end in each 
case and the 3’ coding sequences separated by around 50 kb (Chen et al. 1992).  
The promoter regions for MAO-A and –B genes have been characterised. The promoter 
fragments for both enzymes are GC rich and contain Sp1 binding sites (Zhu et al. 1992). 
Sp1 is a ubiquitous transcription factor shown to be involved in tissue specific regulation 
(Saffer et al. 1991). Homtamisligil and Breakefield 1991 
Hotamisligil and Breakefield (1991) determined the coding sequence of mRNA for MAO-
A. The MAO-A promoter shows bi-directional activity and a repeat element and a number 
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of repeats that have been related to differential promoter activity. The core promoter region 
of MAOA contains two 90 bp repeats, each of which contains GC rich elements that are 
potential binding sites for Sp1 transcription factors, and lacks a functional TATA box (Zhu 
et al. 1994).  
 
Figure 1. 5 A schematic diagram of the MAO-A promoter 
These GC elements bind Sp1 but also a repressor, R1 (RAM2), which is able to inhibit 
MAO-A gene transcription (Chen et al. 2004a). 
The human MAO-B gene is also under the control of GC elements (Wong et al. 2001). The 
MAOB core promoter region contains two sets of overlapping Spl sites which flank a 
CACCC element all upstream of a TATA box (Zhu et al. 1992).  
1.2. NEURODEGENERATION 
Due to the pharmacological importance of neurotransmitter metabolism, MAO has been 
the focus of extensive research with approximately 20,000 papers in the literature since the 
1950s (Edmondson et al. 2007). Association of MAO expression with certain human 
conditions has been an immense area of research, with ageing, neurodegenerative diseases 
and affective disorders linked with MAO. The physiological relevance of both increased 
and decreased MAO expression is discussed further in chapter 5 (section 5.1) and chapter 6 
(section 6.1) respectively. Since, neurodegeneration is of particular relevance to this thesis; 
this section aims to introduce several neurodegenerative diseases (specifically PD), their 
supposed aetiology and the role of MAO in their pathobiology. 
1.2.1 Common pathobiology 
The cause of neurodegenerative diseases (NDs) such as PD and Alzheimer’s disease (AD) 
is extremely complex and the underlying mechanisms are still being elucidated. It is 
generally accepted that susceptibility to ND results from a combination of genetic, 
environmental and cumulative factors. Certain features are common to all ND and these 
include: loss of neuronal cells in key areas of the brain, dysfunction of key cellular 
mechanisms, protein damage, reduced protein clearance, cellular inclusions and increased 
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oxidative stress. Whether or not these factors are the cause and/ or the consequence of the 
diseases remains unknown.  
The death of neuronal cells is ultimately responsible for the symptoms of 
neurodegenerative diseases. MAO is important in ND, not only because of its ability to 
regulate neurotransmitters (which are dysfunctional in ND), but also because it is thought 
to be involved in regulating cell death mechanisms. Atypical expression of MAO may have 
some implications in the aetiology of NDs and could provide a target for new therapies 
and/ or prevention of these diseases.  
1.2.2 Parkinson’s DiseaseParkinson 1817 
PD is a common neurodegenerative movement disorder first described in 1817 by James 
Parkinson, of which the progressive form of the disease affects 1-2 % of the population 
over the age of 65 (Mouradian 2002). The core clinical features of the disease include 
bradykinesia, tremor and rigidity (Ghandi and Wood 2005) and the primary pathology is 
characterised by degeneration of DA-containing neurons in the substantia nigra pars 
compacta (SNpc), where 80 % of dopaminergic neurons have been lost (McNaught 2001). 
Alongside neuronal loss, the presence of Lewy body inclusions are a pathological hallmark 
of PD and have been reported not only in the SNpc, but also in the cerebral cortex, anterior 
thalamus, hypothalamus amygdale and basal forebrain (Galvin et al. 1999).  
1.2.2.1 Molecular pathogenesis of PD 
The most common form of PD is the progressive or sporadic form, which is usually 
associated with old age, however, there are also genetic forms that exists, which can 
develop early in life (also known as early-onset PD, Mouradian 2002). Genetic mutations 
causing PD are rare, accounting for only 5-10 % of the overall PD population. However, 
the striking, consistent specific phenotype of both forms of PD has led researchers to 
believe that a common set of molecular mechanisms underlies PD (Ghandi and Wood 
2005).  
The supposition that sporadic PD may be a result of a combination of environmental toxins 
which cause mitochondrial dysfunction is supported by findings that mitochondrial 
complex I inhibitors such as rotenone (described in chapter 4, section 4.1) and MPTP 
reproduce PD features with dopaminergic neuronal loss in vivo (Burns et al. 1983) and in 
vitro (E.g. De Girolamo 2001, Caneda-Ferron et al. 2008). MPTP is a synthetic neurotoxin 
produced by attempts to synthesise the reverse ester of meperidine, an analogue of heroin 
(Langston et al. 1983). In vivo MPTP is oxidised in glial cells by MAO-B to the 
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intermediate MPDP+ which then auto-oxidises to form the active neurotoxin 1-methyl-4-
phenylpyridinium (MPP+). MPP+ is then taken up by a dopamine transport mechanism into 
dopaminergic neurons (Song and Ehrich 1998). MPP+ accumulates in mitochondria 
(Murphy et al. 1995) and inhibits complex I of the mitochondrial electron transport chain 
(Nicklas et al. 1985) resulting in ATP depletion, the formation of free radicals and cell 
death.  
The mitochondrial dysfunction hypothesis in PD is further supported by studies of rare 
familial forms of PD, where a variety of genetic mutations have been identified. It is the 
case, that many of the wild type proteins coded for by these genes are often 
mitochondrially localised and have putative roles in mitochondrial protection. For 
example, overexpression of the mitochondrial DJ-1 (mutated in some rare forms of PD) 
appears to protect cells against mitochondrial complex I inhibitors and oxidative stress 
(Canet-Aviles et al. 2004). Mutations in mitochondrial kinase, PINK1 and serine protease 
HtrA2/Omi both cause mitochondrial dysfunction leading to ND with PD features. It is 
now known that PINK1 and HtrA2 proteins interact to protect the mitochondria from stress 
(Plun-Favreau et al. 2007). 
Mutations in certain genes encoding proteins involved in the protein aggregation, protein 
clearance and the ubiquitin-proteasome pathway are also associated with familial forms of 
PD. In brief, the ubiquitin-proteasome pathway (UPP) degrades unwanted, misfolded or 
damaged proteins via a cycle of events involving the tagging of proteins for degradation by 
ubiquitin, the action of certain ligases and finally proteolysis by the proteasome (For an 
overview see Hershko 1992). Dysfunction of the UPP in PD has been the focus of many 
publications over the last 20 years, yet there is limited evidence that the UPP is impaired in 
PD (McNaught et al. 2001). However, mutations in genes that code for components of the 
UPP, such as the E3 ligase Parkin, are known to cause early onset PD (Burke 2008). A 
recent study has shown that overexpression of wild type Parkin suppresses the expression 
of MAO-A and –B in vitro (Jiang et al. 2006), suggesting that MAO may be a target of 
signalling via regulatory pathways such as the UPS (see section 6.1).  
The common underlying feature in PD aetiology is oxidative stress, which is the result of 
unregulated production of reactive oxygen species (ROS). High oxygen consumption, 
relatively low antioxidant levels and low regenerative capacity result in brain tissue being 
susceptible to oxidative damage (Barnham et al. 2004). In addition, elevated concentration 
of iron in the SNpc, can act as a catalyst in the Fenton reaction for the formation of 
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hydroxyl radicals from H2O2 (Gu et al. 1998).Oxidative damage may be a result of ageing 
and progression of the disease, but may also contribute further to its progression since 
oxidative stress is involved in cell signalling, cell death and inflammation (Dunnett and 
Bjorklund 1999). 
1.2.2.2 MAO and PD 
The oxidative degradation of DA catalysed by MAO generates hydrogen peroxide, a 
cellular toxin and a source of free radicals. Therefore MAO catalysis may be considered a 
major source of oxygen-derived toxic compounds in dopaminergic neurons. The increased 
turnover of DA in PD might explain the oxidative stress observed in the SNpc (Damier et 
al. 1996). Numerous studies have revealed increased MAO expression in PD (discussed in 
chapter 6, section 6.1). However there is still some debate over these findings, since the 
most of the work has been done on circulatory MAO-B in platelets. Mytilineou et al. 2003 
The symptoms of PD can be alleviated by the administration of L-DOPA, a dopamine 
precursor, or similar drugs that manipulate striatal dopamine function such as dopamine 
agonists, dopamine transport blockers or inhibitors of dopamine degrading enzymes 
catechol-O-methyl transferase (COMT) and MAO-B (Dunnett and Bjorklund 1999). Since 
MAO activity may be indirectly elevated following administration of L-DOPA, it was 
thought that L-DOPA could be neurotoxic, indeed, some studies found that administration 
of L-DOPA caused oxidative stress (Lai and Yu 1997) and inhibited complex IV of the 
mitochondrial electron transport chain (Pardo et al. 1995) in human neuroblastoma cells in 
vitro. However, Mytilineou and colleagues (2003) showed that L-DOPA is toxic to 
dopamine neurons in an in vitro but not an in vivo model of oxidative stress. L-DOPA, 
often in conjunction with MAO-B inhibitors, continues to be the mainstay treatment for PD 
today. Since Knoll and Magyar developed L-deprenyl in the 1970s many new and better 
MAO inhibitors have been developed. Some propargylamine inhibitors are thought to have 
anti-apoptotic and neuroprotective effects that are not a result of MAO inhibition per se. 
For example, the MAO-B inhibitor Rasagiline is thought to protect neuronal apoptosis via 
a mechanism involving up-regulation of the anti-apoptotic protein Bcl-2, PKC and 
prevention of nuclear transcription of apoptotic proteins (Maruyama et al. 2000, 
Maruyama et al. 2002, Youdim et al. 2003). Currently in phase III trails for PD, the MAO 
inhibitors TCH346 and CGP3466 (see Figure 1. 4) are thought to delay or prevent PD by 
promoting neuronal survival. MAO inhibitors are now being seen as inhibitors of ND as 
well as simply slowing dopamine catabolism (Youdim et al. 2006). 
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1.2.3 Alzheimer’s and other neurodegenerative diseases 
1.2.3.1 Alzheimer’s disease 
Alzheimer’s disease (AD) is distinct from PD, since it is mainly catecholaminergic neurons 
that are lost. AD is recognised as being the most common form of dementia, accounting for 
about 50-70 % of the late-onset cases of dementia (Hardy 1997). AD is typically a 
progressive disease that eventually leads to the degeneration of synaptic afferent systems, 
dendritic and neuronal damage, and the presence of large numbers of neuritic plaques and 
neurofibrillary tangles (Isacson et al. 2002). The plaques are largely extracellular lesions 
consisting of a peptide called amyloid. The neurofibrillary tangles are usually intracellular 
and consist of twisted bundles of the cytoskeletal protein tau (Hardy 1997). The key areas 
of the brain affected are those associated with thought, language and learning, namely the 
hippocampus, basal forebrain and cerebral cortex respectively (Highfield 2001). 20% of 
AD cases are thought to be a result of a genetic mutation (Highfield 2001). Genes 
identified to be dysfunctional in AD include the amyloid precursor protein (APP, which 
processes the formation of amyloid), and presenilins (Hardy 1997). There is some evidence 
that MAO levels are increased in AD (see chapter 5, section 5.1) and the MAO-B inhibitor 
deprenyl has been shown be therapeutic in AD by reducing free radical production in the 
brain (Thomas 2000, Emilsson 2002, Riederer et al. 2004). Free radicals have been shown 
to increase abnormal cleavage of APP to produce increased β-amyloid, which in turn 
generates more free radicals (Emilsson 2002).  
1.2.4 Huntington’s disease and Pick’s disease 
1.2.4.1 Huntington’s disease 
Huntington’s disease (HD) is caused by an abnormal polyglutamine expansion within the 
protein huntingtin and the characteristic hallmarks are inclusion bodies containing 
aggregated huntingtin protein in striatal neurons (Arrasate et al. 2004). The formation of 
these inclusion bodies is thought to be a coping mechanism in order to sequester the toxic 
mutant protein (Arrasate et al. 2004). The underlying causes of HD are not known but 
mitochondrial dysfunction and excitotoxicity have been proposed to be a major factor. DA 
toxicity mediated by MAO has been suggested to be involved in mitochondrial dysfunction 
(Jakel and Maragos 2000) in HD. Indeed, increased MAO-B activity in platelets of patients 
with HD has been observed (Mann et al. 1980) 
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1.2.4.2 Pick’s disease 
Pick’s disease and the closely related frontotemporal dementia are rare dementias, with a 
frequency of around 1 % that of AD. The principal pathologies include gross depletion of 
neurons in the frontal lobe and distinctive inclusions known as Pick’s bodies. Alfons Pick 
described the clinical features in 1892 and the inclusion bodies were first described by 
Alois Alzheimer in 1911 (Morris 1995). Although Pick’s disease is degenerative, age is not 
a major factor, with onset ranging between 30-60 years of age (Wise et al. 1995). 20 % of 
cases are due to a genetic mutation that is autosomal dominant (Wise et al. 1995). The 
Pick’s bodies contain tau proteins, ubiquitin and neurofilaments and resemble 
neurofibrillary tangles. The molecular mechanisms underlying this disease are unknown at 
present; however MAO-A and -B activities were found to be increased in different areas of 
Pick’s diseased brains following post mortem (Sparks et al. 1991), therefore MAO 
inhibitors may be therapeutic.  
1.3. FREE RADICALS AND OXIDATIVE STRESS 
A free radical is any chemical species capable of independent existence that contains one 
or more unpaired electrons (Halliwell and Gutteridge 2007). Reactive oxygen species 
(ROS) is a collective term that includes not only oxygen radicals but some non-radical 
derivatives of O2, such as H2O2. Reactive is a relative term; superoxide (O2●-) and H2O2 are 
highly selective in their reactions with biological molecules, whereas the hydroxyl radical 
















Table 1. 1 Reactive oxygen species (Halliwell and Gutteridge 2007) 
1.3.1 Hydrogen peroxide 
Hydrogen peroxide is continually produced in many tissues in vivo and the steady state 
concentration in the cell is thought to be approximately 10-7 M (Giorgio et al. 2007). H2O2 
is only a weak oxidising or reducing agent and is generally poorly reactive. Indeed, this 
probably allows it to play a role in signal transduction (Toledano et al. 2004). However, 
H2O2 is capable of inactivating some enzymes directly, usually by oxidation of sulfhydryl 
groups essential for catalysis and these enzymes include caspases and some protein 
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phosphatases. H2O2 can also oxidise certain keto-acids such as pyruvate and 2-oxoglutarate 
(Halliwell and Gutteridge 2007). Although there are few examples of the direct actions of 
H2O2, cellular damage by H2O2 can be immense because H2O2 can react with iron or 
copper to form more damaging species such as OH● via the Fenton reaction (Halliwell and 
Gutteridge 2007). 
 
Figure 1. 6 The Fenton reactions 
 The production of H2O2 in the cell arises from the activity of certain enzymes including 
xanthine oxidase, urate oxidase, glucose oxidase and superoxide dismutase (SOD). 
Mitochondria are a major source of H2O2, harbouring both MAO and the electron transport 
chain (ETC).  
1.3.2 Mitochondrial ROS 
The ETC is a well documented source of H2O2 from deprotonating O2●. The ETC can 
generate O2● from O2. During mitochondrial respiration, oxidative phosphorylation creates 
a flux of electrons through the ETC. The flux creates a proton gradient across the inner 
mitochondrial membrane (IMM) known as the protomotive force (Abou-Sleiman et al. 
2006), which is used for the synthesis of ATP. Electrons are extracted from reduced 
substrates and are transferred to O2 through the enzymatic steps involving the complexes I 
to IV. Cytochrome c ensures the complete reduction of O2 to water. O2● is generated if O2 
interacts with electrons upstream of complex IV, particularly complexes I and III (Giorgio 
et al. 2007).  
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Figure 1. 7 Schematic representation of the electron transport chain (Abou-Sleiman et al. 2006) 
The membrane spanning complexes of the ETC comprise complex I (NADH-ubiquinone reductase), which 
oxidises NADH, complex II (succinate ubiquinone oxidoreductase)m which oxidises FADH2, complex III 
(ubiquinol cytochrome c oxidoreductase) and complex IV (cytochrome c oxidase). The hydrophobic electron 
carriers coenzyme Q10 (CoQ) and cytochrome c (Cyt c) are also shown.  
The high rate of O2● production at the IMM is functionally related to the localisation of 
SOD in the matrix, which defines the steady state concentration of O2●. The contribution of 
H2O2 at the OMM by MAO to cytosolic and mitochondrial steady state H2O2 
concentrations is thought to have been underestimated and the steady state concentration of 
H2O2 in the mitochondrial matrix, from MAO activity alone has been calculated to be 
around 10-7 M (Cadenas and Davies 2000).  
1.3.2.1 Mitochondrial damage 
The generation of O2● and H2O2 by the ETC in close proximity to active pools of copper 
and iron in the mitochondrial membranes can result in the formation of OH● via the Fenton 
reactions. OH● can attack the deoxyguanosine base of mitochondrial DNA (mtDNA) 
leading to mutations (Cadenas and Davies 2000). The production of H2O2 by MAO-
mediated oxidation of tyramine in rat brain mitochondria elicited significant induction of 
mtDNA single strand breaks (Hauptmann et al. 1996). MAO-catalysed oxidation of DA 
and production of H2O2 inhibit active mitochondrial respiration and causes mitochondrial 
membrane permeabilisation resulting in mitochondrial swelling (Berman and Hastings 
1999, see section 1.5). Uncontrolled, O2● and H2O2 cause oxidative inactivation and 
proteolytic degradation of mitochondrial proteins (Cohen et al. 1997, Cadenas and Davies 
2000). Indeed, subtle elevation of MAO-B levels in vitro, resulted in inhibition of α-
ketoglutarate dehydrogenase and loss of mitochondrial flux (Kumar et al. 2003). 
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Metabolism of monoamines by MAO, by intact rat brain mitochondria suppressed 
pyruvate- and succinate-dependent electron transport, which was reversed by MAO 
inhibition (Cohen et al. 1997).  
1.3.3 Antioxidant defences 
The cell has a sophisticated antioxidant defence system that normally works in parallel 
with ROS production to eliminate excess free radicals and maintain steady state 
concentrations of H2O2 and other ROS.  
1.3.3.1 Glutathione system 
Cellular redox potential is largely determined by glutathione (GSH), a tripeptide of 
glutamate, cysteine and glycine, which is synthesised from its constituent amino acids in 
the cytosol of virtually all mammals (Domenicotti et al. 2003). Upon oxidative stress GSH 
may be oxidised to GSSG (oxidised glutathione) through the glutathione peroxidase (GPx) 
reaction. Oxidative stress in the cell results in an decreased in the GSH to GSSG ratio 
(Jahngen et al. 1997). Increased GSSG level often results in the covalent modification of 
sulfhydryl groups, which is known as glutathiolation. Enzymes that contain active site 
sulfhydryls are particularly vulnerable, and damage to proteins involved in both the ETC 
and UPP by glutathiolation has been reported (Cohen et al. 1997, Jahngen et al. 1997 
respectively). PD is characterised by reduced GSH in the SNpc, including DA-containing 
neurons in this brain region (Pearce et al. 1997). Glutathione depletion triggers increases in 
both ROS and activity of PKC-δ, which leads to apoptosis and growth arrest in human 
neuroblastoma cells (Domenicotti et al. 2003). MAO-generated H2O2 is detoxified within 
the mitochondria by GPx and the resulting glutathiolation causes suppression of SH-
dependent electron transport.  
 
Figure 1. 8 Schematic representation of the MAO-dependent pathway for suppression of 
mitochondrial electron flow and subsequent recovery (Cohen et al. 1997).  
Formation of GSSG forms disulfide linkages (Pr-SSG) with cysteine residues of proteins associated with the 
IMM resulting in suppression of ETC. This inhibition is relieved by reduction of GSSG by GSSG reductase, 
reversing the reaction that forms PrSSG (Cohen et al. 1997).  
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1.3.3.2 Superoxide dismutase and catalase 
SOD exists as three isoforms, including a mitochondrial isoform that is important in 
converting O2●- to O2 and H2O2. The nuclear expression of mitochondrial SOD is known to 
be regulated by mitochondrial redox state (Kim 2005). Mutations in cytoplasmic forms of 
SOD are involved in 20 % of familial cases of amyotrophic lateral sclerosis (ALS, a 
neurodegenerative disorder), implicating antioxidant dysfunctions in ND aetiology 
(reviewed by Anderson 2004).  
Catalase is only present in the cytosol and is an antioxidant enzyme that is capable of 
rapidly decomposing high concentrations of H2O2 but is inhibited by high concentrations 
of L-DOPA and dopamine in rat neuronal cells (Han and Cohen 1996), suggesting that DA 
toxicity or treatment with L-DOPA in PD may be damaging to cytosolic antioxidant 
defences. Antioxidants such as ascorbic acid (vitamin C) and α-tocopherol (vitamin E) also 
play an important role in detoxification (Schulz et al. 2000, see chapter 3, section 3.1).  
1.3.4 Free radical production by MAO in neurons 
DA is capable of autooxidation forming oxygen radicals, and products of DA such as 
quinones and neuromelanin. Most of the DA released into the synapse is stored in vesicles 
to be reutilised. However, some DA does not reach the vesicles but encounters MAO, 
where it is metabolised. MAO oxidation of dopamine results in increase in H2O2, which is 
detoxified by GSH. In PD the neuronal levels of DA are low in the striatum. However, 
turnover of DA may increase during the disease process or during L-Dopa treatment 
(Adams et al. 2001).  
Metabolism of monoamine substrates by MAO can result in the formation of a number of 
reactive oxygen species, primarily H2O2, but also OH●, hydroperoxyl radical, aminium 
radical and iminium radical (Adams et al. 2001). MAO activity also yields aldehyde which 
can interact with aldehyde dehydrogenase to produce 3, 4-dihydroxyphenlacetic acid 
(DOPAC). Complex I activity oxidises NADH to NAD. NAD is used by aldehyde 
dehydrogenase in the oxidation of the aldehyde DOPAL (Adams et al. 2001). Reduced 
complex I activity may result in decreased catabolism of MAO metabolites. Moreover, 
levels of the toxic MAO-A metabolite, 3,4-Dihydroxyphenylglycolaldehyde (DOPEGAL) 
were increased in the locus ceruleus of AD brains (Burke et al. 1999), further implicating 
MAO derived toxic species in mechanisms of neuronal cell death.  
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1.4. CELL SIGNALLING 
Cells communicate using a diverse network of signalling pathways which rely on 
transduction through proteins or hormones for example. For the scope of this thesis three 
important signalling modules will be discussed here; these include (1) protein kinase 
signalling, with emphasis on the mitogen activated protein kinase (MAPK) 
phosphorylation cascades, (2) apoptotic signalling (see section 1.5) and briefly (3) H2O2 as 
a signalling molecule.  
1.4.1 Protein kinase signalling 
Kinase enzymes transfer phosphate groups from high energy molecules such as ATP to 
specific residues of a substrate.  
1.4.1.1 Protein kinase C  
Protein kinase C (PKC) is so called because it is Ca2+ dependent. Rise in cytosolic Ca2+ 
levels triggers PKC translocation from the cytosol to the inner plasma membrane, where it 
interacts with membrane lipid, phosphatidyl serine, Ca2+ and diacylglycerol for activation 
(Alberts et al. 1994). Active PKC phosphorylates serine / threonine residues on target 
proteins such as MAPK and IκB (which release NFκB).  
1.4.1.2 Phophatidylinositol 3’-kinase and Akt/PKB 
Phophatidylinositol 3’-kinase (PI3-K) is important in regulating cell proliferation since it is 
activated by binding of growth factors to cell receptors (Brazil et al. 2004). It 
phosphorylates phosphatidylinositol at the 3’ position hence the name. PI3-K activates 
Akt/PKB because Akt/PKB requires the formation of phophatidylinositol (3,4,5)-
triphosphate (PIP3) in order to translocate to the plasma membrane where it is 
phosphorylated and activated (Alberts et al. 1994). Akt/PKB signalling is critical for cell 
cycle progression, apoptosis and transcription regulation. Akt/PKB controls the cell cycle 
at G1/S by blocking cell cycle inhibitors (Brazil et al. 2004). Activation of Akt/PKB can 
be inhibited by PTEN and can bind to extracellular regulated kinase (ERK) to regulate 
apoptosis (Brazil et al. 2004). Akt/PKB inhibits Raf (a MAP kinase kinase kinase 
[MEKKK]) important in MAPK signal transduction and blocks apoptosis by inhibiting 
BAD (Brazil and Hemmings 2001). 
1.4.1.3 Ras signalling 
Ras is a G-protein, a regulatory hydrolase that cycles between an active and an inactive 
form. Ras is attached to the cell membrane and a crucial factor in transducing mitogenic 
Chapter 1                                                                                                                              General introduction 
 21
signals as a result of ligand-receptor binding (Alberts et al. 1994). Active Ras activates Raf 
(a MEKKK), which triggers a cascade of phosphorylation known as the MAPK pathway. 
1.4.2 Mitogen activated protein kinase (MAPK) signalling 
MAPK pathways are activated by a wide range of signals including growth factors, 
mitogens, cytokines and stress. The general structure of the pathway is a three tier 
serine/threonine phosphorylation cascade where upstream MAP kinase kinase kinase 
(MAPKKK) activate MAP kinase kinase (MAPKK), which activate MAP kinase. Three 
well characterised MAPK pathways have been the focus of immense study. The MAPK 
targets of these pathways are extracellular regulated kinase (ERK), c-jun terminal regulated 
kinase (JNK) and p38. It is generally thought that ERK1/2 is activated by mitogenic/ 
survival stimuli and that JNK and p38 are activated by stressful/pro-death stimuli. 
However, it is more likely that it is the balance between the pathways which is important, 
since lack of ERK1/2 stimulation may activate JNK/p38 (Xia et al. 1995, Wang et al. 
1998). MAPK signalling pathways play a central role in survival/growth signalling and cell 
death pathways. JNK and p38 are important effectors in apoptosis in brain during 
neurodegeneration (Mielke and Herdegen 2000). Cellular stressors that may activate these 
pathways may include deprivation of growth factors, ionising radiation, free radicals and 
ROS, hypoxia, heat shock (Mielke and Herdegen 2000).  
 
Figure 1. 9 MAPK phosphorylation cascade (From www.cellsignal.com) 
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1.4.2.1 ERK MAPK 
ERK1/2 refers to the classical 44 and 42 kDa isoforms respectively, which are referred to 
in this thesis as ERK. The regulation of a large number of cellular processes is dependent 
upon the activation of ERK. ERK is localised in the cytoplasm and upon stimulation, 
detaches from its cytosolic anchor and translocates to the nucleus (Yung et al. 2000). In the 
nervous system ERK is critical for neuronal differentiation, plasticity and may modulate 
neuronal survival (Hetmen and Gozdz 2004). Mice lacking ERK fail to develop and die at 
embryonic stage 10.5 (Nishimoto and Nishida 2006). ERK plays a pivotal role in 
mitogenic signalling and apoptosis induced by withdrawal of growth factors and death 
receptors. Targets of ERK are mainly transcription factors or signalling molecules involved 
in pro-survival. Two examples include the targeting of transcription factors that transcribe 
cell cycle factors (Molnar et al. 1997) and inhibition of the pro-death protease caspase-9 by 
phosphorylation at a key threonine site (Allan et al. 2003). In contrast, ERK can be 
compartmentalised to restrict access to downstream targets and therefore can favour cell 
death in neurons following oxidative stress (Chu et al. 2004). The mechanism by which 
ERK promotes cell death is not known, however the balance between ERK (ERK1/2) and 
ERK5 may be important (Nishimoto and Nishida 2006). Ishikawa and Kitamura (1999) 
proposed that ERK has a dual role in the control of cell survival, since transient up-
regulation of ERK participates in the induction of apoptosis, whereas basal, constitutive 
activity of ERK is required for maintenance of cell survival. Ishikawa and Kitamura 1999 
1.4.2.2 JNK MAPK 
The JNK protein kinases are encoded by three genes that are expressed ubiquitously. The 
genes encode JNK proteins with or without a COOH-terminal extension, thereby forming a 
46 kDa and a 55 kDa isoform (Davis 2000). The JNK pathway is activated by a large 
group of MAPKKK and activation of JNK has been reported following activation the Rho 
GTPase family, in response to cytokines and death receptors (Davis 2000). Commonly 
reported JNK substrates include the transcription factors c-jun and ATF-2, which regulate 
a range of cellular responses including cell proliferation, apoptosis and embryonic 
development (Dunn et al. 2002). JNK has a crucial role in phosphorylating substrates 
involved in cell death, for example the tumour suppressor p53, Fas ligand and 
mitochondrial proteins that are involved in cytochrome-c dependent death signalling 
(Davis 2000, Tournier et al. 2000). JNK signalling is important in neuronal survival 
(Harris et al. 2002). Phosphorylated JNK was found in cortical neurons with 
neurofibrillary tangles in Lewy body dementia, cytoplasmic granules in the vicinity of 
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Lewy bodies and α-synuclein deposits (Ferrer et al. 2001). In a mouse model of PD, JNK-
mediated induction signalling was required for neurodegeneration in mice (Hunot 2003) 
and DA-induced apoptosis in an in vitro PD model (Luo et al. 1998). JKK1, an upstream 
activator of JNK, is activated in AD brains (Zhu et al. 2003) and the amyloid β-peptide 17-
42, a major constituent in AD senile plaques, activates JNK and caspase-8 leading to cell 
death (Wei et al. 2002).  
1.4.2.3 p38 MAPK 
The p38 MAP kinases are activated by cellular stresses including ROS and cytokines 
(Enslen 1998) and play an important role in the regulation of gene expression (Hazzlan et 
al. 1996). The first p38 isoform to be identified was originally described as a 38 kDa 
polypeptide that underwent tyrosine phosphorylation in response to osmotic shock and was 
named p38α. There are now four known p38 isoforms: p38 α, β, γ, and δ, which are 
differentially activated (Alonso et al. 20000). Activation of the p38 pathway results in the 
phosphorylation of various substrates. p38 can directly phosphorylate and activate a 
number of transcription factors including ATF-2, CREB, Elk-1, CHOP and MEF2C. 
Moreover, p38 can indirectly (via phosphorylation of the kinase MAPKAP-2 and Mnk1/2) 
phosphorylate tau protein in AD (Mielke and Herdegen 2000). Activation of the p38 
pathway is strongly associated with activation of cell death pathways and inhibitors of p38 
promote neuronal survival in vitro (Horstmann et al. 1998). Conversely, p38 is known to 
prevent apoptosis from occurring during cellular differentiation by activating the 
transcription factor MEF2 (Okamoto et al. 2000). 
p38 seems to play a major role in gene regulation since it can also regulate gene expression 
at the post transcription level by stabilising mRNA in a mechanism involving adenosine 
and uridine rich elements (AREs) (Clark et al. 2003). 




MEKK2 and 3 
ASK1 
TRAF 2, 5, 6 
RIP 
Rho family GTPases 
Heterotrimeric G proteins 
Adapter coupled proteins coupled 
to TNF receptors 
MAPKAP kinases-2, 3, and 5 








ATF-2, CREB, Elk-1, MEF2, CHOP, STAT1, 
MAX, c-Myc, HMG-14 and Histone –H3 
Table 1. 2 Some characteristics of p38 
(Enslen 1998, Woodgett 2000) 
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1.4.3 Regulation of MAO expression by protein kinase signalling 
As previously described, the MAO-B gene can be regulated by Sp1 and Sp3 transcription 
factors (Wong et al. 2001). In 2002, Wong and colleagues described the activation of 
MAO-B gene expression via c-jun and Egr-1 transcription factors. In the promoter region 
of the MAO-B gene between -246 and -225 bp there are overlapping sequences that are 
recognised by Sp1, Sp3 and Egr-1 transcription factors. Phorbol 12-myristate 13-acetate 
(PMA) is known to increase Egr-1 and c-jun expression. PMA treatment increased MAO-
B but not MAO-A gene expression. A PKC inhibitor blocked the PMA dependent 
activation of MAO-B and co-transfection with dominant forms of Ras, Raf-1, MEKK1, 
MEK1, MEK3, MEK7, ERK2, JNK1 and p38 inhibited the PMA-dependent activation of 
the MAO-B promoter (Wong et al. 2002). This study provided evidence that PKC and 
MAPK signalling pathways are important in PMA-induced MAO-B gene expression. 
 
Figure 1. 10 Protein kinase signalling and MAO gene expression 
Left panel-PMA induced PKC which in turn activates Ras and Raf and MEKK1 kinase. MEK1, 7 and 3 are 
phosphorylated, activating ERK2, JNK and p38 MAP kinases. Downstream targets of MAPK pathway are 
transcription factors Egr-1 and c-jun which induce gene transcription (Wong et al. 2002). Right panel-Serum 
withdrawal activates p38 MAPK which induces MAO-A gene transcription by inhibiting the repressor R1. 
The transcription factor c-Myc can repress MAO-A gene transcription directly, or indirectly by up regulating 
R1 expression (DeZutter and Davis 2001, Ou et al. 2006). 
The MAO-A gene is under the control of the p38 MAPK signalling pathway in apoptosis 
induced by nerve growth factor (NGF) withdrawal. MAO-A gene expression was increased 
following NGF withdrawal and this was prevented by inhibition of the p38 signal 
transduction pathway (DeZutter and Davis 2001). In 2006, Ou and co-workers confirmed 
that the p38 MAPK signalling pathway was involved in regulating MAO-A expression 
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during apoptosis induced by serum deprivation. They also reported that JNK and ERK 
MAPK pathways were not involved in the regulation of MAO-A gene expression. The 
transcription factor c-Myc (involved in cell proliferation) was shown to induce expression 
of the MAO-A repressor R1 and inhibit MAO-A expression.  
1.4.4 H2O2 as a signalling molecule 
ROS can act as second messengers in signal transduction in a variety of cell types (Finkel 
1998). H2O2-initiated cysteine-based redox signalling is tightly controlled by specialised 
H2O2 sensors in Saccharomyces cerevisiae (Toledano et al. 2004), suggesting that 
microbial H2O2 sensors are archetypal redox signalling modules. H2O2 functions as a 
signalling molecule in intracellular and oncogenic growth signalling. Induction of cell 
proliferation by growth factor binding correlates with transient increases in intracellular 
H2O2, mediated by MAPK and NF-κB pathways (Giorgio et al. 2007, Halliwell and 
Gutteridge 2007). H2O2 under certain conditions induces senescence (a permanent state of 
growth arrest) and at high concentrations is a potent inducer of apoptosis ( Giorgio et al. 
2007, Halliwell and Gutteridge 2007). Induction of senescence can occur via inactivation 
of caspases (Allan et al. 2003, Halliwell and Gutteridge 2007) and via the p53 checkpoint 
(Giorgio et al. 2007). Apoptosis is triggered by activation of various cell signalling 
pathways including MAPK pathways (Tan et al. 1998). H2O2 has a dose dependent effect, 
where generally low levels of H2O2 promote survival and high levels promote death (Yoon 
et al. 2002).  
1.4.4.1 Targets of H2O2 
Target(s) Model Reference 
Growth factor signalling Yeast and animal cells Stone and Yang 2006 
Modification of Gαi and Gαo proteins Rat cardiomyocytes 
(primary culture) 
Nishida et al. 2000 
Reversible glutathionylation of ETC proteins 
Reversible glutathionylation of complex I of 
the ETC 
Reversible glutathionylation of α-
ketoglutarate dehydrogenase 
Isolated mitochondria 
from rat brains 
Isolated mitochondria 
from rat liver 
Mitochondria isolated 
from rat heart 
Cohen et al. 1997 
 
Taylor et al. 2003 
 
Nulton-Persoson et al. 2003 
Dopamine transport Rat PC12 cells Huang 2003 
ERK, JNK and p38 pathways Rat smooth muscle 
cells (primary culture) 
Human cervical  
Guyton et al. 1996 
 
Wang et al. 1998 
Dual regulation of Caspase-3  Mouse (Jurkat) cells Hampton and Orrenius 1997 
Transforming growth factor (TFG-β)-
induced increase in gene expression 
Human mesangial cells Inglesias-DeLaCruz et al. 
2001 
MAPK p38 in hypoxia Mouse fibroblast cells Emerling 2005 
Cell proliferation via PI3-K/PKB pathway Human hepatoma cells Liu et al. 2002 
Table 1. 3 Some reported cellular targets of H2O2 signalling 
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1.4.4.2 Targets of H2O2 generated by MAO 
MAO-B produced H2O2 induces ERK-dependent cell mitogenesis in rat embryonic kidney 
cells (Vindis et al. 2000) and in rat renal epithelial cells (Vindis et al. 2001). Activation of 
ERK by H2O2 produced by MAO in rat renal epithelial cells leads to activation of 
apoptosis, which is reversible following MAO inhibition (Bianchi et al. 2003). Apoptosis 
induced by MAO-generated H2O2 has been reported to involve a common oxidative stress 
pathway which begins with H2O2 activating the JNK MAPK pathway, which through 
NFκB and c-jun signals increased p53 expression. Active p53 activates pro-apoptotic Bax 
which induced cytochrome-c release, activation of caspase-3 and execution of apoptosis 
(Del Rio and Velez-Pardo 2002).  
1.5. CELL DEATH 
The molecular definition of cell death historically has been distinguished in mammalian 
cells by morphological criteria. Type I cell death (known as apoptosis) is defined by 
characteristic changes in the nuclear morphology, including chromatin condensation and 
fragmentation; minor changes in cytoplasmic organelles; and overall cell shrinkage, 
blebbing of the plasma membrane and formation of apoptotic bodies. All these changes 
occur before plasma membrane integrity is lost. Type II cell death (known as autophagy) 
is characterised by the accumulation of double-membrane- autophagic vacuoles in the 
cytoplasm. Type III cell death (known as necrosis) lacks the characteristics of type I and II 
but can also be defined by early plasma membrane rupture and dialation of cytoplasmic 
organelles, particularly mitochondria (Golstein and Kroemer 2006). Necrotic cells swell 
and are internalised by a mechanism where only parts of the cell are taken up by the 
phagocytes (Golstein and Kroemer 2006), which often causes inflammation. Apoptotic 
cells usually shrink and are engulfed by phagocytes. Apoptosis is under the tight control of 
unique signalling pathways, which involve the activation of specialised proteases.  
1.5.1 Apoptosis  
Apoptosis (sometimes known as programmed cell death) comprises two major signalling 
pathways known as the mitochondrially mediated pathway (or intrinsic pathway) and the 
death receptor-mediated pathway (or extrinsic pathway). Apoptosis can also arise from the 
endoplasmic reticulum (ER) which is known as the stress-ER pathway.  
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1.5.1.1 Caspases 
Caspases (cysteine-aspartate-specific proteases) are a family of proteins that initiate and 
execute the apoptosis. Caspases are highly specific in their substrate specificity since they 
cleave after aspartic acid residues (Hengartner 2000). At least 14 different caspases have 
been identified in mammals (Ashe and Berry 2003). Caspases stop the control processes 
that protect the cell from death and activate other caspases in a cascade of protease activity. 
Caspases are responsible for the executing the downstream processes that ultimately 
dismantle the cell via cleavage of a variety of substrates. Caspases cleave key components 
of the cytoskeleton, the nucleus, protein kinases and survival factors. Caspases can also 
activate degradation systems by activating nucleases, serine proteases, calpains and the 
proteasome. Caspases 1, 4, 5, 11, 12, 13 and 14 are responsible for cytokine activation and 
the inflammatory response, with the exception of caspase-12 which is involved in the 
stress-ER pathway. Caspases 2, 8, 9 and 10 are involved in the initiation of the apoptotic 
cascade and caspases 3, 6 and 7 are common to all apoptotic pathways since their 
activation represents the point of apoptotic execution, committing the cell to die and are 
therefore often described as executioners.  
Caspase Substrate(s) Function 
1 Pro-IL-1β Cytokine activation 
2  αII spectrin, golgi-160, PKC Apoptotic initiator associated with piddosome formation 
3 Poly(ADP) ribose polymerase 
(PARP), 
DNA-PK, lamins, Fodrin, PKC 
and recruits serine proteases, 
calpains,  
proteasomes, DNaseI, NUC18, 
 CAD and Pak1. 
Central effector caspase responsible for the cleavage 
Of important proteins including JNK. Important in 
mediating apoptosis in the nervous system 
4 PARP (closely related to caspase1) Cytokine activation, maturation of caspase-1 
Induces apoptosis at high concentrations 
5 PARP (closely related to caspase1) Cytokine activation and apoptosis at high concentrations 
6 Caspase-3 and therefore substrates 
of caspase-3 but less active (~150 
fold less) 
Effector caspase via caspase-3 
7 Same as caspase-3 Effector caspase important in receptor mediated 
apoptosis and mediator of cytotoxic T-cell killing 
8 PARP, Bid and all known caspases 
including caspase-3 
Apoptotic initiator essential in death receptor-induced 
apoptosis 
9 Effector caspases Apoptotic initiator essential for the formation of the 
apoptosome in the mitochondrially mediated pathway 
and under the control of ERK 
10 Same as caspase-8 Apoptotic initiator activated through death effector 
domains (DEDs) and associated with death receptor-
mediated pathway 
12 Other caspases including caspase-9 Cytokine activation and essential in stress-ER pathway 
Table 1. 4 Some substrates and functions of important caspases 
(Bortner et al. 1995, Cohen 1997, Hengartner 2000, Nakagawa and Yuan 2000, Lassus et al. 2002, Salvesen 
2002, Allan et al. 2003, Ashe and Berry 2003, Enemoto et al. 2003, Zhivotsky and Orrenius 2005).  
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1.5.2 Mitochondria-mediated apoptosis 
1.5.2.1 Bcl-2 family proteins 
The mitochondrial outer membrane harbours the protein Bcl-2 and other anti-apoptotic 
members of the Bcl-2 family of proteins such as Bcl-xl. These are central regulators of 
apoptosis by integrating diverse signals from inside and outside the cell. They regulate 
apoptosis by opposing the pro-apoptotic Bcl-2 family members such as Bax, Bak and Bad. 
Bcl-2 family proteins control mitochondrial membrane permeability. The OMM can 
become perforated and proteins sequestered inside the mitochondria are then allowed to 
leak into the cytoplasm and participate in apoptotic signalling. Bcl-2 localises to other 
membranes including the nuclear envelope and the ER membrane, where it continues to 
protect the mitochondria (Thomenius and Distelhorst 2003). Bcl-2 localises to other 
membranes because it lacks a signal that directs other Bcl-2 family proteins such as BclXL 
to the mitochondrial surface (Kaufmann et al. 2003). The localisation of Bcl-2 may be an 
important factor in regulating the survival/apoptotic balance. Regulation of pro- and anti-
apoptotic Bcl-2 family members also involves the action of BH3-only proteins which act 
as sensors for apoptotic stimuli. Following stimulus, a BH3-only protein is modified and 
travels to the OMM where via its BH3 domain interacts with anti-apoptotic Bcl-2 proteins 
causing OMM perforation or interacts with pro-apoptotic family members stimulating their 
oligomerisation (Kaufmann et al. 2003). Bcl-2 can also change its conformation to inhibit 
Bax oligomerisation (Dlugosz et al. 2006), which is triggered by active Bid (Figure 1. 11). 
 
Figure 1. 11 An overview of the mitochondrially mediated apoptotic pathway 
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1.5.2.2 Mitochondrial membrane pore opening 
The release of cytochrome c (Cyt-c) from the IMM is essential for the formation of the 
apoptosome (Figure 1. 11). Release of apoptosis inducing factor (AIF) from the 
mitochondria is also important since it translocates to the nucleus where it binds to DNA 
and promotes chromatin condensation (Figure 1. 11). AIF functions independently of 
caspases (Joza et al. 2001, Cande et al. 2002).  
Prior to release of mitochondrial proteins, the mitochondrial membranes undergo 
morphological changes that resemble events associated with mitochondrial fission and 
fragmentation (Youle and Karbowski 2005, Arnoult 2006). However there is some debate 
as to whether these processes are essential for mitochondrial outer membrane permeability 
(MOMP). The alternative model proposes MOMP to be initiated at the IMM. Signals such 
as increased Ca2+ or ROS promote mitochondrial permeability transition (MPT) involving 
a permeability transition pore (PTP) complex. Major components of the PTP complex 
include the OMM located voltage-dependent anion channel (VDAC), the IMM protein 
called adenine nucleotide translocator (ANT) and cyclophilinD (CypD), which is resident 
in the matrix (Garrido et al. 2006). MOMP does not always occur through the PTP, 
osmotic swelling and rupture of the IMM can also release IMM proteins into the cytosol. 
Bcl-2 family members are also known to form low selectivity channels by undergoing 
oligomerisation (Hengartner 2000). 
 
Figure 1. 12 Schematic of mitochondrial permeability transition (Abou-Sleiman et al. 2006) 
1.5.2.3 Formation of the apoptosome and caspase activation 
Once released from the mitochondria, Cyt-c interacts with the C-terminal domain of Apaf-
1 and in the presence of ATP cause a conformational change in Apaf-1 that allows it to 
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undergo self oligomerisation into two complexes that recruit caspase-9 via its N-terminal 
caspase activation-recruitment domain (CARD) and allows the catalytic activation of 
caspase-9 that can then proceed to activate caspase-3 and -7 (Bratton and Cohen 2001).  
1.5.2.4 Regulation by phosphorylation and apoptotic inhibitors 
Mitochondria are primary control centres for energy production and survival/ death and 
recent studies have reported that phosphorylation by mitochondrial kinases, phosphatases 
and phoshoproteins is important in the regulation of mitochondrial processes. Some of 
these events have been characterised and include the phosphorylation of Bad by protein 
kinase A, the phosphorylation and dephosphoylation of pyruvate dehydrogenase, 
phosphorylation and inhibition of cytochrome c oxidase (Pagliarini 2006). Mitochondrially 
mediated apoptosis is also regulated by ‘inhibitor of apoptosis’ proteins (IAPs which 
suppress apoptosome formation). The mitochondrial proteins HtrA2/Omi and Smac 
regulate IAPs (Orrenius et al. 2003). Figure 1.13 shows an overview of mitochondrial 
signalling. 
 
Figure 1. 13 An overview of mitochondrial signalling (Pagliarini 2006) 
1.5.3 Death receptor-mediated apoptosis 
Death receptor-mediated apoptosis is introduced in chapter 4, section 4.1. 
1.5.4 Calcium and apoptosis 
Cellular Ca2+ import through the plasma membrane largely occurs via receptor-operated, 
voltage sensitive and store-operated channels. Inside the cell, Ca2+ can interact with Ca2+ 
binding proteins or become sequestered into the ER or mitochondria. The cytoplasmic Ca2+ 
concentration is maintained by uptake into the ER and by extrusion into the extracellular 
space. Ca2+ release by the ER is regulated by phospholipase C. Mitochondria take up Ca2+ 
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through a uniport transporter and can be released by either: reversal of uniporter Ca2+ 
exchange (through the PTP) and calmodulin regulated release (Orrenius et al. 2003). 
Mitochondrial Ca2+ fluxes are integrated parts of cellular signalling and uptake of Ca2+ by 
the mitochondria stimulates Ca2+ sensitive matrix dehydrogenases of the ETC. Ca2+ has 
two roles in apoptosis, one is by contributing to the calcineurin-catalysed phosphorylation 
of Bad and the other is regulation of OMM permeabilisation. As described previously, 
VDAC forms part of the PTP and VDAC becomes activated by a high concentration of 
Ca2+. Opening of the PTP causes a rapid flux of Ca2+ into the cytoplasm. Depletion of 
intracellular calcium stores is toxic to neuronal cells (Nguyen et al. 2002). There is some 
evidence that Ca2+ may interact or play a role in Bcl-2 family function via Ca2+ mediated 
events that take place at the ER (Orrenius et al. 2003).  
1.5.5 Apoptosis and neurodegeneration 
A universal pathology in all neurodegenerative disease is the loss of neurons in key areas 
of the brain. Cell death is an important feature in the development of the nervous system 
and deficit of death in some circumstances can give rise to cancers. Apoptosis might serve 
to remove damaged or dysfunctional neurons as a protective mechanism and this may 
explain the evolution of mechanisms to regulate the cellular response to stress. It appears 
that the complexity of cell death signalling reflects the necessity for fine tuning the cellular 
response to deal with stressors accordingly.  
Alzheimer’s disease Parkinson’s disease 
Altered expression of apoptosis-related genes (Bcl-
2 family members, DNA response genes, p53) are 
found in neurons associated with plaque formation 
in AD brains (De La Monte et al. 1998, Mattson et 
al. 1998) 
Bcl-XL is required for the proper 
development of the mouse SNpc 
(Savitt et al. 2005) 
Neurons from caspase-2 and caspase-12 knockout 
mice are protected against β-amyloid induced 
apoptosis (Nakagawa and Yuan 2000, Troy et al. 
2000) 
Caspase-3 is a vulnerability factor 
and final effector in apoptotic death 
of dopaminergic neurons in PD 
(Hartmann et al. 2000) 
Mutant presenelin-1 expression causes 
mitochondrial dysfunction and sensitises cells to 
apoptotic insults (Guo et al. 1999) 
Mutations in the anti-apoptotic 
mitochondrial kinase PINK1 cause 
PD-like symptoms (Plun-Favreau et 
al. 2007) 
Activation of caspase-3 and -9 and subsequent 
cleavage of tau leads to the formation of 
neurofibrillary tangles (Rohn et al. 2002) 
Mutations in anti-apoptotic DJ1 
cause early onset PD 
(reviewed by Burke 2008) 
Table 1. 5 Evidence for apoptosis in AD and PD 
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1.6. OVERALL AIMS OF THESIS 
The overall purpose of the work was to investigate the role of MAO in neuronal cell death. 
The first approach was to develop a variety of apoptotic models in vitro that would reflect 
the different types of apoptosis evident in neuronal cells in vivo. Three types of apoptotic 
cell death were induced in a human neuroblastoma cell line: 
(i) Classic mitochondria-mediated apoptosis was induced by the PKC inhibitor 
staurosporine; 
(ii) Chronic deprivation of serum was used to induce apoptosis associated with the 
withdrawal of survival signals, which include protein kinase signalling and up-regulation 
of pro-apoptotic genes; 
(iii) Mitochondrial complex I inhibition by rotenone was used to induce cell death that is 
associated with mitochondrial dysfunction and mimic the cell death observed in PD.  
The role of MAO in these death processes was investigated by monitoring the levels of 
MAO mRNA, protein and catalytic activity. To uncover the mechanisms by which MAO 
may be involved in cell death, MAPK signalling pathways, Bcl-2 levels, ROS levels and 
caspase activation were examined in the presence and absence of two unrelated MAO 
inhibitors.  
The second approach was to study the effects of MAO overexpression and knockdown in 
human neuroblastoma cells. The MAO status and general viability of the transfected cells 
was assessed and cell growth, ROS production, caspase activity and MAPK/apoptotic 
signalling components were monitored to verify the relevance of MAO in these cellular 
processes. 
Finally, neuroblastoma clones with stable alterations in MAO expression were exposed to 
the three apoptotic inducers (described above) to confirm the role of MAO in different 
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MATERIALS AND METHODS 
2.1. MATERIALS 
Materials are listed with the company from which they were purchased. 
2.1.1 Cell culture 
2.1.1.1 Reagents 
Dulbecco’s Modified Eagles Medium (DMEM), Hank’s buffered salt solution (HBSS), 
foetal bovine serum (FBS), penicillin/streptomycin, L-glutamine and trypsin-versene 
solution, all from Cambrex Biosciences (now Lonza), Berkshire, U.K. 
DMEM/Ham’s F12 medium, Roswell Park Memorial Institute (RPMI) – 1640 medium, 
MEM non-essential amino acid solution and 0.4 % (v/v) trypan blue solution, all from 
Sigma-Aldrich Chemical Company, Poole, UK. 
G418 sulphate (50mg ml-1), Blasticidin (50 mg) and 1 X Dulbecco’s PBS (without Ca and 
Mg) from PAA Laboratories, Pasching, Austria. 
2.1.1.2 Plastic ware 
All plastic ware was supplied by Starstedt, Nümbrecht, Germany, except cryo-vials and 
Lab-Tek CC chamber slides which were purchased from NUNC, Rosklide, Denmark.  
2.1.2 General laboratory reagents 
All laboratory reagents were of the highest quality and purchased from Sigma-Aldrich 
Chemical Company, Poole, U.K, unless otherwise stated. 
2.1.3 Specialised laboratory reagents 
Specialised laboratory reagents are listed and were purchased from Sigma Aldrich 
Chemical Company, Poole, U.K unless otherwise stated. 
1-methyl-4-phenyl pyridinium iodide (MPP+), 2’, 7’-Dichlorodihydroflourescein diacetate 
(DCDHF, Alexis Biochemicals, Nottingham, U.K), 3-(4, 5-dimethylthiazol-2-yl)-2, 5-
diphenyltetrazolium bromide (MTT), 3, 3’-Diaminobenzidine (DAB). 3-[(3-
Cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS). 3MM 
chromatography paper (Fisher Scientific, Leicestershire), UK. 5-bromo-4-chloro-3-indolyl-
phosphate (di-sodium salt) (BCIP, Melford Laboratories Ltd, Ipswich, UK) and 14C-
labelled tyramine hydrochloride.  
(A) Acetyl-Asp-Glu-Val-Asp-7-amido methyl Coumarin. Acrylogel 3 solution Electran 
(containing 2.5 % NN’-methylenebisacrylamide, final ratio 29:1:0.9 (VWR International 
Ltd, Poole, UK), all-trans Retinoic acid. ascorbic acid (vitamin C). 
(B) BCA protein assay reagent. Bio-Rad protein assay dye reagent concentrate (Bio-Rad 
Laboratories Ltd, Hemel Hempstead, UK).  
(C) Caspase-8 fluorogenic assay kit (Calbiochem, Nottingham, U.K).  
(D) Dimethylsulfoxide (DMSO, Fisher Scientific UK Ltd, Loughborough, UK), 
Dithiothreitol (DTT, Melford Laboratories Ltd, Ipswich, UK), 3-hydroxytyramine [3,4-
Dihydroxyphenethylamine (dopamine)] and Dual colour precision plus protein standards, 
(Bio-Rad Laboratories, CA, U.S.A). 
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(E) ECL Western blotting detection reagents (Amersham Pharmacia Biotech UK Ltd, 
Bucks, UK).  
(F) Folin and Ciocalteu’s phenol reagent (Fisher Scientific UK, Leicestershire, UK) and 
FluroMAO monoamine oxidase A and B detection kit (Cell Technology Inc, Mountain 
view, CA, U.S.A).  
(G) GBX developer/replenisher, GBX fixer/replenisher. 
(I) Igepal CA-630 and Interleukin-4 (IL-4) human cytokine (PeproTech, New Jersey, 
U.S.A). 
(L) Levodopa-carbidopa (Sinemet®) was a kind gift from Bristol Myers-Squibb, New 
York, U.S.A. 
(M) MitoQ was a kind gift from Michael Murphey, University of Cambridge, U.K. 
Mitotracker (Molecular probes, Invitrogen, Karlsruhe, Germany) and MPP+ Iodide. 
(N) N-acetylcysteine (NAC), Nitro Blue Tetrazolium (NBT, Melford Laboratories Ltd, 
Ipswich, UK) and Nitrocellulose (0.22 µM pore size, Genetic Research Instrumentation, 
Essex, UK). 
(P) Phenylmethylsulfonyl fluoride (PMSF), Pre-stained SDS molecular weight standard 
markers (SDS-7B), Protease inhibitor cocktail (for use with mammalian cell and tissue 
cultures) and Protein-G sepharose fast flow (recombinantly expressed in E. coli).  
(R) Rotenone  
(T) TNFα (210-TA-010/CF) Human tumour necrosis factor alpha was purchased from R 
and D Systems, Abingdon, U.K.  
(S) Sodium-orthovanadate. 
(V) Vectashield mounting medium and Vectashield mounting medium with propidium 
iodide (Vector Laboratories Ltd, Peterborough, UK). 
(X) XAR-5 Kodak film. 
2.1.4 MAO inhibitors 
• Clorgyline 
• L-Deprenyl 
• Moclobemide was a kind gift from F. Hoffmann-La Roche Ltd, Basel, Switzerland 
2.1.5 Kinase inhibitors 
• CEP-11004 mixed lineage kinase inhibitor, Cephalon Inc, Frazer, U.S.A. 
• PD98059 MEK inhibitor, Calbiochem, Nottingham, U.K. 
• SB202190 p38 MAPK inhibitor, Calbiochem, Nottingham, U.K. 
• Staurosporine, Sigma Aldrich Chemical Company, Poole, U.K. 
2.1.6 Antibodies 
2.1.6.1 Primary antibodies 
Anti-ERK 1 (K-23) antibody, Anti-phospho ERK 1/2 (E-4) antibody, Anti-phospho JNK 
(G-7) antibody, Santa Cruz Biotechnology, California, U.S.A 
Monoclonal Bcl-2 antibody (clone Bcl-2-100), SAPK/JNK, c-jun, Cleaved caspase-3 
(Asp175-clone 5A1), PARP (Cat #9542) and phospho p38 (Thr180/Tyr182, Cat #9211) 
were all purchased from Cell Signalling Technologies, MA, U.S.A. 
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Total p38 antibody, New England Biolabs, Ipswich, MA, U.S.A 
Caspase-8 mouse monoclonal antibody (clone 1-1-37), caspase-9 mouse monoclonal 
antibody (clone 962-22), Anti-Fas (clone CH11) human activating monoclonal antibody, 
Upstate Biotechnology (now part of Millipore), MA, U.S.A. 
Cytochrome c oxidase 1 (C-20), cytochrome c (7H8), GAPDH (6C5), Santa Cruz 
Biotechnology Inc, CA, U.S.A. 
2.1.6.2 Secondary antibodies 
Purchased from DAKO Ltd, Cambridge, U. K. 
• Goat anti-mouse immunoglobulins alkaline phosphatase conjugated  
• Goat anti-mouse immunoglobulins horseradish peroxidase conjugated  
• Goat anti-rabbit immunoglobulins alkaline phosphatase conjugated  
• Goat anti-rabbit immunoglobulins horseradish peroxidase conjugated  
• Rabbit anti-mouse immunoglobulins FITC conjugated 
• Rabbit anti-mouse immunoglobulins TRITC conjugated 
Donkey Anti-goat immunoglobulins TRITC-conjugated was purchased from Molecular 
probes, Invitrogen, Karlsruhe, Germany. 
2.1.7 Molecular biology 
2.1.7.1 Reagents 
Purchased from Sigma Aldrich Chemical Company, Poole, U.K unless otherwise stated. 
100 bp DNA ladder and 1kb DNA ladder (Promega, Southampton, U.K). 
(A) Advantage 2 polymerase kit (Takara Bio Europe, St-Germain, France). Ampicillin 
ready made solution (100 mg/ ml). 
(C) Competent bacterial cells (TOP10, Invitrogen, Karlsruhe, Germany) and (XL1, 
Stratagene, CA, U. S. A). 
(D) Deoxynucleotide triphosphates (dNTPs, Promega, Southampton, U.K). 
(L) Miller LB Agar (Miller) Miller LB Broth (Miller) 
(O) Oligonucleotides were purchased from Biotez, Berlin, Germany, Invitrogen, 
Karlsruhe, Germany and Sigma Aldrich Chemical Company, Poole, U.K. Oligo (dT)15 was 
purchased from Promega (Southampton, U.K). 
(R) RNAsin (Promega, Southampton, U.K), RNAse Zap and RNAse OUT riboneclease 
inhibitor (Ambion, Austin, U.S.A). 
(S) Superscript II reverse transcriptase (Invitrogen, Karlsruhe, Germany), Sybr green 
supermix (Bio-Rad Laboratories, CA, U.S.A). 
(T) TURBO DNA free and Tri Reagent (Ambion, Austin, U.S.A). 
(V) Vectors pCR2.1 and pcDNA3.1(-) Invitrogen  were a kind gift from Harmut Kuhn’s 
laboratory, University Medicine Berlin-Charité, Berlin, Germany.  
2.1.7.2 Restriction enzymes 
Bam HI, Bss HII and Eco RI were purchased from Promega, Southampton, U.K. 
Hind III, Msc I, Bgl II, Not I, Sal I, Spe I and Xho I were purchased from New England 
Biolabs, Ipswich, MA, U.S.A. 
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2.1.7.3 Kits 
RNeasy Mini kit, Qiashredder, Qiaprep spin miniprep kit, Qiagen plasmid Midi kit, 
Qiaquick gel extraction kit, DNeasy tissue kit,  and Qiaquick PCR purification kit were all 
purchased from Qiagen, Hilden, Germany. 
BLOCK-iT Pol II miR RNAi Expression Vector Kit and TOPO TA Cloning kit were 
purchased from Invitrogen, Karlsruhe, Germany. 
Cell line Nucleofector Kit V was purchased from Amaxa GmbH, Cologne, Germany.  
2.1.8 Specialised equipment 
• Aida Software, Raytest GmbH, Straubenhardt, Germany. 
• ATTO HorizBlot, ATTO corporation, Japan. 
• Biometra Agagel, standard horizontal gel electrophoresis apparatus, Thistle 
Scientific, Glasgow, U.K. 
• Bio-Rad mode 680 microplate reader, Bio-Rad Laboratories, CA, U.S.A. 
• Bio-Rad Power Pac 300, Bio-Rad Laboratories, CA, U.S.A. 
• Bio-Rad Trans-Blot electrophoretic transfer system, Bio-Rad Laboratories, CA, 
U.S.A. 
• Fluorescence/Luminometer, MWG Biotechnology,  
• GeneTools/GeneSnap gel analysis/quantification system, Syngene, Cambridge, 
UK. 
• iCycler Real time PCR machine, Bio-Rad Laboratories, CA, U.S.A.  
• iCycler Real time PCR Quantification Software, Bio-Rad Laboratories, CA, U.S.A. 
• LAS-3000 image analyser, Fuji Film Co. Ltd., Tokyo, Japan. 
• Leica CLSM confocal laser microscope, Leica, Germany. 
• MC6 centifuge 230V including rotor, strip rotor and adapter sets, Starstedt, 
Nümbrecht, Germany. 
• MIKRO 22R microfuge, Hettich, Germany. 
• Mini-PROTEAN II system, Bio-Rad Laboratories, CA, U.S.A. 
• NEB Cool cooling rack, New England Biolabs, Ipswich, MA, U.S.A. 
• Nikon Digital Net camera DN100, Nikon, Japan. 
• Nikon Eclipse TS 100 inverted microscope, Nikon, Japan. 
• Nucleofector™ device, Amaxa GmbH, Cologne, Germany.  
• PCR cap strips (ultra clear, strips of 8) and PCR tubes (ultra clear, strips of 8) were 
purchased from Bioline, London, U.K.  
• Pharmacia electrophoresis power supply EPS 500/400, Pharmacia, UK. 
• Sanyo Incubators 
• Shakers for bacteria 
• Shakers for blots 
• Sanyo Harrier 18/80 refridgerated centrifuge, Sanyo Gallenkamp PLC, 
Leicestershire, UK. 
• Soniprep 150, MSE scientific instruments, UK. 
• Walker class II microbiological safety cabinet, Walker safety cabinets Ltd, 
Derbyshire, UK. 
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2.2. TISSUE CULTURE METHODS 
2.2.1 Cell culture 
Wild type human SH-SY5Y neuroblastoma cells were purchased from The European 
Collection of Animal and Cell Cultures (ECACC), which were characterised in our 
laboratory by Dr Katy Beck and referred in her PhD thesis (K. E. Beck, 2004) as ‘ECACC 
new clone’. In this work the ECACC new clone cells will now be referred to as SH-SY5Y 
or wild type SH-SY5Y. Hybridoma cells secreting anti-MAO-A antibody 6G11-E1 and 
anti-MAO-B antibody 5A11-2F4 were made in the laboratory of Prof. Ellen Billett. Human 
U937 cells were a kind gift from the laboratory of Prof. Hartmut Kuhn, University 
Medicine Berlin-Charité, Berlin, Germany. Stably transfected SH-SY5Y clones that were 
routinely used in this work are referred to as mock (clone 2D8), MAO-A+ (clone 1A9), 
neg (clone 2G11) and MAO-A- (clone 10D8L).  
2.2.1.1 Maintenance of SH-SY5Y cells 
Cell culture was carried out in a class II safety cabinet using aseptic techniques. Cells were 
cultured in 25 cm2 (T25), 75 cm2 (T75) and 175 cm2 (T175) flasks in Dulbecco’s Modified 
Eagles Medium (DMEM) HAMs-F12 containing 10% (v/v) foetal bovine serum, 2mM Ŀ-
glutamine, 1% (v/v) non-essential amino acid solution, 100 U/mL penicillin and 100 
µg/mL streptomycin at 37°C in a 5% CO2 humidified atmosphere until 70-90 % confluent.  
2.2.1.2 Sub-culture of SH-SY5Y cells 
Growth medium was removed and the cell monolayer rinsed twice with Dulbecco’s PBS to 
remove traces of serum. Cells were detached using trypsin (100 µg/ml)/versene (40 µg/ml) 
in Dulbecco’s PBS at 37°C. Growth medium ten times the volume of trypsin solution was 
added to quench the action of trypsin. The suspension was centrifuged at 300 × g for five 
minutes. Supernatant was removed and the pellet resuspended in 1 ml fresh growth 
medium. A volume of cell suspension (depending on requirement) was transferred to an 
appropriate sterile flask containing fresh growth medium and incubated as described in 
section 2.1.1.1.  
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2.2.1.3 Viable cell counting and seeding 
A 1:10 dilution of cell suspension, prepared during sub-culture was made in trypan blue 
solution 0.4% (v/v). A cell count was performed in four fields (each 1 mm2) on a 
haemocytometer (0.1 mm depth chamber) using light microscopy. Cell number was 
calculated as follows: 
Cell number / ml = mean cell number × 104 × dilution factor 
Once the required number of cells was seeded, cells were incubated as described in 2.1.1.1.  
2.2.1.4 Cryo-preservation of cells 
Cells underwent long-term storage in the vapour phase of liquid nitrogen in freezing 
medium containing, 95 % (v/v) foetal bovine serum and 5 % (v/v) sterile dimethyl 
sulfoxide (DMSO). Two million cells were pelleted by centrifugation at 300 × g for 5 
minutes, the supernatant discarded and the pellet resuspended in 1 ml of freezing medium 
and transferred to a cryovial (on ice). The vial was then rapidly transferred to a -70°C 
freezer overnight before transferring to liquid nitrogen storage for the long term. 
2.2.1.5 Resuscitation of cryo-preserved cells 
Cells inside the cryovial were thawed rapidly in a 37°C water bath and immediately 
transferred to a sterile tube containing 10 mL fresh growth medium. The cell suspension 
was centrifuged at 300 × g for 5 minutes. Supernatant was removed and the cell pellet 
resuspended in 1 ml fresh growth medium (using a Pasteur pipette) before transfer to a T25 
flask containing growth medium and incubated as described in section 2.1.1.1. 
2.2.1.6 Hybridoma cells 
Hybridoma cells were routinely maintained as described above for SH-SY5Y except the 
growth medium was RPMI-1640. Hybridoma cells do not require trypsin for detachment 
from the flask; instead they are detached by gentle squirting of media down the monolayer. 
For collection of antibody, dead cells in suspension were centrifuged at 300 × g for 5 
minutes and the supernatant only (which contains the antibody) is kept in a sterile 
container at + 4 °C.  
 Chapter 2                                                                                                                          Materials and Methods 
40 
2.2.1.7 Mock /2D8 and MAO-A+/1A9 stably transfected SH-SY5Y cells 
Stable transfection with pcDNA3.1(-) vector confers resistance to the antibiotic G418 
sulphate (geneticin), which is required in the growth medium at all times. The correct 
concentration of G418 sulphate was determined (see appendix) and used at a final 
concentration of 700 µg/ml in SH-SY5Y growth medium. Cells were maintained as 
described for SH-SY5Y with the exception of the addition of G418 sulphate in the growth 
medium. It is not necessary to have G418 sulphate in media used for sub-culturing. 
2.2.1.8 Neg/2G11) and MAO-A-/10D8 stably transfected SH-SY5Y cells 
Transfection with Pol II miR RNAi expression vectors confers resistance to the antibiotic 
blasticidin. Therefore, blasticidin is required in the growth medium at all times. The correct 
concentration of blasticidin was determined (see appendix) and used at a final 
concentration of 6 µg/ml in SH-SY5Y growth medium. Cells were maintained as described 
for SH-SY5Y with the exception of the addition of blasticidin in the growth medium. It is 
not necessary to have blasticidin in media used for sub-culturing. 
2.3. BIOCHEMICAL METHODS 
2.3.1 Assessment of cell viability 
2.3.1.1 MTT reduction assay 
MTT is a substrate that is taken up by cells and reduced by mitochondrial and endoplasmic 
reticulum dehydrogenase enzymes, to yield a purple formazan product that accumulates 
within cells depending on cell integrity (Cookson et al. 1995). Cells were seeded in 96-
well plates at a density of 20,000 cells/well and grown to 70-80 % confluence. MTT stock 
solution in PBS was added to each well to give a final concentration 0.5 mg/ml and 
incubated for 30 min. The media containing the MTT was removed and the formazan 
crystals solubilised in 100 µl of dimethylsulfoxide (DMSO) and absorbance measured at 
595 nm with a microtitre plate reader.  
2.3.1.2 Trypan blue exclusion assay (estimation of viable cell number for sub-culture) 
Trypan blue is taken up by dead cells (where the cell membrane is no longer intact) where 
it stains the cytoplasm, causing the cells to shine blue when observed by light microscopy. 
Viable cells however, exclude trypan blue and remain colourless (or white) and can be 
counted using a haemocytometer (see cell counting, page 39).  
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2.3.1.3 Trypan blue exclusion assay (For estimation of viable cell number following 
treatment with apoptotic inducers) 
Growth medium following treatment was removed and kept to one side in a sterile tube. 
The remaining cells were detached by trypsinisation and transferred to the tube containing 
the floating cells. The cell suspension was centrifuged at 300 × g for 5 minutes, the 
supernatant discarded and the cell pellet resuspended in 1 ml growth medium. A small 
aliquot of this cell suspension was transferred to a sterile 1.5 ml tube containing a volume 
of trypan blue solution (0.4 % [v/v]). Cells were counted in a haemocytometer chamber as 
described in section 2.1.1.3. Cell counts were performed on at least two independent cell 
populations exposed to the same treatment conditions for each experiment.  
2.3.1.4 Trypan blue exclusion assay (For estimation of viable cell number from 24-well 
plates for cell growth studies) 
A cell count was performed as described in section 2.2.1.3 and 100,000 cells seeded per 
well of a 24 well plate in duplicate. The original cell suspension was then re-counted for 
accuracy. At each time point, the medium was removed from each well and the monolayer 
rinsed with Dulbecco’s PBS. 100 µl trypsin (100 µg/ml)/versene (40 µg/ml) in Dulbecco’s 
PBS at 37°C was added to detach the cells (with gentle squirting down the monolayer). 
The action of trypsin was quenched with 1 ml growth medium and the cell suspension 
transferred to a sterile Eppendorf tube. The cells were pelleted by centrifugation at 300 × g 
for 5 minutes. The supernatant was discarded and the cell pellet resuspended in 50 µl of 
trypan blue solution (0.5 % trypan blue solution diluted 1:1 with growth medium). Viable 
cells in the cell suspension were counted in a haemocytometer chamber as described in 
section 2.1.1.3. The total number of viable cells per well at each time point were plotted on 
a graph as cell number ±S.D. To calculate doubling time the following equation was 
applied: 
 
Where t2 is the time (in hours) at point two on the linear part of the graph, t1 is the time (in 
hours) at point one on the linear part of the graph, q2 is the cell number at time point 2, q1 
is the cell number at time point 1 (Jones et al. 1998). 
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2.3.1.5 ATP assay 
The ViaLight HS kit is based upon the measurement of ATP by luminescence, utilising the 
luciferase enzyme which catalyses the formation of light from ATP and luciferin. Cells 
were cultured in 96-well plates and once confluent, assayed for ATP levels according to 
the manufacturer’s instructions. ATP standards were prepared in the range of 0.5-5000 
pmoles/assay and results were expressed as mean ATP pmoles/ µg total protein ± S.D. 
2.3.2 Treatment of SH-SY5Y cells 
SH-SY5Y cells were treated with a number of toxins and other reagents alongside an 
appropriate control. Experimental conditions are described in figure captions in the results 
chapters. For quick reference, details of routinely used treatments are listed below in Table 
2. 1. 

































GM Dopamine 500 µM 1-72 h 24-48 h 
BSO 






















ylcypromine 1 µM 






alone NAC/Vit C 1 mM N/A N/A 
Table 2. 1. Details of commonly used experimental treatments in this thesis 
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2.3.3 Cell extraction 
Following the experimental period, treatment medium was poured into a sterile centrifuge 
tube (as it may contain apoptotic cells that are no longer attached to the monolayer), the 
monolayer rinsed using sterile PBS or DMEM and the adherent cells removed by 
trypsinisation. Trypsinised cells were quenched with growth media and combined with the 
treatment medium (containing floating cells). The cell suspension was centrifuged for 5 
minutes at 300 × g. The supernatant was discarded and the cell pellet washed by re-
suspending it in 1 ml sterile PBS, transferred into a sterile 1.5 ml tube and re-centrifuged 
for 5 minutes at 300 × g. The supernatant was discarded and any remaining supernatant 
around the cell pellet removed using a 20-200 µl pipette. The cell pellet was stored at -
20°C (short term) and -80°C (long term). 
2.3.4 Estimation of total protein in cell extracts 
The protein content of samples was estimated by one of three methods, depending on 
compatibility of the constituents of the buffer that the samples remain in following assay.  
2.3.4.1 Mini Lowry 
This Lowry method (Lowry et al. 1951) is based on Biuret and Folin and Ciocalteau 
reactions. Interference can occur with a number of substances (importantly detergents) and 
the method has a limited pH range (strong acids interfere). 
A calibration graph was obtained using bovine serum albumin (BSA) as standard protein 
0-100 µg. Protein standards and test samples were diluted appropriately to a final volume 
of 100 µl (where both standards and sample contain the same amount of the buffer that 
then sample is resuspended in). The working Lowry reagent was freshly prepared on the 
day as 2 % (w/v) NaCO3, 1 % (w/v) CuSO4, 2.7 % NaK tartrate in 0.1 M NaOH. 1 ml of 
working Lowry reagent was added to each standard and sample, mixed and incubated at 
room temperature (RT) for 15 min. 100 µl Folin and Ciocalteau reagent (diluted 1:1 with 
distilled water, dH2O) was added, mixed and incubated at RT for a further 30 min. The 
solutions were mixed again and the absorbencies measured spectrophotometrically on a 
multi-plate reader at 750 nm.  
2.3.4.2 Bio-Rad protein assay 
The Bio-Rad protein assay is based on the Bradford method, a colorimetric protein assay, 
where an absorbance shift in the coomassie dye changes from red to blue upon binding of 
the protein. The main advantages of the Bio-Rad assay are it is less susceptible to 
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interference from detergents (SDS ≤ 0.1 %, Triton X-100 ≤ 0.1%). The disadvantages 
however, are that the assay is linear over a shorter range of protein concentration and 
therefore samples may need to be diluted several times to make sure that the sample is 
within the range of the linear calibration graph. The Bio-Rad assay was performed in 
accordance with the manufacturer’s instructions.  
2.3.4.3 Bicinchoninic acid assay 
The bicinchoninic acid assay (BCA) is based on the Lowry and Bradford method (Smith et 
al. 1985). The main advantage of the method is its compatibility with many chemicals and 
detergents. The BCA assay was performed according to the manufacturer’s instructions 
(Sigma Aldrich Chemical Company, Poole, U.K).  
2.3.5 Biochemical Assays 
2.3.5.1 Caspase-3 fluorogenic assay 
Caspase-3 activity was monitored using a fluorescence-based assay with Ac-DEVD-AMC 
as substrate. 500,000 cells were seeded in 25 cm2 flasks. On reaching 70-80% confluence, 
the cells were treated for the appropriate times for each experimental condition. Following 
treatment cell were harvested as described in section 2.2.4. Cell pellets were resuspended 
in 200-300 µl lysis buffer (50 mM HEPES, 5mM CHAPS and 5 mM DTT, pH 7.4) and 
incubated on ice for 20 min. The lysates were centrifuged at 200g at 4°C for 5 min to 
remove cell debris. The assay was prepared in triplicate. 30 µl of cell lysate was transferred 
to a black 96-well plate and made up to 80 µl with assay buffer (20 mM HEPES pH7.4, 
0.1% [w/v] CHAPS, 5 mM DTT and 2mM EDTA). Reactions were initiated by the 
addition of Ac-DEVD-AMC to a final concentration of 200 µM in a total reaction volume 
100 µl. Fluorescence was measured (excitation 450 nm and emission 360 nm) every 5 min 
for 3 h at 37°C. Data were normalised for protein content, which was determined by the 
Lowry method and expressed as ∆ fluorescence units/min/µg total protein.  
2.3.5.2 Monoamine oxidase activity assay 
2.3.5.2.1 Radioassay 
Monoamine oxidase activity was monitored using a radiometric assay with 14C-labelled 
tyramine hydrochloride as substrate, based on the method of Russell and Mayer (Russell 
and Mayer, 1983) with modifications. Treated cells were harvested as described in section 
2.2.4 and the pellet resuspended in 200 µl potassium phosphate buffer (20 mM K2HPO4, 
20 mM KH2PO4, pH 7.4) and 30 µl aliquots transferred to scintillation vials, in triplicate. 
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Samples were made up to 200 µl with potassium phosphate buffer and then incubated at 
37°C for 5 min. Sample blanks were prepared in parallel containing, in addition, 200 µl 0.5 
M HCl. To each sample 20 µl 1 mM 14C-labelled tyramine hydrochloride (1 mCi/mmol) 
was added and incubated for 1 h at 37°C. The reaction was stopped by the addition of 200 
µl 0.5 M HCl. Finally, 3 ml scintillant (1:1 Ethyl acetate: toluene, 1 % [w/v] PPO) was 
added to each vial, and a sample of the organic phase containing the product transferred 
into a scintillation vial. MAO activity was measured in a liquid scintillation counter 
(Cambera-Packard, Schwadorf, Germany). Preliminary assays were undertaken to ensure 
that MAO activity was linear beyond the 1 h time point. Data were normalised for protein 
content, which was determined either by the Lowry method (Lowry et al. 1951) or BCA 
method and rates expressed as pmoles/min/mg protein. 
2.3.6 Immunohistochemistry 
Human liver sections (4 µm) fixed in 2 % (v/v) para-formaldehyde in PBS for 4 h, cryo-
protected in 15 % sucrose solution for 72 h and incubated at -20ºC for 20 min, were 
permeabilised with 0.5 % (v/v) Triton X-100 in PBS for 5 min at room temperature then 
washed in PBS. Slides were blocked for 20 min with 20 % (v/v) normal swine serum in 
PBS and then incubated overnight in monoclonal antibody, anti-MAO-A (6G11-E1) or 
anti-MAO-B (3F12-G10-2E3) (tissue culture supernatants), or PBS as a negative control at 
room temperature. The slide was washed in PBS and then incubated with secondary 
antibody; horseradish peroxidase conjugated anti-mouse immunoglobulin G (dilution 
1:100) in 5 % v/v normal swine serum in PBS for 30 min at room temperature. The slide 
was washed in PBS and antibody binding revealed by incubation in DAB substrate for 40 
min and stopped with excessive washing in cold water. 
2.3.7 Immunocytochemistry 
SH-SY5Y cells grown on Lab-Tek (NUNC, Rosklide, Denmark) chamber slides were 
fixed in 90 % (v/v) ice cold methanol in TBS and incubated at -20ºC for 20 min, were 
permeabilised with 0.5 % (v/v) Triton X-100 in PBS for 5 min at room temperature then 
washed in PBS. Slides were blocked for 20 min with 20 % (v/v) normal swine serum in 
PBS and then incubated overnight in monoclonal antibody, anti-MAO-A (6G11-E1) or 
anti-MAO-B (3F12-G10-2E3) (tissue culture supernatants), or PBS as a negative control at 
room temperature. The slide was washed in PBS and then incubated with secondary 
antibody; horseradish peroxidase conjugated anti-mouse immunoglobulin G, followed by 
DAB as described in 2.3.6.  
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2.3.8 Immunofluorescence 
SH-SY5Y cells grown on Lab-Tek (NUNC, Rosklide, Denmark) chamber slides were 
fixed in 90 % (v/v) ice cold methanol in TBS and incubated at -20ºC for 20 min, were 
permeabilised with 0.5 % (v/v) Triton X-100 in PBS for 5 min at room temperature then 
washed in PBS. Slides were blocked for 20 min with 20 % (v/v) normal swine serum in 
PBS and then incubated overnight in primary antibody (for dilution of primary antibody 
for immunocytochemistry, see vendors recommendation), or PBS as a negative control at 
room temperature. The slide was washed in PBS and then incubated with secondary 
antibody; FITC/TRITC-conjugated anti-mouse, rabbit or goat immunoglobulin G (dilution 
1:1000) in 5 % v/v normal swine serum in PBS for 30 min at room temperature. The slide 
was washed in PBS and air dried. Slides were mounted using Vectashield (with or without 
propidium iodide) and antibody binding revealed by confocal microscopy.  
2.3.9 Detection of ROS 
2.3.9.1 Short term treatments (e. g. STS) 
Cells were grown to ~70-80 % confluence on Lab-Tek (NUNC, Rosklide, Denmark) 
chamber slides prior to pre-treatment for 2 h with antioxidants or inhibitors if required. 
Media were removed and replaced with DMEM containing 100 µM DCDHF and 
incubated at 37°C for 50 min. Following incubation the dye was removed and replaced 
with Hanks buffered salt solution (HBSS) alone or HBSS + treatment. Changes in DCDHF 
fluorescence were immediately monitored using a Leica CLSM inverted confocal laser 
scanning microscope. Increase in cytosolic dichloro-fluorescein (DCF) fluorescence 
reflected elevated intracellular ROS production. Images in each independent experiment 
were taken using the same laser power, gain and objective. 
2.3.9.2 Long term treatments (e.g. serum withdrawal/ rotenone) 
Cells were grown to ~50 % confluence on Lab-Tek (NUNC, Rosklide, Denmark) chamber 
slides prior to treatment for the required time (in the presence or absence of antioxidants or 
inhibitors). Media were removed and replaced with DMEM containing 100 µM DCDHF 
and incubated at 37°C for 50 min. Following incubation the dye was removed and replaced 
with HBSS alone or HBSS + original treatment. Changes in DCDHF fluorescence 
(Excitation 502 nm, Emission 523 nm) were immediately monitored using a Leica CLSM 
inverted confocal laser scanning microscope. Increase in cytosolic dichloro-fluorescein 
(DCF) fluorescence reflected elevated intracellular ROS production. Images in each 
independent experiment were taken using the same laser power, gain and objective. 
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2.3.10 Mitotracker 
Mitotracker Red CMXRosamine (Molecular Probes, Invitrogen, Karlsruhe, Germany) is a 
specialised dye taken up by active mitochondria and can be used for live confocal 
microscopy, but also remains in fixed cells and can be used for conventional confocal 
microscopy. For live confocal microscopy, Mitotracker was added to each well in DMEM 
at a final concentration of 100 nM and incubated at 37°C for 30 min. The medium 
containing the Mitotracker was removed and replaced with HBSS either alone or 
containing treatment. Mitotracker fluorescence (Excitation 579 nm, Emission 599 nm) 
were immediately monitored using a Leica CLSM inverted confocal laser scanning 
microscope. Images in each independent experiment were taken using the same laser 
power, gain and objective. 
2.3.11 Gel electrophoresis and Western blotting 
Cells were extracted into extraction buffer (50 mM Tris, 5 mM EDTA, 150 mM NaCl, 1 
mM sodium orthovanadate, 2 mM PMSF, 1 % [w/v] SDS, and 0.2 % [v/v] protease 
inhibitor cocktail) and immediately boiled for 5 min. Equal protein aliquots (80-100 µg for 
analysis of MAPK proteins and 20 µg for all others proteins) per sample were subjected to 
electrophoresis on a 12 % (v/v) SDS-polyacrylamide gel. Separated proteins were 
transferred onto a nitrocellulose membrane and equal protein loading assessed by staining 
with 0.05 % (w/v) copper phthalocyanine in 12 mM HCl, checked by immunodetection of 
total ERK, total JNK or total P38. Blotted membranes were blocked for 1 h in either 3-5 % 
(w/v) dried skimmed milk (depending on primary antibody, method may vary, see vendors 
recommendations) in TBS or PBS containing 0.1 % (v/v) Tween-20 and incubated 
overnight at 4°C with primary antibody diluted in 3-5 % (w/v) dried skimmed milk (Due to 
the presence of phosphatases in milk, all phospho protein primary antibodies were diluted 
in 3-5 % [w/v] BSA). Membranes were washed and incubated for 2 h at room temperature 
with peroxidase-conjugated anti-mouse or anti-rabbit immunoglobulin G (dilution 1:1000). 
Antibody binding was revealed with the ECL Western blotting detection reagent (Pierce, 
Rockford, Illinois, and U.S.A). Digital images were captured using a LAS-3000 image-
analyser (Fuji Film Co. Ltd., Tokyo, Japan), and band intensity quantified using Aida 
software (Raytest GmbH, Straubenhardt, Germany). 
2.3.12 Dot blotting 
Treated cells were harvested as described in section 2.2.4 and resuspended in 150 µl MAO 
extraction buffer (50 mM Tris, 150 mM NaCl, 5 mM EDTA, 1 mM Na orthovanadate, 0.5 
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% [w/v] Triton X-100, 2 mM PMSF and 0.2 % [v/v] protease inhibitor cocktail) and 
incubated on ice for 20 min. Samples were centrifuged for 10 min at 300×g at 4°C. The 
supernatants were sonicated (3× 3 second pulses at 60 Hz). Equal protein samples, in 
triplicate, were loaded onto a Dot blot manifold and bound to a nitrocellulose membrane 
filter. Membranes were blocked for 1 h in 3 % (w/v) dried skimmed milk in TBS 
containing 0.1 % Tween-20 and incubated overnight in monoclonal antibody anti-MAO-A 
6G11-E1 (tissue culture supernatant) at 4°C. Membranes were washed and incubated for 2 
at room temperature with phosphatase-conjugated anti-mouse immunoglobulin G (dilution 
1:1000). Antibody binding was revealed in substrate buffer (0.75 M Tris, pH 9.5) 
containing 0.13 mM nitroblue tetrazolium and 0.29 mM bromochloroindolyl phosphate. 
Digital images were captured using a LAS-3000 image-analyser (Fuji Film Co. Ltd., 
Tokyo, Japan), and band intensity quantified using Aida software (Raytest GmbH, 
Straubenhardt, Germany). 
2.4. MOLECULAR BIOLOGY METHODS 
Basic methods used in molecular biology, such as purification of nucleic acids, assays of 
nucleic acid concentration in solution, agarose gel electrophoresis, ligation and 
transformation have been achieved using standard methods provided by the manufacturer. 
Sequencing was carried out by MWG Biotechnology.  
2.4.1 Preparation of RNA and reverse transcription 
For monitoring of MAO mRNA expression, SH-SY5Y cells were harvested as described in 
section 2.3.3, homogenised using Qiashredder (Qiagen, Hilden, Germany) and RNA 
isolated using the RNeasy mini kit (Qiagen, Hilden, Germany). DNase digestion when 
required was performed using the TURBO DNAfree kit (Ambion, Austin, U.S.A) 
according to the manufacturer’s instructions.  
The conversion of the resulting RNA into cDNA was carried out by reverse transcription 
using the M-MLV (Moloney murines Leukaemia-Virus) reverse transcriptase (Superscript 
II, Invitrogen, Karlsruhe, Germany). RNA was denatured for 5 min at 70°C and cooled 
immediately on ice. The reverse transcription reaction was started as follows: 1-3µg total 
RNA; 50 mM Tris-HCL, pH 8.2; 8 mM MgCl2; 1 mM DTT; 100 µg/ml BSA; 30 units 
RNasin; 0.166 mM dNTPs; 150 mM Oligo-dT15-primer and 50 units Superscript II reverse 
transcriptase. The reaction was incubated for 90 minutes at 37°C and finally deactivated at 
70°C for 15 min. 
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2.4.2 Real-Time-PCR (qRT-PCR) 
Primer Sequence 5’-3’ Fragment size 
GAPDH 
       GAPDH-forward 
       GAPDH-reverse 
 
CCA TCA CCA TCT TCC AGG AGC GA 




       MAO-A-forward 
       MAO-A-reverse 
 
GCC CTG TGG TTC TTG TGG TAT GT 
TGC TCC TCA CAC CAG TTC TTC TC 
 
368 bp 
Table 2. 2 Primer combinations used for qRT-PCR 
Real time PCR allows the quantification of DNA molecules in a given sample. The 
kinetics of DNA amplification were measured by continuously measuring the fluorescence 
intensity of a dye (Sybrgreen) that intercalates with double stranded DNA as it is being 
synthesised. Quantification of DNA was obtained on a Bio-rad iCycler following 
manufacturer’s instructions. The qRT-PCR reaction contained 5 µl (1 X) Bio-Rad 
Sybrgreen supermixes (which contain reaction buffer, dNTPs, MgCl2 and Taq 
polymerase), 0.6 µl (5 µM) primer combination (containing forward primer and backwards 
primers), 3.4 µl PCR grade water plus of the following PCR templates, 1 µl cDNA (RT 
product) or 1 µl DNA standard (see below). A template free mix was used as a control. 
DNA was amplified using the following program: 
Denaturing: 95°C  3 min 
PCR cycle 94°C  20 s 
  65°C  30 s 
  72°C  30 s and measurement of fluorescence  
    Repeating of the PCR cycle 45 times 
Meltcurve 60°C  1 min  
    60-99°C in 0.5°C increments  
    (at each step wait 5 s and measure the fluorescence) 
The melting curves are a control of the homogeneity of the PCR amplification. A unique 
PCR product melts at a given temperature. The first derivative of the fluorescence signal 
plotted against temperature should show only one peak if only one specific product is 
formed. The analysis of PCR curves was achieved on Bio-Rad iCycler software. Standard 
dilutions of the studied gene sequences were used to quantify the relative amount of 
transcription. The gene-specific external Standards necessary for the exact quantification 
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were prepared as follows: The desired DNA fragments (cDNA obtained from human brain 
tissue, Invitrogen, Karlsruhe, Germany) containing each primer combination was amplified 
using Advantage II polymerase mix according to the manufacturer’s directions. The 
amplified DNA was separated by electrophoresis on a 1% agarose/1X TAE-gel. The 
corresponding bands were cut out of the gel, purified using the Qiaquick gel extraction kit 
(Qiagen, Hilden, Germany) and used as a template for re-amplification using Advantage II 
polymerase mix. The resulting PCR product was purified using Qiagen PCR purification 
kit and the DNA concentration determined. The PCR fragments were cloned into pCR2.1 
vector and transformed into TOP10 E.coli using the TOPO-TA cloning kit according to the 
manufacturer’s instructions (Invitrogen, Karlsruhe, Germany). Restriction digestions (see 
section 2.4.4) were performed on prepared DNA (QIAprep Spin Miniprep kit, Qiagen, 
Hilden, Germany) expressed from the bacterial clones to check for the presence of the 
insert and the DNA sequences of positive clones verified. Following confirmation by 
sequencing that DNA sequences were free from mutations, the pCR2.1 TOPO vector was 
subjected to quantitative restriction digestion to yield the linearised vector including the 
insert (which was checked by agarose electrophoresis). Following purification of the 
linearised vector, the concentration of DNA was determined. In order to calculate the 
number of double-stranded DNA molecules per µl of this solution (termed original 
solution or UL) the following calculation is applied: 
 
c......... Concentration 
NA…..6.022 ×1023 molecules / mol Avogadro’s number 
Mr…...660 g / mol × bp (molecular mass of double stranded DNA) 
The correct standard dilutions were prepared based on this calculation which was used for 
the determination of molecular count in the samples. The expressed standard dilutions in 
the range from 1 to 108 molecules were used as a DNA template for qRT-PCR. The 
iCycler software calculated the absolute amount of transcription with regards to the pre-
defined standard solution series. For quantification of the relative amounts of DNA 
transcription (mRNA levels), RNA was prepared from SH-SY5Y cells, the RNA reversely 
transcribed (see section 2.4.1) to cDNA and the single strands of cDNA used as a PCR 
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template for the qRT-PCR. Amount of transcript obtained were normalised to the amount 
of transcription of the housekeeping gene GAPDH. 
2.4.3 Conventional PCR 
Conventional (semi-quantitative) RT-PCR was performed using the Advantage 2 
polymerase kit according to the manufacturer’s recommendations (Takara Bio Europe, St-
Germain, France). A template free PCR-mix was used as a control in each reaction. DNA 
was amplified using the following program. 
Denaturing:  95°C  3 min 
26-34 PCR cycles 95°C  0.5 min 
   68°C  1 min 
   68°C  2 min  
Primer Sequence 5’-3’ Fragment size 
GAPDH 
       GAPDH-forward 
       GAPDH-reverse 
 
CCA TCA CCA TCT TCC AGG AGC GA 




       MAO-A-forward 
       MAO-A-reverse 
 
GCC CTG TGG TTC TTG TGG TAT GT 




       MAO-B-forward 
       MAO-B-reverse 
 
ACT CGT GTG CCT TTG GGT TCA G 




       Caspase-8-forward 
       Caspase-8-reverse 
 
GAT GAT GAC ATG AAC CTG CTG 




       Caspase-8-forward 
       Caspase-8-reverse 
 
TTG GTG ATG TCG AGC AGA AAG 
AGT GAG CCC ACT GCT CAA AGA 
 
276 bp 
Table 2. 3 Primer combination for conventional PCR 
2.4.4 Restriction endonuclease digestion reactions 
Restriction endonuclease digestions using the appropriate restriction endonucleases were 
performed for the analysis of DNA sequences; from plasmids to confirm successful 
cloning or the presence of a particular sequence. All digestions were carried out according 
to the recommendation of the manufacturer.  
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2.4.5 Overexpression of MAO-A in SH-SY5Y cells 
Human MAO-A was stably over expressed in the human neuroblastoma (SH-SY5Y) cell 
line by cloning human MAO-A cDNA into the expression vector (pcDNA3.1-, Invitrogen, 
Karlsruhe, Germany), which was then transformed into competent bacteria. The expressed 
plasmid DNA was purified using DNA mini and DNA midi kits (Qiagen, Hilden, 
Germany) and transfected into SH-SY5Y cells by electroporation (Amaxa, Cologne, 
Germany). Stable SH-SY5Y clones were selected by their resistance to geneticin (G418) 
which is conferred by the plasmid vector pcDNA3.1 
2.4.5.1 TOPO Cloning 
First human MAO-A DNA was amplified using PCR primers specific to a homologous 
region of human MAO-A cDNA (underlined sequence shown in Figure 2. 2A) and 
containing the restriction endonuclease sites of XhoI/NotI at their respective 5’ end. The 
template used for the PCR reaction was cDNA previously prepared by reversely 
transcribing RNA purified from SH-SY5Y cells. 
TOPO TA® cloning is a highly efficient one step cloning strategy for the insertion of 
amplified PCR products into a plasmid vector (Invitrogen, Karlsrhue, Germany). During 
PCR amplification Taq polymerase has a nontemplate-dependent terminal transferase 
activity that adds a single deoxyadenosine (A) to the 3` end of PCR products. The 
linearised pCR2.1 vector has single, overhanging 3` deoxythymidine (T), which allows the 
PCR product to ligate efficiently with the vector (Invitrogen Corporation, 2006). 
Topoisomerase I activates and guides the unravelling of DNA by binding to duplex DNA 
at specific sites and cleaves the phosphodiester backbone after 5` CCCTT. The energy 
released from the cleaved bond is conserved by the formation of a covalent bond between 
the 3` phosphate of the cleaved strand and the tyrosyl residue (Tyr-274) of topoisomerase I 
The reaction can be reversed and the topoisomerase enzyme released (Simply, 
topoisomerase cuts one duplex DNA strand, passes the other through it and reanneals the 
cut strand). Figure 2. 1B (step1) illustrates the cloning of human MAO-A cDNA into the 
pCR2.1 vector. 
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Figure 2. 1 Overview of cloning procedure 
(A) PCR primers for amplification of human MAO-A DNA for cloning into pcDNA2.1 (Invitrogen, 
Karlsruhe, Germany) via XhoI/NotI restriction sites. Top sequence shows forward primer and Bottom 
sequence shows reverse primer, where the underlined region in both cases is homologous to human MAO-A 
cDNA. (B) A step by step overview of cloning human MAO-A into pcDNA3.1(- Invitrogen, Karlsruhe, 
Germany). Cloning of the PCR product (MAO-A cDNA) directly into the pcDNA3.1(-) expression vector is 
not viable. Therefore MAO-A cDNA was first cloned via the TOPO TA system (Invitrogen, Karlsrhue, 
Germany) into pCR2.1 vector (step 1.), transformed into competent E.coli for expression (step 2.), purified, 
the hMAO-A insert cut out again using restriction endonucleases (step 3.) and ligated with the pcDNA3.1(-) 
expression vector via the action of T4 ligase (step 4.). Complete pcDNA3.1(-) containing the human MAO-A 
DNA insert was then transformed into competent E.coli cells (step 5.), grown and expressed plasmid DNA 
purified using DNA mini or midi kits (Qiagen, Hilden, Germany).  
The cloned pCR2.1 vector was transformed into competent bacteria (E.coli TOP10 cells). 
Isolated bacterial clones allowed to grow overnight yielded significant amounts of bacterial 
plasmid DNA, which is purified and sequence analysed by sequential sequence reactions 
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and from a clone devoid of mutations, plasmid DNA is purified and restriction digestion of 
the pCR2.1 vector performed (Figure 2. 1B step 2). Digestion with specific restriction 
endonucleases results in the MAO-A insert being cut out from the vector backbone (Figure 
2. 1B step3). The MAO-A insert is a 1.6 kb fragment which can be excised and 
distinguished from the large empty vector fragment (3.9 kb) by agarose gel electrophoresis. 
The excised DNA fragments are purified and sent for sequencing to check for mutations. 
Meanwhile the eukaryotic expression plasmid pcDNA3.1(-) containing a human COX2 
insert (a kind gift from the laboratory of Professor Hartmut Kuhn, University Medicine 
Berlin-Charité, Berlin, Germany) was digested using restriction endonucleases to remove 
the COX2 insert. Human MAO-A DNA (see above) was then used in the ligation step, 
combining the MAO-A insert with the pcDNA3.1(-) vector using the T4 ligase enzyme 
(Figure 2. 1B, step 4). The complete pcDNA3.1(-) vector can now be transformed into 
competent bacterial cells for the collection of expressed plasmid DNA (Figure 2. 1B, step 
5).  
2.4.5.2 Stable transfection  
For transient transfection studies, the intact pcDNA3.1(-) plasmid containing the MAO-A 
insert was transfected. For stable transfection the plasmid was linearised using restriction 
endonuclease BglII which cuts the plasmid vector only once without interfering with either 
the MAO-A coding sequence or the neomycin resistance gene. 
SH-SY5Y cells were transfected with 1 µg of pcDNA3.1(-) containing the hMAO-A insert 
or 1 µg of the empty pcDNA3.1(-) vector via electroporation using the Amaxa 
nucleofection system (Figure 2. 2). The method of electroporation using the Amaxa 
nucleofector was optimised for SH-SY5Y cells following the manufacturer’s instructions. 
Electroporated SH-SY5Y cells were seeded in 6-well tissue culture plates in normal 
growth medium, which was replaced after 24 hours. 48 hours post-transfection, cells were 
passaged and seeded at 25% confluence in growth medium containing G418 sulphate 
(geneticin) at a concentration of 700 µg/ml (as previously determined by titration, see 
appendix ). The media was replaced every 3-4 days until resistant foci were visible (Figure 
2. 2). Resistant cells were diluted in 96 well plates at a density of 0.5 cell/well (Invitrogen 
Corporation, 2006). Single clones were expanded and assayed for MAO-A expression. 
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Figure 2. 2 Stable over expression of MAO-A in SH-SY5Y cells 
Flow chart-Stable transfection method using electroporation. Method development work was carried out 
achieve optimal transfection conditions for SH-SY5Y cells. 1 µg plasmid DNA was mixed with 3-4 million 
SH-SY5Y cells re-suspended in a special electroporation buffer (supplied by Amaxa GmbH) and 
electroporated. The cells were seeded equally between a 6-well plate, in normal growth medium for 24 hours. 
After 48 hours a viable cell count is performed and the cells seeded into flasks at 25% confluence in selective 
growth medium (normal growth medium containing G418 sulphate). The media is changed every 3-4 days 
until resistant foci are visible (this may take some weeks). Resistant cells are then serially diluted to seed (in 
theory) half a cell per well in >10X 96-well plates. Once confluent, cells from each well are studied using 
light microscopy to ensure that the colony of cells has arisen from a single cell. Stable clones are then 
expanded for assay.  
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2.4.6 MAO-A knockdown in SH-SY5Y cells 
A description of RNAi technology can be found in chapter 6, section 6.1. Initially pre-
designed human MAO-A siRNAs made by Santa Cruz Biotechnology were used to knock 
down MAO-A expression. However these experiments were unsuccessful. miRNA 
technology was then chosen to knock down MAO-A in the cells since this technique was 
thought to be advantageous over siRNA or shRNA technologies.  
Human MAO-A was stably knocked down in the human neuroblastoma (SH-SY5Y) cell 
line by means of the BLOCK iT Pol II miR expression vector technology (Invitrogen, 
Karlsruhe, Germany). The pcDNA6.2-GW/miR expression vector facilitates the generation 
of an expression clone containing one or more double stranded oligonucleotide encoding a 
pre-miRNA sequence directed against MAO-A mRNA. The resulting expression construct 
was transformed into competent bacteria and the expressed plasmid DNA purified and 
transfected into SH-SY5Y cells by electroporation. Stable SH-SY5Y clones were selected 
by their resistance to the antibiotic Blasticidin.  
2.4.6.1 Cloning procedure 
An overview of the cloning procedure is shown in Figure 2. 3. Two single stranded DNA 
oligonucleotides encoding pre-miRNA for human MAO-A were designed using online 











TGC TGC CAT TTG TCA GCA TGT TGA GCG TTT TGG CCA 
CTG ACT GAC GCT CAA CAC TGA CAA ATG G 
CTT GCC ATT TGT CAG TGT TGA GCG  TCA GTC AGT GGC 








TGC TGA TTG AAG ACC TCC CTA GCT GCG TTT TGG CCA 
CTG ACT GAC GCA GCT AGA GGT CTT AAA T 
CCT GAT TTA AGA CCT CTA GCT GCG TCA GTC AGT GGC 
CAA AAC GCA GCT AGG GAG GTC TTA AAT C 
 
64 bp 
Table 2. 4 Oligonucleotide sequences encoding human MAO-A pre-miRNA 
For each of the two oligonucleotide sequences designed (617 and 1544) the following 
procedure was applied. The single stranded DNA oligonucleotides were annealed to 
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generate a double stranded (ds) DNA oligonucleotide following the manufacturer’s 
instructions. A small amount of the annealed product was run on a 4 % agarose, 1 X TAE 
gel to confirm successful annealing (the presence of one 64 bp dsDNA fragment). The 
dsDNA oligonucleotide was diluted, cloned into the pcDNA 6.2-GW/miR vector and 
transformed into competent bacterial cells according to the manufacturer’s instructions. 
Restriction digests were performed to confirm successful cloning and DNA from positive 
bacterial clones were sent for sequencing following quantitative digestion using the 
restriction enzyme MScI. Following confirmation that the DNA sequence was free from 
mutations, transient transfections of SH-SY5Y cells with the DNA from a ‘617 Sh-hMAO-
A sequence containing’ clone, from a ‘1544 Sh-hMAO-A sequence containing’ clone and 
the negative control plasmid DNA (Negative control plasmid DNA was prepared 
according to the instructions of the manufacturer) were performed. Both RNA and total 
extracts from these cells were taken for qRT-PCR and catalytic activity assays to 
determine the level of MAO-A knockdown. Sufficient knockdown was not achieved. 
Therefore, miRNA chaining of both sh-hMAO-A inserts (617 and 1544) and cloning into 
one pcDNA 6.2-GW/miR vector was performed to achieve a more efficient knockdown. 
The miRNA chaining procedure was performed by a number of quantitative digestion steps 
and cloning which is described in Figure 2. 3. Instructions for miRNA chaining are 
provided in the BLOCK iT Pol II miR manual (Invitrogen, Karlsruhe, Germany). As 
before restriction endonuclease digests were performed to confirm successful cloning 
following transformation into bacteria and the plasmid DNA from a positive clone 
containing the chained miRNA insert was sent for sequencing. Following confirmation that 
DNA was free from mutation, transient transfections were performed using purified 
plasmid DNA. Data suggested significant knockdown of MAO-A mRNA after 48 h. 1 µg 
of the chained (clone 10) DNA was used to stably transfect SH-SY5Y cells by 
electroporation as suggested by the manufacturers (see Figure 2. 2). The antibiotic 
blasticidin was used for the selection procedure.  
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Figure 2. 3 Overview of cloning procedures used for knockdown of MAO-A using BLOCK-iT miRNA 
expression vector kit 
In order to achieve better cloning efficiency, a second round of stable transfection was 
performed using the linearised vector. 1µg of the chained DNA was linearised with the 
restriction endonuclease BssHII. Linearisation was confirmed by agarose gel 
electrophoresis. The linearised plasmid was purified (Qiagen PCR purification kit) then 
used for the transfection of the cells. MAO-A- stable clones used in this thesis were a 
result of this transfection. 
Name of sh- oligo’ 
sequence 
Number given 
to the successful 
clone used 
DNA purified and 






Amount of plasmid 
DNA used for 
transfection and time 
point for extraction or 
stable cloning 
617 4 Yes (Midi-prep) Yes 1 µg, 48 h 
1544 7 Yes (Midi-prep) Yes 1 µg, 48 h 
N/A (chained 617 
and 1544) 
10 Yes (Mini-prep) Yes 1 µg, 48 h 
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THE ROLE OF MAO IN MITOCHONDRIA-MEDIATED 
NEURONAL APOPTOSIS 
3.1. INTRODUCTION 
Oxidative deamination of amines by MAO produces H2O2 as one of the reaction’s by-
products. This is a key contributor to increased steady state concentrations of ROS 
(Cadenas and Davies 2000) which cause oxidative damage to mitochondrial DNA 
(Hauptmann et al. 1996), the electron transport system and antioxidant defence systems 
(Cohen and Kesler 1999). Thus elevated MAO activities are likely to cause damage to the 
cell, according to the ROS theory of cell death. The damaging effects of H2O2 and its 
involvement in cell death processes are well known (Cadenas and Davies 2000, Chandra et 
al. 2000). More recently, H2O2 has been shown to be an essential redox signalling 
molecule (Toledano et al. 2004), a mitogen in cell survival/proliferation (Sohal and 
Weindruch 1996, Vindis et al. 2000, Yoon et al. 2002) and involved in G protein 
activation (Nishida et al. 2000) and MAPK signalling (Guyton et al. 1996 Finkel 1998, 
Wang et al. 1998, Crossthwaite et al. 2002, Ruffels et al. 2003).   
3.1.1 Previous work 
The role of MAO in neuronal cell death has been the focus of three recent publications. 
Induction of apoptosis in rat PC12 cells was paralleled by an increase in MAO-A 
expression (DeZutter and Davis 2001), mediated by the stress activated p38 MAPK signal 
transduction pathway. On the contrary, MAO-A has been found to be a target of a 
dopaminergic toxin, N-methyl-R-salsolinol, and in this case inhibition of MAO appears to 
lead to apoptosis in human SH-SY5Y cells (Yi et al. 2006a). Most recently, Ou and co-
workers (Ou et al. 2006) have reported that growth factor deprivation led to concomitant 
reduction in the transcription factor repressor R1 (RAM2/CDCA7L/JPO2), increase in 
MAO-A expression and activity in human SH-SY5Y cells, and a reduction in 
oxidoreductase activity (MTT assay used as a means of cell viability). 
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3.1.2 An In Vitro Model of Neuronal Apoptosis 
3.1.2.1 SH-SY5Y human neuroblastoma cell line 
Whilst animal models are extremely useful with regard to pathological changes occurring 
as a result of apoptosis in a physiological setting, their use is often limited for a number of 
reasons, notably species differences and ethical issues.  
Studies on Parkinson’s disease and other neurodegenerative diseases have greatly benefited 
from the use of post mortem samples. However, human post mortem brain samples are not 
only extremely difficult to obtain (due to strict ethical regulations) and their value usually 
restricted because of post mortem delay (the period between death and harvesting) or 
samples are derived from individuals in the final stages of the disease, subjected to 
intervention with numerous drugs (which themselves may affect the final pathology). It is 
worth noting that although it is well established that neuronal cells die progressively in 
neurodegenerative diseases (Friedlander and Yuan 1998), the type of cell death may vary 
between conditions. Nevertheless there is a wealth of evidence suggesting that apoptotic 
type cell death occurs predominantly in chronic neuronal diseases such as Huntington’s 
disease, Parkinson’s disease, ALS, Alzheimer’s disease and dementia, whilst acute brain 
injury such as ischemic stroke is thought to involve a combination of apoptotic and 
necrotic cell death (reviewed by Friedlander 2003).  
In vitro experiments allow investigation of biochemical and molecular events in a specific 
cell type in a controlled environment. The SH-SY5Y human neuroblastoma cell line was 
previously characterised in our group (Beck 2004).  
Human neuroblastoma is a cancer of early childhood and arises from the neural crest 
(Ciccarone et al. 1989). The neuroblastoma cell line SK-N-SH was established from the 
metastatic bone tumour of a young female (Biedler et al. 1973) and thrice cloned to 
produce the SH-SY5Y cell line (Biedler et al. 1973). The SH-SY5Y cell line has been 
further characterised by Ross (Ross et al. 1983) and then Ciccarone (Ciccarone et al. 1989) 
who described the cell line as possessing three morphologically distinct cell types,  the N 
type is neuroblast-like, having small cell bodies and short neurite processes, poorly 
adherent but able to form aggregates. The S type is epithelial/fibroblast like, larger and 
flatter than the N type and is highly substrate adherent. Finally the I type is an intermediate 
cell type, expressing properties of both the N and S type (Ross et al. 1983). SH-SY5Y cells 
undergo spontaneous bi-directional phenotypic and biochemical interconversion between 
the neuroblast and fibroblast like types, termed transdifferentiation (Ross et al. 1983). The 
 Chapter 3                                                       The Role of MAO in mitochondria-mediated neuronal apoptosis 
 62
previously reported general characteristics of the SH-SY5Y cell line are presented in Table 
3. 1 
GROWTH BIOCHEMICAL KARYOTYPE 
High cell densities at 
stationary phase (Ross et 
al. 1983) 
Uptake mechanisms for 
noradrenaline (Ross et al. 
1983; Ciccarone et al. 1989), 
epinephrine, dopamine, MPP 
ion and other neuotransmitters 
 Abnormalities (+7 position) 
on chromosome 9 and 
chromosome 22 (Ross et 
al. 1983) 
Extensive multi-layering 
of cells (Ross et al. 1983) 
Biosynthetic enzymes for 
neurotransmitter synthesis 
(Ciccarone et al. 1989) 
Complex duplication of the 
long arm of chromosome 1 
(Ross et al. 1983) 
Formation of dense focal 
aggregates (Ross et al. 
1983) 
Contains three neurofilaments 
(200 kDa, 150 kDa and 68 
kDa, Ciccarone et al. 1989) 
 
 
Dopamine rich (Song et al. 
1996; Song and Ehrich, 1998) 
 
 
Expresses dopamine uptake 
receptor (Song et al. 1996; 
Song and Ehrich, 1998) 
 
  
Contain MAO enzymes (Song 
and Ehrich, 1998) 
  
Table 3. 1 General Characteristics of the SH-SY5Y Human Neuroblastoma Cell Line 
The most important characteristics of SH-SY5Y cells with regards to this work are that 
they contain MAO enzymes, are able to synthesise dopamine and have neuronal 
characteristics. The existence of MAO activities in the SH-SY5Y cell line were revealed 
when Song and others were investigating the uptake and metabolism of the neurotoxins 
MPTP and MPP+ (Song et al. 1996, Song and Ehrich 1998). The nature of the MAO 
isoforms was not determined in these studies. Zhu et al, (1992), had showed that MAO-A 
mRNA expression was predominant over MAO-B mRNA expression (Zhu et al. 1992); 
nevertheless MAO-B mRNA expression was detected, later confirmed by Yi and co-
workers (2006a).  
3.1.2.2 Neuronal apoptosis induced by staurosporine 
Staurosporine (STS) is an alkaloid produced by Streptomyces staurosporeus that possesses 
inhibitory activity against fungi and yeasts but has no significant effect on bacteria 
(Meksuriyen and Cordell 1988). STS is a potent inhibitor of a broad-spectrum of protein 
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kinases, including protein kinase C (PKC), cAMP-dependent kinases and receptor protein 
kinases (Boix et al. 1997). Its chemical structure contains an indole carbozole 
chromophore, which characterises a family of protein kinase inhibitors that act by blocking 
the ATP binding site of protein kinases (Hidaka and Kobayashi 1992). STS is widely 
employed as an inducer of apoptosis in many mammalian cell types (Kruman and Guo 
1998) and is of particular interest in cancer chemotherapy (Meksuriyen and Cordell 1988). 
 
Figure 3. 1 Chemical structure of staurosporine from Streptomyces staurosporeus 
Numerous morphological changes typical of STS induced apoptosis have been observed in 
neuronal cell lines, the most common being cell body shrinkage and chromatin 
condensation (Koh et al. 1995). It appears that STS-induced apoptosis in neurons is 
triggered by disruption of the cell cycle (Gong et al. 1994) and a rapid and prolonged 
elevation of intracellular free calcium (Ca2+) levels, since calcium chelators have been 
shown to protect rat PC12 cells from STS-induced apoptosis (Kruman and Guo 1998). 
Accumulation of mitochondrial ROS occurs in the early phase of apoptosis and treatment 
with free radical scavengers protects PC12 cells from apoptosis (Kruman and Guo 1998). 
There is some controversy regarding the depletion of the anti-apoptotic protein Bcl-2; 
which has been claimed to be both essential (Kruman and Guo 1998, Tieu et al. 1999) and 
non-essential (Yuste et al. 2002) for STS-mediated apoptosis. Zhang and colleagues have 
shown that overexpression of Bcl-2 in a melanoma cell line protects from STS-induced 
early phase but not late phase apoptosis (Zhang et al. 2004). Increased free calcium levels 
and ROS (and possibly the depletion of Bcl-2) cause early activation of caspases including 
caspase-3 (Kruman and Guo 1998). Activation of caspases in PC12 cells by STS is 
followed by increased lipid peroxidation, loss of mitochondrial membrane potential and 
finally nuclear changes (Kruman and Guo 1998), including DNA laddering (Koh et al. 
1995). STS treatment of SH-SY5Y cells has been reported to be associated with activation 
of the upstream initiator caspase-9 (mitochondrial apoptotic pathway) and caspase-3 but 
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not with activation of initiator caspase-8 (receptor mediated apoptotic pathway, Lopez and 
Ferrer 2000). Collectively, the evidence to date shows that STS is a potent inducer of 
apoptotic cell death and importantly this toxin is of particular relevance to this project 
since it induces the intrinsic apoptotic pathway (associated with the mitochondria and its 
function).  
3.1.2.3 Caspases in SH-SY5Y cells 
For a good model of neuronal apoptosis that will accurately reflect in vivo mechanisms of 
neuronal apoptosis, molecular components of the apoptotic signalling cascades should be 
present and inducible in SH-SY5Y cells. The activation of the executioner caspase-3 
following STS exposure in SH-SY5Y is well documented (Enari et al. 1998, Lopez and 
Ferrer 2000, Tang et al. 2000) and STS treated cells are often used as a positive control for 
commercial caspase-3 activity assay kits (O' Brian et al. 2003). Although staurosporine is 
known to activate caspase-3, its essentiality in STS-induced apoptosis has been argued, 
with several studies claiming that STS-induced apoptosis (measured by down stream 
events such as DNA laddering) can still occur in the presence of Z-VAD-fmk (a caspase-3 
inhibitor, Deas et al. 1998, Janicke et al. 1998). Nonetheless, as indicated earlier caspase-3 
has been shown to be activated in SH-SY5Y cells following STS treatment (McGinnis 
1999a, McGinnis 1999b, Lopez and Ferrer 2000). The upstream initiator caspase-9 is 
known to exist and be activated following apoptotic stimuli in SH-SY5Y cells (Lopez and 
Ferrer 2000, Xia et al. 2001). However, the presence and activation of the initiator caspase-
8 in these cells is the focus of some debate. Lopez and Ferrer found no evidence of 
caspase-8 activation following STS treatment in SH-SY5Y cells (Lopez and Ferrer 2000). 
Numerous publications have suggested that caspase-8 protein is not expressed in SH-
SY5Y cells because of gene silencing due to methylation (Eggert et al. 2001, Harada et al. 
2002). Hopkins and co-workers were unable to show caspase-8 mRNA, protein expression 
or caspase-8 activity in control SH-SY5Y (which the authors class as N-type 
neuroblastoma) cells or in cells that were induced to undergo receptor-mediated apoptosis 
induced by the death ligand TRAIL (Hopkins et al. 2002). They did however find 
expression of caspase-8 in S-type human neuroblastoma cells. Hopkins and co-workers 
suggested that the caspase-8 gene was not deleted in the SH-SY5Y (N-type) cells, since 
caspase-8 expression was seen when the cells were made sensitive to TRAIL using the 
chemotherapy drug doxyrubicin (Hopkins et al. 2002). The authors concluded that 
caspase-8 expression was merely silenced in malignant neuroblastoma and that this 
correlated to tumour severity. Conversely, although no activation of caspase-8 was found 
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in SH-SY5Y cells following treatment with Aβ protein (Wei et al. 2002), the full length 
caspase-8 proform protein was detected and levels reduced during Aβ-induced apoptosis. 
Recently, caspase-8 proform protein only was detected by Miller and colleagues in 
undifferentiated SH-SY5Y cells (Miller et al. 2006), suggesting that variable findings in 
SH-SY5Y cells reflect clonal differences.  
In summary, staurosporine is thought to activate caspase-9 but not caspase-8 in SH-SY5Y 
cells. Whether or not caspase-8 protein exists and can be activated by staurosporine in the 
SH-SY5Y clone used in our laboratory should be investigated.  
3.1.3 Antioxidants 
3.1.3.1 Vitamin C and N-Acetyl-L-cysteine (Podmore et al. 1998) 
Vitamin C (L-ascorbate) is an essential nutrient and an important antioxidant in vivo, 
protecting against cancer and other diseases by scavenging ROS (Halliwell 1999). It is 
widely believed that vitamin C protects against cardiovascular diseases and some forms of 
cancer (Halliwell 1999). However, Podmore and colleagues (1998) suggested that vitamin 
C could damage DNA. The toxicity of vitamin C is still debated and is probably dependant 
on concentration. It is known to stimulate free radical reactions in vitro under certain 
conditions by reducing Fe (III) to Fe (II, Halliwell 1999). N-Acetyl-L-cysteine (NAC) is a 
powerful antioxidant known to protect against apoptosis (Mayer and Noble 1994). NAC is 
an aminothiol antioxidant in its own right and a synthetic precursor of intracellular cysteine 
and glutathione (Zandwijk 1995). The thiol reducing agent glutathione plays an essential 
role in the cell’s antioxidant defence system. Glutathione serves as a sulfhydryl buffer, 
cycling between its reduced thiol form (GSH) and an oxidised form (GSSG) and plays a 
key role in cell detoxification by reacting with hydrogen peroxide and organic peroxides 
(Stryer 1996). In addition, enzymes such as glutathione peroxidise and glutathione-S-
transferase play key roles in detoxification. Nonetheless, reduction of total glutathione 
levels and oxidised glutathione levels are the earliest known biochemical indicators of 
nigral degeneration in the human brain (Anderson 2004).  
3.1.3.2 MitoQ 
MitoQ (mitoquinone) is an antioxidant, similar in structure to coenzyme Q10, which is 
specifically targeted to the mitochondria by covalent attachment to a lipophilic 
triphenylphosphonium cation (Figure 3. 2). Because of the large mitochondrial membrane 
potential, the cations accumulate within mitochondria up to 1,000 fold compared to non-
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targeted antioxidants such as coenzyme Q10 or its analogues (Antipodean Pharmaceuticals 
2007). Once there MitoQ is reduced to its active ubiquinol form, which has been used to 
prevent mitochondrial oxidative damage, reduce ROS-induced apoptosis (Kelso et al. 
2000) and demonstrate the involvement of mitochondrial ROS in cell signalling pathways 
(James et al. 2004). MitoQ was invented at The University of Otago, New Zealand by 
Robin Smith and Michael Murphy (the latter now at The University of Cambridge, U.K). 
MitoQ is being developed by Antipodean Pharmaceuticals and is currently in phase II 
clinical trails for Parkinson’s disease. The experimental control used alongside MitoQ is a 
compound called decyltriphenylphosphonium bromide (DTPP), which contains the TPP+ 
moiety (the cationic moiety that drives the compound to the mitochondria) but has only 
weak antioxidant properties (Figure 3. 2).  
 
Figure 3. 2 Chemical structures of Decyl TPP and MitoQ 
Left panel shows the chemical structure of Decyltriphenylphosphonium bromide (Decyl TPP or DTPP), the 
control compound often used in conjunction with MitoQ. DTPP consists of a lipophilic 
triphenylphosphonium cation moiety attached to a compound with very mild antioxidant properties. Right 
panel shows the chemical structure of MitoQ, which comprises the lipophilic triphenylphosphonium cation 
moiety linked with a quinone group antioxidant. 
3.1.4 Aims of Chapter 
Human neuroblastoma cells (SH-SY5Y) display a neuronal phenotype, have 
neurotransmitter uptake mechanisms and are dopamine rich, providing an excellent human 
neuronal cell model. 
The aims of this chapter of the thesis were: 
• To determine the MAO status of human neuroblastoma cells 
MAO activity levels were measured by titration with MAO-A and –B specific 
inhibitors in vitro. To support the MAO activity data, expression of the MAO isoforms 
were investigated at the protein and messenger RNA level. Analysis of MAO proteins 
involved the use of MAO isoform-specific monoclonal antibodies made in our 
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laboratory, which were previously characterised (Church et al. 1994, Rodriguez et al. 
2000, Sivasubramaniam et al. 2002, Billett and Mayer 1986). Analysis of MAO mRNA 
expression was carried out using oligonucleotide primers, designed to probe and bind 
to MAO-A or MAO-B specific cDNA sequences. This involved a conventional RT-
PCR approach and secondly a more sensitive and quantitative RT-PCR method (real 
time- or q-RT-PCR).  
• To characterise apoptotic cell death induced by staurosporine in human 
neuroblastoma cells 
The concentration of STS commonly used to induce apoptotic cell death in SH-SY5Y 
cells ranges between 0.5 µM-1 µM (Boix et al. 1997; Lopez and Ferrer, 2000; Yuste et 
al. 2002). An initial titration of STS to determine its effect on cell viability and cell 
morphology was undertaken to ensure induction of apoptotic cell death and not 
differentiation. A time course of cell viability (MTT assay) and execution of apoptosis 
(caspase-3 activation assay) was monitored. Caspase-3 is a well established 
biochemical marker of apoptosis (Hartmann et al. 2000, Ashe and Berry 2003). 
Caspase-3 is common to all apoptotic pathways, representing the point where the 
execution of apoptosis begins, committing the cell to die. Activation of upstream 
caspases-8 and -9 were assessed to determine whether the receptor-mediated or 
mitochondrially mediated route was predominant in STS-induced apoptosis. Finally, 
expression of caspase-8 and -9 at the mRNA level and protein level was investigated 
using conventional PCR, quantitative PCR and western blotting to confirm the 
presence of these apoptotic components in our SH-SY5Y clone.  
• To assess the role of MAO in STS-induced apoptosis 
The objectives were to monitor changes in MAO catalytic activity, protein and mRNA 
expression levels during STS-induced apoptosis. To confirm the relevance of MAO in 
the apoptotic cascade, caspase-3 activation, cell viability (MTT reduction), changes in 
morphology and upstream caspase activation were measured during STS-induced 
apoptosis with or without MAO inhibition. To improve the validity of the data two 
unrelated MAO inhibitors were used. 
• To define how MAO mediates apoptosis 
MAPK phosphorylation cascades are activated following oxidative stress (Finkel 1998) 
and are involved in the activation of MAO-B expression (Wong et al. 2002) and in pro-
apoptotic MAO-A expression (DeZutter and Davis, 2001). The Bcl-2 family of 
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proteins are critical in apoptotic signalling because of their anti- and –pro-apoptotic 
effects at the mitochondrial surface. To investigate the mechanism of involvement of 
MAO in STS induced apoptosis, changes in MAO were related to production of ROS, 
activation of caspases, Bcl-2 levels and MAPK signalling pathways. 
3.2.  RESULTS 
3.2.1 Characterisation of apoptotic model 
3.1.1.1 MAO isotype status of SH-SY5Y cells 
MAO activity was measured in vitro in SH-SY5Y cell homogenates following titration 
with specific and irreversible inhibitors of MAO-A (clorgyline) and MAO-B (deprenyl) 
(Figure 3. 3A). Complete inhibition of MAO activity was achieved with 10-8 M clorgyline 
or 10-5 M deprenyl (Figure 3. 3A), suggesting MAO-A prevalence in this cell line. MAO-A 
but not MAO-B protein was detected in SH-SY5Y cells (Figure 3. 3B) using 
immunohistochemical analysis with monoclonal antibodies specific to MAO-A and MAO-
B. In contrast, control human liver sections exhibited positive staining for both MAO-A 
and –B (Figure 3. 3B).  
Conventional RT-PCR revealed an intense signal for MAO-A indicating strong expression 
of the MAO-A messenger (Figure 3. 3C). In contrast, no signal was observed for the 
MAO-B messenger. Finally, using the more sensitive approach of qRT-PCR, average 
MAO-A mRNA expression of 2.58±1.00 molecules/1000 molecules GAPDH was 
measured, whereas MAO-B mRNA levels were insignificant (0.0006±0.0005 
molecules/1000 molecules GAPDH, data not presented). Since, approximately 4000 fold 
more MAO-A mRNA than MAO-B mRNA was detected using quantitative RT-PCR, it 
appears that only the MAO-A isoform is present in SH-SY5Y cells. 




Figure 3. 3 MAO-A is predominant in SH-SY5Y human neuroblastoma cells  
(A) MAO activity in SH-SY5Y cells was measured following addition of 0, 10-9, 10-8, 10-7, 10-6, 10-5 M 
clorgyline or deprenyl via a radiometric method using 14C-Tyramine as a substrate. MAO activity was 
determined in the presence or absence of the inhibitors and expressed as % residual activity. (B) SH-SY5Y 
cells and human liver sections were probed using MAO-A (6G11-E1) and MAO-B (3F12/G10/2E3) specific 
primary antibodies (see section M&M) using 3, 3’-Diaminobenzidine as substrate for the secondary antibody. 
Control sections were incubated in the absence of MAO-specific antibodies but subjected to the same 
conditions. MAO immunoreactivity is represented by dark brown/red staining. The images shown are from a 
representative experiment. Scale bar represents 20 µm. (C) Agarose gel showing positive PCR controls 
(lanes 1,4 and 7), SH-SY5Y samples (lanes 2, 5 and 8) and negative PCR controls (lanes 3, 6 and 9) for 
GAPDH, MAO-A and MAO-B gene expression. 
3.1.1.2 Cell viability  
Initially, we used the MTT reduction assay (which is a measure of cell viability / 
proliferation) to obtain a dose response to STS administered to the cells in serum free 
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medium (Figure 3. 4).  At 1 h following STS insult no loss of cell viability was observed. 
After 16 h, doses of 0.5 and 1 µM STS significantly reduced cell viability (~25% reduction 
to ~50% reduction, respectively). By 24 h 0.05 µM STS reduced cell viability by ~40% 
and higher concentrations reduced cell viability by ~60% (Figure 3. 4).  
 
Figure 3. 4 Concentration of STS required to reduce the cell viability of SH-SY5Y Cells 
Cell viability was measured in SH-SY5Y cells over 24 h, following the addition of 0.05, 0.1, 0.5, 0.75, and 1 
µM STS or no STS. MTT reduction was determined and expressed as mean absorbance values at 570 nm ± 
SEM. Replicates in assay=12 and n=2. 
The concentration of STS commonly used to induce apoptotic cell death in SH-SY5Y cells 
ranges between 0.5 µM-1 µM (Boix et al. 1997, Lopez and Ferrer 2000, Yuste et al. 2002). 
A 1 µM concentration of STS was chosen for further studies on cell morphology. Images 
of cells were taken following exposure to 1 µM STS over a 3 h period (Figure 3. 5). 
Control cells were exposed to serum free medium only (-STS) and show the normal SH-
SY5Y neuronal phenotype which is: flat, elongated, approximately 20-30 µm in length 
with limited neurite-like structures over this short time course. Serum free medium was 
used as the vehicle and control for all experiments using STS. Following the addition of 
STS, the cells immediately show classical hallmarks of apoptosis which are: shrinkage, 
rounding, surface blebbing, shininess and nuclear condensation. These characteristics are 
evident after as little as 0.5 h in STS and are also present after 1 and 3 h (Figure 3. 5).  
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Figure 3. 5 STS induces apoptotic morphologies in SH-SY5Y cells 
SH-SY5Y cells were exposed to 1 µM STS for up to 3 h Cell morphologies were visualised using a Nikon 
eclipse TS100 microscope. Photomicrographs (× 10 objectives, taken on Nikon DN100 digital camera) are 
shown at 0.5 h, 1 h and 3 h post-treatment and are representative of 3 independent experiments. Scale bar 
represents 20 µm. Photomicrographs have been enlarged in each case and a small area shown inset. 
To further monitor cell viability following exposure to 1 µM STS, MTT reduction was 
measured again, but over a 6 h period. Cell viability is only significantly reduced following 
4 h exposure to STS (Figure 3. 6). 
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Figure 3. 6 STS induces loss of cell viability in SH-SY5Y cells 
Cell viability was measured in SH-SY5Y cells over 6 h, following the addition of 1 µM STS using the MTT 
reduction assay. MTT reduction is expressed as mean percent cell viability compared to control ± S. D, 
where replicates in assay=12 and n=3. Treated samples were statistically compared to untreated controls 
using the Student’s t-test where *p<0.05 and *** p<0.001. 
3.1.1.3 Apoptotic markers 
Since the MTT reduction assay only measures loss of cell metabolism it was necessary to 
investigate whether apoptotic cell death was occurring following exposure to 1 µM STS. 
Treatment with 1 µM STS consistently resulted in caspase-3 activation (around twenty fold 
of control levels, peaking at around 3 h, Figure 3. 7), before returning to baseline levels.  
 
Figure 3. 7 Caspase-3 is activated following STS exposure in SH-SY5Y cells.  
Following addition of 1 µM STS, Caspase-3 activity was measured to monitor the apoptotic time course, 
using Acetyl-Asp-Glu-Val-Asp-7-Amidomethylcoumarin as substrate and expressed as change FU/min/µg 
protein. All data represent triplicate values from three independent experiments (n=3) and are expressed as 
mean ± S.D. Treated samples were statistically compared to untreated controls using the Student’s t-test 
where *** p<0.001. 
To further characterise the apoptotic cell death pathways in this model, activation of 
upstream initiator caspases was assessed. Throughout the apoptotic time course induced by 
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STS, caspase-9 was consistently activated (detected after 1 h STS exposure and remaining 
active for the following 5 h, Figure 3. 8A). However, no activation of caspase-8 was 
detected, despite the presence of the caspase-8 proform (Figure 3. 8B) in both untreated 
and treated cells, confirming the presence of procaspase-8 protein in our clone. 
 
Figure 3. 8 The intrinsic but not extrinsic pathway in active in STS-induced apoptosis 
(A) Western blot analysis of caspase-9 activation (pro-from / active form) in cell extracts of SH-SY5Y cells 
exposed to 1 µM STS over a 6 h period. Equal protein aliquots (20 µg) were separated on a 12 % (v/v) 
acrylamide SDS-PAGE gel prior to transfer to nitrocellulose membranes. The blot was probed with anti-
caspase-9 antibody (2 µg/ ml) which detected both the pro-form (46 kDa) and the active-form (34 kDa). (B) 
Western blot analysis of caspase-8 activation (pro-from / active form) in cell extracts of SH-SY5Y cells 
exposed to 1 µM STS over a 6 h period. Equal protein aliquots (50 µg) were separated on a 12 % (v/v) 
acrylamide SDS-PAGE gel prior to transfer to nitrocellulose membranes. The blot was probed with anti-
caspase-8 antibody (2 µg/ ml) which detected the pro-form (56 kDa) but not the active-form (28 kDa). Equal 
loading in both cases was checked by probing for total ERK (1: 1000 dilution) The Western blots shown are 
representative of three separate experiments. 
To confirm caspase-8 and caspase-9 expression in SH-SY5Y, conventional RT-PCR and 
the more sensitive qRT-PCR approach were applied to detect mRNA expression in both 
SH-SY5Y and U937 cells (Figure 3. 9). The human U937 cell line used in our laboratory 
was used as a positive control for caspase-8 expression since it is known to contain 
caspase-8 and is sensitive to Fas ligand stimulation (Niikura et al. 2002). Figure 3. 9 shows 
the presence of both caspase-8 and caspase-9 mRNA expression in SH-SY5Y and U937 
cells (see chapter 4).  
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Figure 3. 9 Caspase-8 and -9 mRNA is detectable in SH-SY5Y cells 
(A) Agarose gel showing SH-SY5Y samples (lanes 1,4 and 7), U937 samples (lanes 2, 5 and 8) and negative 
PCR controls (lanes 3, 6 and 9) for caspase-9, caspase-8 and GAPDH gene expression. (B) Quantitative RT-
PCR data expressed as single values for each independent SH-SY5Y or U937 cell sample (sample 1, S1 and 
sample 2, S2).  
3.2.2 Changes in MAO in STS-induced apoptosis 
Peak caspase-3 activation following exposure to 1 µM STS (approximately 3 h, Figure 3. 
7) was preceded by a significant (two- to –threefold) increase in MAO catalytic activity 
(Figure 3. 10) which peaked at around 1 h and remained high during the subsequent 5 h 
period.  




Figure 3. 10 Changes in MAO and caspase-3 activities following STS treatment 
Following addition of 1 µM STS, MAO activity was measured in SH-SY5Y via a radiometric method, using 
14C-Tyramine as a substrate. MAO catalytic activity was expressed as pmoles/min/mg protein. Caspase-3 
activation was measured to monitor the apoptotic time course, using Acetyl-Asp-Glu-Val-Asp-7-
Amidomethylcoumarin as substrate and expressed as ∆FU/min/µg protein. All data represent triplicate values 
from three independent experiments (n=3) and are expressed as mean ± S.D. Treated samples were 
statistically compared to untreated controls using the Student’s t-test where * p<0.05, ** p<0.01, *** 
p<0.001. 
Increased MAO activity was associated with a significant but transient increase in MAO-A 
protein (two- to threefold, Figure 3. 11). MAO-A protein levels were significantly elevated 
in a time dependent manner, reaching maximal activity at 1 h post STS treatment (Figure 
3. 11). MAO-A protein levels then return back to control level over the following 2 h 
(Figure 3. 11).  
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Figure 3. 11 STS-induced apoptosis causes increased MAO-A protein 
Left panel shows a dot blot of MAO-A protein levels following STS exposure. Equal protein homogenates 
were loaded on to a nitrocellulose membrane and probed with a MAO-A specific antibody. Mitochondrial 
outer membranes from human liver are the positive control and no primary antibody was the negative 
control. Right panel. Quantification of dot blots. Blots were digitised and densitometry was performed to 
quantify relative MAO-A protein levels in all blots. These data represents values from four separate 
experiments (n=4) and expressed as mean arbitrary units (a.u.) ± S. D. Statistical analysis of treated cells in 
comparison to untreated controls was carried out using the Student’s t test, where  ** p<0.01, *** p<0.001. 
To determine whether the increased MAO-A protein levels were a result of increased 
MAO-A mRNA expression, quantitative RT-PCR analyses were performed. No significant 
changes in MAO-A mRNA levels were detected following 1 µM STS over a 3 h apoptotic 
time course (Figure 3. 12).  
 
Figure 3. 12 MAO-A mRNA expression levels are unaffected by STS 
MAO-A mRNA expression was measured by qRT-PCR following the addition of 1 µM STS for 3 h.  Data 
represent duplicate values from three independent experiments (n=3). Values are expressed as means (% 
untreated control) ± S.D. Statistical analysis of treated cells in comparison to untreated controls was 
performed using the Student’s t-test, where no data was significant at p<0.05. 
3.2.3 Relevance of MAO in STS induced apoptosis 
Two unrelated MAO inhibitors, clorgyline and tranylcypromine, inhibit in situ MAO 
activity in SH-SY5Y cells in the presence and absence of STS during a 4 h time period 
(Figure 3. 13). Caspase-3 activity was measured following inhibition of MAO-A in this 
apoptotic model to investigate the relevance of MAO in the apoptotic cascade. Both 
clorgyline and tranylcypromine significantly reduced caspases-3 activation by 50 % and 35 
% respectively (Figure 3. 13B). 
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Figure 3. 13 Inhibition of MAO-A reduces caspase-3 activity in STS-induced apoptosis 
(A) MAO activity was measured in untreated SH-SY5Y cells, and in cells at 3 h following the addition of 1 
µM clorgyline (Clor), 1 µM tranylcypromine (TCP), 1 µM STS, 1 µM STS + 1 µM clorgyline (STS+Clor) or 
tranylcypromine (STS+TCP), using 14C-Tyramine as a substrate. Changes in MAO activity were determined 
and expressed as experimental mean pmoles/min/mg protein ± S.D. (B) Caspase-3 activity was measured in 
untreated SH-SY5Y cells, and in cells at 3 h following the addition of 1 µM clor, 1 µM TCP, 1 µM STS, 1 
µM STS + 1 µM clorgyline or 1 µM tranylcypromine, using Acetyl-Asp-Glu-Val-Asp-7-
amidomethylcoumarin as a substrate. Caspase-3 activity was expressed as mean ∆FU/ min/µg protein (% 
STS alone) ± S.D, where n=3. MAO/Caspase activities from STS+MAO inhibitor treated cells were 
compared to activities from cells exposed to STS alone using the Student’s t-test, where ** p=<0.01, *** 
p=<0.001. MAO/Caspase activities from STS treated cells were compared to activities from untreated cells 
using the Student’s t-test, where * p=<0.05, *** p=<0.001. MAO/Caspase activities from MAO inhibitor 
treated cells were compared to activities from untreated cells using the Student’s t-test, where *** p=<0.001. 
Activation of the upstream initiator caspases-9 during STS induced apoptosis was 
significantly reduced to ~50% by clorgyline (Figure 3. 14). 
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Figure 3. 14 Inhibition of MAO-A reduces caspase-9 activation in STS-induced apoptosis 
Top. Activation of caspase-9 (pro-form/active form) was assessed in extracts of SH-SY5Y cells exposed for 3 
h to 1 µM STS in the presence or absence of 1 µM clorgyline. Equal protein aliquots (20 µg) were separated 
on a 12 % (v/v) acrylamide SDS-PAGE gel prior to transfer to nitrocellulose filters. Western blots were 
probed with anti-caspase-9 antibody (2 µg/ml). Bottom. Western blots were digitised and densitometry was 
performed to quantify relative caspase-9 proform and active protein levels. These data represents values from 
three separate experiments (n=3) and expressed as mean caspase-9 activity (by dividing the active band 
intensity by the proform band intensity) ± S. D. Statistical analysis of STS treated cells in comparison to STS 
+ clorgyline treated cells was carried out using the Student’s t test, where  * p<0.05. 
Inhibition of MAO-A also improved the viability of STS treated cells. STS reduced cell 
viability (measured using MTT assay) by around 10%. The MAO inhibitors clorgyline and 
tranylcypromine reduced this effect, which was significant after 1 h (Figure 3. 15A). 
Morphological observations also demonstrated that inhibition of MAO-A improved cell 
viability. Figure 3. 15B shows that after 3 h exposure, STS treatment results in a typical 
apoptotic phenotype, with cells being shrunk and rounded [panels (a and d)]. The addition 
of clorgyline and tranylcypromine at the same time as STS significantly improved the 
condition of the cells, with axonal outgrowths being evident [compare panels (b and c) 
with, respectively, panels (e and f)].  
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Figure 3. 15 Inhibition of MAO-A reduces loss of cell viability in STS-induced apoptosis 
(A) Cell viability (proliferation rate/MTT reduction) was measured in SH-SY5Y cells over 3 h, following the 
addition of serum free medium, clorgyline 1 µM, tranylcypromine 1 µM, STS 1 µM, STS 1 µM + clorgyline 
1 µM (STS+Clor) or STS 1 µM + tranylcypromine (STS+TCP) using the MTT reduction assay. MTT 
reduction was determined and expressed as mean percent cell viability compared to control ± S. D, where 
replicates in assay=12 and n=3. MTT reduction in the presence of STS and the MAO inhibitor was compared 
to MTT reduction with STS alone using the Student’s t-test, where * = p<0.05 and **= p<0.01. (B) SH-
SY5Y cells were exposed to serum free medium [a], 1 µM clorgyline [b], 1 µM tranylcypromine [c], 1 µM 
STS [d], 1 µM STS + 1 µM clorgyline [e] or 1 µM STS + 1 µM tranylcypromine [f]. Cells were visualised 
using a Nikon eclipse TS100 microscope. Photomicrographs (× 20 objectives, taken on Nikon DN100 digital 
camera) are shown at 3 h post-treatment and are representative of 3 independent experiments. Scale bars 
represent 30 µm.  
To support MAO-A inhibition data, the location of glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) in STS treated cells and those concomitantly treated with 
clorgyline was investigated. As discussed later (section 3.3), GAPDH translocates to the 
nucleus during apoptosis (Chuang et al. 2005). The effect of clorgyline on the translocation 
of GAPDH induced by STS was revealed using confocal microscopy (Figure 3. 16). In 
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control cells GAPDH remains in the cytosol, whereas in STS treated cells, at least some 
GAPDH translocates to the nucleus (Figure 3. 16). Addition of clorgyline had no effect on 
GAPDH translocation to the nucleus in STS treated cells (Figure 3. 16). 
 
Figure 3. 16 Effect of clorgyline on translocation of GAPDH to the nucleus following STS insult 
SH-SY5Y cells were then exposed to 1 µM clorgyline alone, 1 µM STS alone or 1 µM clorgyline + 1 µM 
STS for 3 h. Cells were probed with a primary antibody specific to GAPDH and the presence of GAPDH 
(green fluorescence) revealed using a secondary antibody coupled to FITC. Nuclei (shown in red) were 
detected by counterstaining with propidium iodide. The presence of GAPDH in the nucleus is shown by the 
yellow signal. Images were visualised using a CLSM Leica microscope. Scale bar represents 20 µm 
3.2.4 MAO enhanced apoptosis: mechanism of action 
To examine the potential involvement of MAPK signalling in MAO-enhanced apoptosis, 
the levels of phosphorylated (activated) ERK, JNK and p38 during STS-induced apoptosis 
were examined. As shown in Figure 3. 17A, STS treatment resulted in sustained increases 
in the levels of phosphorylated JNK and p38 compared with controls and a transient 
reduction in phosphorylated ERK followed by increased phosphorylation of ERK, all 
starting at approximately the same time as MAO activation (Figure 3. 17). Inhibition of 
MAO-A with clorgyline attenuated these effects, reducing these levels of phosphorylated 
p38, JNK and ERK back to control levels.  
As presented in Figure 3. 17B, STS induced depletion of Bcl-2 levels and clorgyline alone 
had no effect on Bcl-2 levels, using the time zero data as a control. When the cells were 
exposed to clorgyline and STS together, Bcl-2 protein expression was maintained at the 
control level (Figure 3. 17B). 
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Figure 3. 17 Staurosporine induces changes in MAPK signalling and Bcl-2 levels: attenuation by 
clorgyline 
Equal protein aliquots (80 µg for MAPK proteins and 20 µg for Bcl-2) of cells extracts from SH-SY5Y cells 
exposed to 1 µM clorgyline, 1 µM STS or 1 µM STS + 1 µM clorgyline for a 3 h period were separated on a 
12 % (v/v) acrylamide SDS-PAGE gel prior to transfer to nitrocellulose membranes. Blots were probed with 
antibodies directed to pERK (1:1000 dilution), pJNK (1:500 dilution) and pP38 (1:1000) (A) or by anti-bcl-2 
antibody (1:750) (B) Equal loading was checked by probing for total ERK (1:1000 dilution), total JNK 
(1:750 dilution) and total p38 (1:1000 dilution). Blots shown are representative of three separate experiments. 
MAO-A produces H2O2 as a by-product of its enzymatic action and therefore MAO 
derived ROS might contribute to apoptotic signalling in this cell model. Hence 
antioxidants may mimic the effects of MAO-A inhibition in apoptotic signalling. Exposure 
of SH-SY5Y cells to 1 µM STS resulted in the production of high levels of ROS (Figure 3. 
18A). This effect was lessened by concomitant treatment with 1 µM clorgyline or the 
antioxidant NAC (1mM, Figure 3. 18B). However, 1 mM vitamin C was less effective 
(Figure 3. 18B). NAC but not vitamin C significantly protected cells from caspase-3 
activation following STS insult (Figure 3. 18C). These data indicate that MAO-generated 
oxidative stress is involved in apoptotic signalling.  
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Figure 3. 18 Effect of MAO inhibitor clorgyline and antioxidants on ROS production in Staurosporine 
exposed SH-SY5Y cells 
(A) Cells were exposed to 1 µM clorgyline, 1 µM STS or 1 µM STS + 1 µM clorgyline. DCDHF 
fluorescence was monitored over a 4 h period and visualised using a CLSM Leica microscope. 
Photomicrographs are shown at 2 h post-treatment, are laser power matched and are representative of 3 
independent experiments. Scale bar represents 20 µm. (B) Cells were exposed to 1 mM antioxidant alone, 1 
µM STS or 1 µM STS + 1 mM antioxidant. DCDHF fluorescence was monitored over a 4 h period and 
visualised using a CLSM Leica microscope. Photomicrographs are shown at 2 h post-treatment and are laser 
power matched and are representative of 3 independent experiments. Scale bar represents 20 µm (C) The 
effects of antioxidants NAC and vitamin C on caspase-3 activity were measured following treatment for 2 h 
using Acetyl-Asp-Glu-Val-Asp-7-Amidomethylcoumarin as a substrate. Caspase 3 activity was expressed as 
mean ∆FU/min/µg protein ± S.D, where n=3. Statistical analysis of antioxidant treatment in the presence of 
STS was compared to STS treatment alone using the Student’s t-test where ** p<0.01. 
In order to investigate whether increased ROS produced by MAO at the mitochondrial 
surface could influence mitochondrial function, ROS produced following STS insult was 
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detected in live cells that were stained for active mitochondria using Mitotracker-Red™. 
Figure 3. 19 shows ROS as green and intact mitochondria as red (brightly stained area). 
Co-localisation of ROS and mitochondria is seen as orange-yellow (depending on levels). 
The merge shows that a considerable amount of ROS produced following STS insult is in 
the mitochondria or in close vicinity (Figure 3. 19). 
 
Figure 3. 19 ROS co-localised with intact mitochondria in STS-induced apoptotic SH-SY5Y cells 
SH-SY5Y cells incubated with DCDHF (dye fluorescing in presence of ROS, green) and mitotracker red 
(dye fluorescing in intact mitochondria, red) were then exposed to 1 µM STS and visualised using a CLSM 
Leica microscope. Photomicrographs are shown at 1.5 h post-STS treatment. Scale bar represents 20 µm. 
To further confirm that ROS produced by MAO during STS-induced apoptosis was in the 
mitochondria. MitoQ and the control compound DTPP were assessed for their anti-
apoptotic properties. Figure 3. 20 demonstrates that MitoQ reduces caspase-3 activity in 
STS-treated cells at a 100 nM concentration. In addition, 100 nM MitoQ significantly 
reduces ROS production in STS-treated cells; this was not the case for DTPP (Figure 3. 
21). 
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Figure 3. 20 Effect of DTTP and MitoQ concentration on caspase-3 activity 
Following addition of 50, 200 and 500 nM DTTP alone, MitoQ alone, DTTP + 1µM STS, or MitoQ + 1µM 
STS, caspase-3 activity was measured in SH-SY5Y using Acetyl-Asp-Glu-Val-Asp-7-
Amidomethylcoumarin as substrate and expressed as caspase-3 activity (% untreated control). All data 
represent triplicate values from three independent experiments (n=3) and are expressed as mean ± S.D.  
 
Figure 3. 21 ROS in STS treated SH-SY5Y cells: Effect of mitochondrially directed antioxidant MitoQ 
Cells exposed to 1 µM STS, 1 µM STS + 100 nM DCTP (compound directed to mitochondria with only 
weak antioxidant properties), 1 µM STS + 100 nM MitoQ (antioxidant directed to mitochondria) or untreated 
cells were monitored for DCDHF fluorescence, visualised using a CLSM Leica microscope. 
Photomicrographs are shown at 1.5 h post-treatment and are representative of 2 independent experiments. 
Scale bar represents 100 µm.  
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3.3. DISCUSSION 
3.3.1 Development of an in vitro model of neuronal apoptosis 
SH-SY5Y cells contain solely MAO-A mRNA, MAO-A protein and MAO-A catalytic 
activity (Figure 3. 3). These data confirm previous claims on MAO isoform mRNA 
expression in these cells (Zhu et al. 1992, Yi et al. 2006a).  
In SH-SY5Y cells, STS activates caspase-9 (Figure 3. 8) and -3 (Figure 3. 7) and thus 
initiates the intrinsic apoptotic pathway. In contrast, the extrinsic route, which depends on 
agonist binding to cell surface death receptors, is unaffected (Figure 3. 8), despite the cells 
containing procaspase-8 protein and caspase-8 mRNA (Figure 3. 9). These data are 
consistent with previously reported data obtained in a similar cellular model (Lopez and 
Ferrer 2000). It is not clear whether lack of caspase-8 activation in the STS model of 
apoptosis is due to the receptor-mediated pathway not being required or whether caspase-8 
(although present) is non-functional. Loss of caspase-8 function may be a direct cause of 
malignancy and may be a consequence of gene silencing resulting from the cloning process 
or due to the loss of death receptor function, or both. Nevertheless, the activation of the 
mitochondrial apoptotic pathway in this model is of special interest considering the 
mitochondrial localisation of MAO in the outer mitochondrial membrane. This model of 
neuronal cell death may be useful for research on conditions such as PD for a number of 
reasons: SH-SY5Y cells contain MAO-A and neurotransmitter uptake systems, the 
neuroblastoma cells die by apoptosis, the apoptotic pathway is associated with 
mitochondrial function, mitochondrial dysfunction being a major factor in 
neurodegenerative disease aetiology (reviewed by Schapira 2006).  
3.3.2 The role of MAO in STS-induced neuronal apoptosis 
MAO activity increased significantly prior to activation of caspase-3 (Figure 3. 10) and 
increased ROS induced by STS was reduced by MAO inhibition (Figure 3.18), signifying 
that increased oxidative stress resulting from increased MAO catalytic activity is involved 
in early apoptotic events upstream of apoptotic execution. Increased ROS in STS-induced 
apoptosis may also be linked to a rapid increase in Ca2+ levels (Kruman and Guo 1998) and 
Ca2+ has very recently been shown to selectively increase the catalytic activity of MAO-A 
in protein extracts from mouse neurons (Cao et al. 2007). Increased MAO activity at the 
mitochondrial surface will result in increased formation of H2O2, which if removal 
pathways are inactive or overloaded is converted to the highly damaging hydroxyl radical, 
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which is capable of inducing intense oxidative stress in mitochondria, (Mathai and 
Sitaramam 1994).  
MAO inhibition significantly reduced caspase-3 activation (Figure 3. 13) and loss in cell 
viability (Figure 3. 15), confirming that MAO-generated ROS was involved in STS-
induced apoptosis. To improve the reliability of the experimental data, two independent 
MAO inhibitors were used. Clorgyline preferentially inhibits MAO-A, but is structurally 
related to the MAO-B inhibitor deprenyl and other propargyl deprenyl analogues such as 
N-propargyl-1 (R)-aminoindan (rasagiline) and the compound CGP3466 (now in clinical 
trials for PD). The propargylamine-containing deprenyl analogues are reported to possess 
neuroprotective and anti-apoptotic properties (Tatton et al. 1994, Akao et al. 2002, Sharma 
et al. 2003, Holt et al. 2004), although this is not always the case (Ferger et al. 1998). 
These neuroprotective properties, rather than being a result of MAO inhibition, are thought 
to be due to the inhibition of pro-apoptotic translational machinery (Tatton et al. 1994, 
Kragten et al. 1998, Berry and Boulton 2000), induction of anti-apoptotic Bcl-2 proteins 
(Akao et al. 2002, Maruyama et al. 2002) and hydroxyl radical scavenging activity 
(Sharma et al. 2003). It has been suggested that the key event in these processes is the 
specific binding of propargylamines to glyceraldehydes-3-phosphate dehydrogenase 
(GAPDH), which has been implicated in apoptosis (reviewed by Chuang et al. 2005). The 
mechanism by which GAPDH promotes apoptosis is still unclear, however early work 
showed that GAPDH overexpression induced programmed cell death (Tajima et al. 1999), 
depletion of GAPDH mRNA inhibited apoptosis (Chuang and Ishitani 1996) and GAPDH 
was instrumental in cell transport (Robbins et al. 1995). Importantly, GAPDH translocates 
to the nucleus during apoptosis (Chuang et al. 2005) and here it is thought to be involved 
in translational control, DNA replication, DNA repair and nuclear tRNA transport (Sirover 
2005); propargylamines are thought to inhibit translocation of GAPDH to the nucleus and 
hinder its pro-apoptotic activities. Clorgyline has previously been shown to protect against 
apoptosis (Malorni et al. 1998, DeZutter and Davis 2001), serum withdrawal-induced loss 
in cell viability (Ou et al. 2006) and MPTP-induced neurotoxicity (De Girolamo 2001). 
Whether or not the protective effects are due solely to MAO inhibition has not been fully 
confirmed. Nevertheless, in the present study, clorgyline had no effect on Bcl-2 levels in 
control cells (Figure 3. 17B) and did not inhibit translocation of GAPDH to the nucleus 
(Figure 3. 16).  
To verify the effects of clorgyline in STS-induced apoptosis were a result of MAO 
inhibition, a second MAO inhibitor that did not contain the propargyl moiety was needed. 
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Initially the MAO-A inhibitor moclobemide was chosen. It was found that a high 
concentration of this inhibitor (at least 1 mM) was required to inhibit MAO in vitro and in 
situ, and that non-toxic concentrations did not inhibit MAO (see appendix, Figure A1.1). 
Therefore, TCP was chosen as a second MAO inhibitor as it contains no propargyl moiety, 
but interacts irreversibly with the flavin group and inhibits both MAO-A and MAO–B. 
TCP also protects cells from STS-induced apoptosis and since MAO-B is absent in our cell 
model, this confirms that MAO-A is functional in apoptosis induced by STS. Although 
links between MAO and mitochondrial damage have previously been made (Berman and 
Hastings 1999, Cohen and Kesler 1999, Kumar et al. 2003, Alves et al. 2007) and 
mitochondrial function is vital in apoptotic signalling, a direct role for MAO-A in 
apoptosis has only been claimed by DeZutter and Davis 2001 and, very recently by Ou et 
al. 2006. However, these authors have not linked the apoptotic effects to ROS production 
by MAO-A activity.  
 Reactive oxygen species formation was substantially increased following STS 
treatment (Figure 3. 18A) and inhibition of MAO by clorgyline and treatment with the 
antioxidant NAC reduced STS-induced ROS to a similar extent (Figure 3. 18B). The fact 
that both clorgyline and NAC also reduced caspase-3 activation (Figure 3. 13 and Figure 3. 
18C) indicates that ROS produced by MAO are activating apoptosis. The antioxidant 
vitamin C was also used but was less effective than NAC or clorgyline in reducing STS-
induced ROS and caspase-3 activation (Figure 3. 13 and Figure 3. 18C). The reason for 
this may be related to the fact that vitamin C, although a potent antioxidant, is considered 
to be toxic in some circumstances, especially in the presence of metal ions and H2O2 
(reviewed by Halliwell 1999). Use of Mitotracker-Red™ and DCDHF together in live cells 
revealed that the majority of ROS produced following STS insult was localised in 
mitochondria (Figure 3. 19). This again supports the importance of MAO-generated 
oxidative stress at the mitochondrial surface in this model. The role of mitochondrial ROS 
was further supported by the fact that the novel antioxidant MitoQ also reduced ROS 
production in the presence of STS (Figure 3. 21), whilst the same concentrations of its 
control compound DTTP was less effective (Figure 3. 21). 
3.3.3 Effects of STS on MAO expression 
The nature of an apoptotic inducer (or trigger) of death signalling has a profound impact on 
the apoptotic mechanisms. Nonetheless, apoptosis is thought to be the predominant form of 
 Chapter 3                                                       The Role of MAO in mitochondria-mediated neuronal apoptosis 
 88
neuronal cell death in chronic neurodegenerative disease (Friedlander 2003, Emerit et al. 
2004). Thus the fact that MAO has an active role in this process is of high significance. 
 MAO protein levels were increased following STS exposure (Figure 3. 11), albeit 
transiently, and without a concomitant increase in MAO-A mRNA levels (Figure 3. 12). 
This implies that in this apoptotic model, increases in MAO protein are due to post-
transcriptional events. The exact mechanism has not been addressed here, but this could be 
attributed to a number of scenarios. Reduction in MAO protein degradation is feasible 
since protein degradation pathways (the ubiquitin-proteasome system in particular) are 
likely to be overloaded or impaired following such stress (discussed in Ciechanover and 
Brundin 2003). Indeed mitochondrial complex I inhibition by rotenone (Shamoto-Nagai et 
al. 2003) and MPP+ (Caneda-Ferron et al. 2008) in SH-SY5Y cells inactivates the 
proteasome and importantly, caspase activation was shown to inhibit proteasome function 
during Jurkat cell apoptosis (Sun et al. 2004). Exactly how MAO is degraded is unknown, 
however the proteasome is particularly sensitive and preliminary data indicate STS 
induced loss of chymotrypsin-like proteasome activity, which was reduced following 
MAO inhibition (see appendix, Figure A1.2). An increase in MAO protein levels, without 
increased mRNA expression, could also result from increased translation of existing MAO-
A mRNA following STS insult. Post-translational modifications, such as the addition of 
functional groups or conformational change can in turn contribute to protein function.  
 Since increased MAO catalytic activity is maintained throughout the apoptotic time 
course whilst MAO-A protein is increased only transiently, the increased MAO-A protein 
may not be exclusively responsible for the increases in catalytic activity of MAO. The 
catalytic turnover of an enzyme can be affected by a number of factors. In the case of 
MAO-A catalysis, the availability of its flavin cofactor, the requirement for metal ions 
(such as copper) and disruption of negative feedback mechanisms could be involved. 
Another consideration for the control of MAO-A catalytic activity is its special relationship 
with the mitochondrial membrane. MAO is an integral membrane protein and only 
following its insertion into the outer mitochondrial membrane (which requires ATP and 
ubiquitin), can it become catalytically active (Zhuang et al. 1992). Very recent work by 
Cao and co-workers showed increased MAO-A catalytic activity in hippocampal cells 
exposed to increased free calcium, which was not paralleled by increased MAO-A mRNA 
expression or MAO protein levels (Cao et al. 2007), supporting the suggestion that MAO 
can be more active without more enzyme being made.  
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 In contrast, transcriptional activation of the MAO-A gene was seen following 
withdrawal of nerve growth factor in rat PC12 cells (DeZutter and Davis 2001; which has 
been related to stress MAPK activation and apoptotic signalling). In addition, Ou et al. 
(2006) recently found that MAO-A mRNA expression is induced following serum 
starvation, mediated by a reduction in the expression of the transcriptional repressor R1.  
These very different findings suggest that there are various regulatory mechanisms of cell 
death that could regulate MAO-A activity, dependent on the inducer. 
3.3.4 Regulation of apoptosis by MAO 
Bcl-2 is an anti-apoptotic protein that plays a central role in mitochondrially mediated 
apoptosis and survival as a result of its strong influence on the balance of pro- and anti-
apoptotic proteins that also reside on the mitochondrial surface. Depletion of Bcl-2 is 
thought to be one of the first initiators of the intrinsic apoptotic cascade, as this shifts the 
balance of Bcl-2 family proteins in favour of apoptosis, triggering the release of 
cytochrome c from the mitochondria (Hengartner 2000). STS treatment resulted in 
depletion of Bcl-2 in this model (Figure 3. 17B), which was prevented by clorgyline, 
suggesting that MAO acts upstream of changes in Bcl-2. This is contrary to the situation in 
serum deprivation, where MAO appears to act downstream of Bcl-2 (see Chapter 4 and Ou 
et al. 2006). These differences may again reflect the different apoptotic inducers used and 
further work needs to be carried out to clarify the relationship between MAO and Bcl-2. 
The highly conserved MAPK cascades are among the pathways often used to transduce 
mammalian stress signals (Robinson and Cobb 1997). They have been extensively 
described as being crucial in regulating stress/survival responses and hence play an 
important and universal role in mechanisms of cell death. Following STS-induced 
apoptosis, ERK (generally thought to be activated by pro-survival stimuli and influenced 
by JNK/p38) was eventually activated, coinciding with increases in MAO activity (Figure 
3. 10 and Figure 3. 17A). Activation of p38 and JNK (generally thought to be activated by 
stressful stimuli and influenced by ERK) occurred slightly before activation of ERK 
(Figure 3. 17A). MAO inhibition by clorgyline attenuated the activation of these pathways 
to control levels (Figure 3. 17A). Thus MAPK signalling modules are involved in STS-
induced apoptosis and ROS generated by MAO are involved in initiating these pathways 
(as MAO inhibition reduced MAPK activation). Indeed, H2O2 has previously been shown 
to activate MAPK proteins (Guyton et al. 1996). Whether or not the MAO gene is also a 
target of the MAPK pathways as described by DeZutter and Davis (2001) and Wong et al. 
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(2002) was not addressed in the present chapter, but would seem unlikely given that MAO-
A mRNA levels were unchanged following STS treatment. However, in this model MAPK 
signalling might be recruited to transmit pro-apoptotic stress signals following STS 
exposure.  
In this apoptotic model it is likely that MAO exerts its pro-apoptotic effects mainly by 
influencing the major stress/survival signalling pathways such as MAPK pathways via its 
production of reactive oxygen species, most likely as a result of H2O2 production but the 
effects of other reaction products such as aldehyde and ammonia may also be considered. 
The targets of MAPK pathways activated during STS-induced apoptosis could include a 
wide range of transcription factors, ultimately targeting specific genes involved in cell 
death/survival. MAPK signalling also involves a large amount of cross talk with other 
signalling pathways that could be recruited such as PKC or Ras and MAPK pathways may 
play a role in many cellular responses such as receptor desensitisation and cytokine 
signalling. It should be noted that MAO generated oxidative stress could have a direct 
influence on apoptosis by its action at the mitochondrial surface. Not only by influencing 
the balance of pro-apoptotic and anti-apoptotic Bcl-2 family proteins that also reside there, 
but by directly compromising the integrity of mitochondrial function directly. This is 
possible since MAO-generated ROS can pass through the mitochondrial outer membrane, 
directly damaging the electron transport system (Cohen et al. 1997, Berman and Hastings 
1999) and mitochondrial DNA (Hauptmann et al. 1996). Certainly, ATP levels are 
significantly reduced in SH-SY5Y cells over expressing MAO-A (Chapter 5, Figure 5.9).  
3.3.5 Conclusion 
Data in this chapter suggest a dynamic role for MAO-A in STS-induced neuronal 
apoptosis, driven by the ability of MAO to generate oxidative stress at the mitochondrial 
surface. The data supports the hypothesis that MAO plays a key role in the modulation of 
apoptotic signalling in response to biological stressors. Here the stressor STS initiated 
classical apoptosis, having severe and rapid consequences on the cell (Figure 3.22). The 
nature of the inducer and its rapid effects may explain why there were no changes in 
MAO-A at the gene level and opens up questions regarding the role of MAO in neuronal 
apoptosis in the broader sense. It is likely that MAO can act as an enhancer of cell death 
(in addition to its role as a deaminating enzyme) but that the mechanisms involved depend 
on the nature of the stressor, enabling MAO to fine tune death/survival responses. These 
findings may have wider implications for the therapeutic use of the dopamine precursor, 
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levodopa, in PD, predisposition to neurodegenerative diseases and mechanism of acute 
apoptotic cell death associated with brain damage and stroke.  
 
 
Figure 3. 22 Overview of STS-induced apoptosis: role of MAO-A 
STS inhibits PKC which triggers an array of stressful stimuli within the cell. Whilst MAO-A mRNA 
expression remains unaffected, MAO-A protein and catalytic activity are greatly increased, generating 
amplified levels of its catalytic product H2O2. In turn, free radical levels are elevated (which can be reduced 
by MAO–A inhibition). Bcl-2 levels are depleted and levels of phosphorylated (activated) MAPK signalling 
components JNK, ERK and p38 are increased. The upstream apoptotic caspase-9 is cleaved (activated) and 
finally the executioner caspase-3 is activated, initiating the final stages of apoptosis. Inhibition of MAO-A 
protects cells from apoptotic commitment (caspase-3) and also reduces activation of upstream apoptotic 
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THE ROLE OF MAO-A IN SELECTED MODELS OF 
NEURONAL APOPTOSIS 
4.1. INTRODUCTION 
Cell death mechanisms are extremely varied and how cells respond to stress both in vitro 
and in vivo depends on many factors including the nature of the stressor and the cell type. 
Data in chapter 3 indicate MAO may be involved in modulating cell death in STS-treated 
SH-SY5Y cells. The present chapter addresses whether the role of MAO in cell death is 
universal or whether it is only evident in specific types of cell death.  
4.1.1 Receptor-mediated apoptosis 
Receptor-mediated apoptosis is characterised by the interaction of extracellular ligands 
with cell surface receptors, which induces the formation of death inducing signalling 
complex (DISC), activating caspase-8 (Hengartner 2000). Receptor-mediated apoptosis is 
distinct from mitochondrially-mediated apoptosis, since the apoptotic trigger arises from 
events on the cell surface rather than events at the mitochondria. Intracellular events that 
occur following ligand-receptor binding are somewhat complicated by the large amount of 
cross-talk between signalling pathways. For example, caspase-8 often activates the 
intrinsic pathway, whereas caspase-9 seldom activates caspase-8. 
4.1.1.1 Fas / Fas ligand system 
Fas (also known as CD95) is a member of the tumour-necrosis receptor family of death 
receptors, which can induce apoptosis or conversely, deliver growth signals (Desbarats et 
al. 2003). Fas receptor-mediated apoptosis is summarised in Figure 4. 1. Caspase-8 
cleavage is characteristic of Fas-induced apoptosis (Nagata 1997, Hengartner 2000). SH-
SY5Y cells express the cell-surface Fas receptor (Desbarats et al. 2003) and express Fas 
mRNA (Russo et al. 2004). However, numerous publications have reported that SH-SY5Y 
cells do not undergo caspase-8 mediated apoptosis due to gene silencing (see section 
3.1.2.3). 
4.1.1.2 TNFα 
Tumour necrosis factor alpha (TNFα) is secreted by immune cells including monocytes 
macrophages and T lymphocytes. TNFα is a pro-inflammatory cytokine playing a key role 
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in host defence responses against injury and infection (Alberts et al. 1994) and acts by 
binding to two distinct cell surface receptors known as TNF receptor 1 and -2 (Kamata et 
al. 2005). TNFα activates and can be activated by the gene regulatory protein NF-κB 
(Alberts et al. 1994) and is known to increase oxidative stress in target cells (Halliwell and 
Gutteridge 2007). SH-SY5Y cells have been reported to undergo apoptosis in response to 
TNFα (Kenchappa et al. 2004, Kweon et al. 2004). 
 
Figure 4. 1 Fas and TNF receptor mediated apoptosis 
Fas system-Fas engagement by Fas ligand (FasL), or by antibodies directed against Fas, initiates receptor 
clustering and binding of the intracellular death domain of Fas to an adapter protein known as FADD, 
coupling Fas to the caspase cascade via formation of DISC (Thomas et al. 2002, Desbarats et al. 2003). 
Caspase-8 cleavage is characteristic of Fas-induced apoptosis (Nagata 1997, Hengartner 2000). Apoptosis 
mediated by caspase-8 is then amplified through the mitochondrial release of cytochrome c, thus activating 
caspase-9 and the formation of the apoptosome (Kuwana et al. 1998). TNF system- TNF receptors initiate 
activation of caspase-8 in a similar manner to Fas receptors, except for an extra adapter protein called 
TRADD that together with FADD and pro-caspase-8 forms the DISC. Activation of ROS production by 
TNFα appears to involve mitochondria (Hughes et al. 2005). TNFα induced ROS is known to cause JNK 
activation, p38 activation, loss of Bcl-2, cytochrome-c release and caspase-3 cleavage resulting in apoptosis 
in Cos-7 cells and mouse models (Grethe et al. 2004, Kamata et al. 2005). 
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4.1.2 Complex I inhibitors 
The neurotoxin MPP+ is used both in vitro and in vivo to induce Parkinson-like features 
and its effect on SH-SY5Y cells has previously been extensively characterised (Itano 1995, 
Song and Ehrich 1998, Fall and Bennett 1999). MPP+ is a neurotoxin that causes increased 
oxidative stress and inhibition of mitochondrial complex I in SH-SY5Y cells (Fall and 
Bennett 1999). The pro-toxin MPTP is a substrate of MAO, being converted to the active 
toxin MPP+ by MAO (Song and Ehrich 1998). Unfortunately, MPP+ significantly inhibits 
MAO activity (Singer and Ramsay 1993, Tipton and Singer 1993). Therefore another 
mitochondrial complex I inhibitor, rotenone, was required to mimic PD cell death. 
Rotenone is a naturally occurring chemical obtained from the roots of several plant species 
belonging to the genus Lonchocarpus (lancepod) from the family fabaceae (pea, Tomlin 
2000) and is commonly used in the U.K as a pesticide (British Crop Protection Council, 
2001). Following experiments in rats, rotenone was shown to inhibit complex I of the 
mitochondrial electron transport chain (Heikkila et al. 1985, Sherer et al. 2003b). Long 
term exposure to rotenone reproduces features of PD including selective nigrostriatal 
degeneration and α-synuclein-positive inclusions in rats (Betarbet et al. 2000, Sherer et al. 
2003a). In SH-SY5Y cells, rotenone causes dose-dependent ATP depletion, oxidative 
damage and cell death (Sherer et al. 2003b). Thus, rotenone is an excellent toxin to use in 
vitro to mimic oxidative stress in PD. 
 
Figure 4. 2 Chemical structure of rotenone and location of mitochondrial complex I 
 (A) Chemical structure of rotenone. (B) Location of complex I of the mitochondrial respiratory chain 
(electron transport chain). Mitochondrial redox carriers or complexes I, II, III and IV (labelled) span the inner 
mitochondrial membrane (IMM), with the exception of complex II that sits on the IMM. The yellow complex 
represents ATP synthase and the black complex represents cytochrome c. Rotenone inhibits the action of 
complex I of the respiratory chain. Modified from (Stryer 1996, Abou-Sleiman et al. 2006). 
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4.1.3 Serum withdrawal 
Neuronal cells require growth factors for development and survival including a range of 
polypeptides and glycoproteins that act transiently and are tightly controlled by the cell. 
They act locally by binding to receptors on target cell surfaces, exerting effects at low 
concentrations. Absence or withdrawal of growth factors in neuronal cells (normally 
supplied by the addition of serum to the growth medium) leads to apoptosis; this has been 
demonstrated in rat PC12 cells following serum deprivation (DeZutter and Davis 2001) 
and in human neuroblastoma (SH-SY5Y) cells following serum withdrawal (Macleod et al. 
2001).  
4.1.3.1 Serum withdrawal in human neuroblastoma  
Neuroblastoma cells express insulin-like growth factor (IGF) and NGF receptors (Pahlman 
et al. 1995) and primary cultured low stage tumour cells were shown to be dependent on 
NGF for their survival and differentiation (Nakagawara et al. 1993). In contrast, 
neuroblastoma cell lines are established from high-stage, highly malignant tumours and are 
arrested in their differentiation (Pahlman et al. 1995). Differentiation of SH-SY5Y cells 
can be achieved in vitro via addition of phorbolester (TPA, Pahlman et al. 1981) and 
retinoic acid (Pahlman et al. 1984, Beck 2004). Growth factors alone act as mitogens in 
SH-SY5Y cells but do not induce differentiation. However, brain-derived neurotrophic 
factor (BDNF) in combination with retinoic acid causes fully differentiated and neuron-
like SH-SY5Y cells (Encinas et al. 2000) and growth factors added to SH-SY5Y cells 
alongside phorbol ester treatment enhance TPA-induced differentiation (Pahlman et al. 
1995).  
In contrast, complete removal of growth factors normally supplied in tissue culture media 
to neuroblastoma cell lines is lethal. Differentiated SH-SY5Y cells undergo apoptotic cell 
death in response to serum withdrawal (Macleod et al. 2001, Iglesias et al. 2003) and 
serum withdrawal causes reduced proliferation and loss of cell viability in undifferentiated 
human neuroblastoma cells (Ou et al. 2006). In SH-SY5Y cells, caspase-3 activation has 
been suggested to follow serum withdrawal by detection of total caspase-3 protein levels 
(Ou et al. 2006), caspase-3-like Ac-DEVD-amc fluorescent substrate cleavage and 
detection of caspase-3 processing (Macleod et al. 2001). Activation of caspase-3 in both 
PC12 and SH-SY5Y neuroblastoma following serum withdrawal occurs as an early event 
(within the first 24 h) and ranges between ~2-3 fold control level (Macleod et al. 2001, 
Vaghefi et al. 2004). 
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4.1.3.2 Mechanisms involved in serum withdrawal-induced neuronal apoptosis 
 
Figure 4. 3 Mechanisms of serum withdrawal-induced apoptosis 
Apoptosis following serum withdrawal is characterised by membrane disruption (Vaghefi et al. 2004), 
DNA/nucleosome fragmentation (DeZutter and Davis 2001, Vaghefi et al. 2004) and reduced cell viability 
(Macleod et al. 2001, Vaghefi et al. 2004). Serum withdrawal-induced apoptosis is caspase dependent 
(Vaghefi et al. 2004) and caspases -2, -3, -6 and -9 have all been shown to be involved (DeZutter and Davis 
2001, Dowds and Sabban 2001, Macleod et al. 2001, Vaghefi et al. 2004). The ERK/MAPK cascade 
mediates growth factor-supported survival in PC12 cells, retinal ganglion cells, cerebellar granule neurons 
and cortical neurons (Xia et al. 1995, Poser et al. 2003). The phosphotidylinositol 3 (PI3)-kinase pathway 
(Yao and Cooper 1995) and the action of cyclic AMP (Poser et al. 2003) are also thought to be involved in 
mediating serum withdrawal-induced apoptosis. Apoptosis induced by withdrawal of trophic factors has been 
shown to be mediated by p38 MAPK in rat neurons (Xia et al. 1995, Kummer et al. 1997, DeZutter and 
Davis 2001) and in human neuroblastoma (Ou et al. 2006). Growth factors in serum stimulate progression of 
the cell cycle in mouse fibroblasts (NIH-3T3) and p38 MAPK is required for its inhibition at G1/S (Molnar et 
al. 1997). 
4.1.3.3 Role of MAO in serum withdrawal-induced apoptosis 
Generation of free radicals via monoamine oxidation by MAO was the focus of a great 
deal of publications during the 1990s and into the 2000s and many links were made 
between MAO, mitochondrial dysfunction and neurodegeneration. Nevertheless, the first 
evidence for a direct role of MAO in apoptosis was in 2001, when following serum 
withdrawal (NGF withdrawal) in rat PC12 cells, MAO-A mRNA, protein and activity were 
increased (DeZutter and Davis 2001). Increased expression of MAO following serum 
withdrawal was reduced by inhibition of p38 MAPK by the inhibitor PD169316 (DeZutter 
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and Davis 2001), suggesting that the pro-apoptotic expression of MAO was mediated by 
the p38 signal transduction pathway. The involvement of MAO in serum withdrawal 
induced apoptosis was confirmed when MAO inhibition reduced both nucleosome 
fragmentation and the appearance of apoptotic nuclei (DeZutter and Davis 2001). Very 
recently Ou et al (2006) provided evidence for the mechanism by which MAO may be 
regulated to enhance apoptosis. Following serum withdrawal from human neuroblastoma 
cells, MAO-A expression (mRNA, protein and catalytic activity) is increased and R1 (a 
transcription factor repressor of the MAO-A promoter) expression is decreased. Although 
these data support the supposition that MAO plays a pro-apoptotic role and provides 
evidence for a mechanism, the authors have assumed that serum withdrawal induces 
apoptosis since no attempt was made to directly measure apoptosis. Indeed, apoptotic cell 
death was assumed on the basis of MTT assays (which give an indication of cell viability/ 
proliferation through measurement of cell metabolism) and total caspase-3 levels rather 
than caspase-3 activity. Nonetheless, serum withdrawal in human neuronal cells induces 
increased expression of MAO-A and this involves the p38 MAPK signalling pathway, 
since the p38 inhibitor PD169316 reduced MAO-A protein levels and loss in cell viability 
(Ou et al. 2006). An important finding from this work is the elucidation that the novel 
transcription factor repressor R1 is a target of the p38 stress-MAPK signalling pathway 
following serum withdrawal. 
4.1.4 Rationale 
When work commenced on this chapter of the thesis, MAO at that time had only been 
shown to have a direct involvement in apoptotic cell death in rat neuronal cells following 
serum deprivation (DeZutter and Davis 2001). The staurosporine-induced model of human 
neuronal apoptosis (chapter 3) allowed the investigation of MAO in a very potent, fast, 
mitochondrially-mediated and highly oxidative type of apoptosis. MAO modulates 
staurosporine-induced neuronal cell death by heightening the oxidative environment via its 
production of reactive species following increased catalytic activity. MAPK and caspase 
cascades may be involved in transducing MAO mediated pro-apoptotic signals, however 
the MAO gene was not up-regulated and therefore not a target of apoptotic or stress 
signalling pathways.  
This chapter aims to elucidate whether MAO has a universal role in apoptotic signalling in 
human neuroblastoma cells. This was achieved by the use of a number of apoptotic 
inducers including serum withdrawal. 
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4.1.5 Aims of Chapter 
• To develop different in vitro models of apoptosis in SH-SY5Y cells 
SH-SY5Y cells were exposed to an analogue of Fas ligand (Fas activating antibody), the 
cytokine TNFα or the complex I inhibitor rotenone and also subjected to withdrawal of 
growth factors. Cells were monitored for biochemical and morphological changes 
characteristic of apoptosis in order to confirm whether or not the cells are sensitive to each 
treatment. If apoptotic cell death was confirmed, a time course of apoptosis was 
characterised. 
• To investigate the role of MAO different apoptotic models 
Once an apoptotic time course had been characterised, changes in the expression of MAO-
A mRNA, protein and catalytic activity were monitored. To confirm the relevance of 
MAO-A in receptor mediated apoptosis, the effect of MAO-A inhibition on the apoptotic 
cascade/cell status would be investigated.  
• To asses the signalling mechanisms involved in MAO-mediated apoptosis 
induced by serum withdrawal 
Caspase activation of ROS and changes in MAPK signalling pathways were measured 
using western blotting and confocal microscopy. To study the involvement of MAP 
kinases ERK, JNK and p38 in controlling MAO-A expression during apoptosis, specific 
MAPK inhibitors were used in conjunction with the apoptotic inducer.  
4.2. RESULTS 
4.2.1 Treatment of SH-SY5Y cells with agonistic anti-Fas antibody 
SH-SY5Y cells were exposed to an agonist of Fas, which is an analogue of Fas ligand, an 
agonistic anti-Fas antibody (AAF). Recommended concentrations of AAF for use in the 
human jurkat cell line range between 10-50 ng/ml, based on a previous publication (Dotti 
et al. 2005) and vendors recommendation (Millipore, C.A, U.S.A). Doses 15-250 ng/ml 
AAF did not induce loss of cell viability in SH-SY5Y cells over a 24 h time course (Figure 
4. 4).  
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Figure 4. 4 MTT reduction in SH-SY5Y cells following treatment with AAF 
Cell viability was measured in SH-SY5Y cells over 24 hours, following the addition of 15, 100, 150, 200 and 
250 ng/ml human AAF (Fas-Ab). MTT reduction was determined and expressed as mean MTT reduction % 
untreated control (SFM). Replicates in assay=12 and n=2. 
High doses of AAF did not induce apoptotic morphologies in SH-SY5Y cells in 6 h 
(Figure 4. 5) or 24 h (Figure 4. 6A). To compare agonistic AAF response in SH-SY5Y 
cells to the response in rat glioma cell line (C6), cells were exposed to 500 ng/ml AAF for 
24 h. C6 cells showed some apoptotic morphologies such as cell shrinking and rounding 
(Figure 4. 6B). Nevertheless, SH-SY5Y cells remain viable following high doses of AAF 
and caspase-3 activity (Figure 4. 6C) remained unchanged over a 72 h time course. 
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Figure 4. 5 The effect of agonistic anti-Fas antibody on SH-SY5Y morphology 
SH-SY5Y cells were exposed to 250 ng/ml agonistic anti-Fas antibody (Fas-Ab) for up to 6 h. Morphologies 
of the cells were visualised using a Nikon eclipse TS100 microscope. Photomicrographs (× 20 objectives, 
taken on Nikon DN100 digital camera) are shown at 1 h, 4 h and 6 h post-treatment and are representative of 
3 independent experiments. Scale bar represents 20 µm. Photomicrographs have been enlarged in each case 
using Corel draw software and show ~ 4 representative cells enlarged by ~ 300%. 
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Figure 4. 6 Agonistic anti-Fas antibody does not induce apoptosis in SH-SY5Y cells 
(A) SH-SY5Y cells or (B) C6 cells were exposed to 500 ng/ml agonistic anti-Fas antibody (Fas-Ab) for 24 h. 
Morphologies of the cells were visualised using a Nikon eclipse TS100 microscope. Photomicrographs (× 20 
objectives, taken on Nikon DN100 digital camera) and are representative of 3 independent experiments. 
Scale bar represents 20 µm. Photomicrographs have been enlarged in each case using Corel draw software 
and show ~ 4 representative cells enlarged by ~ 300%.. (C) SH-SY5Y cells were exposed to 500 ng/ml Fas-
activating antibody (Fas-Ab) for 24 h Caspase-3 activation was measured using Acetyl-Asp-Glu-Val-Asp-7-
Amidomethylcoumarin as substrate and expressed as mean change FU/min/µg protein ± SEM. All data 
represent triplicate values from two independent experiments (n=2).  
Loss of caspase-8 proform (58 kDa) was observed in SH-SY5Y cells exposed to Fas 
antibody for 4 and 6 h. However, the active form of caspase-8 (28 kDa) was not detected in 
either SH-SY5Y cells (Figure 4.7, middle panel) or in positive control U937 cells that 
undergo apoptosis following TNFα exposure (Figure 4.7, left panel). Activation of 
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caspase-9 was not detected in SH-SY5Y cells following Fas antibody exposure over a 6 hr 
time course (Figure 4.7, right panel).  
 
Figure 4. 7 AAF does not activate caspase-8 or caspase-9 
Western blot analysis of caspase-8 and -9 activation (pro-from / active form) in cell extracts of SH-SY5Y 
cells exposed to 500 ng/ml agonistic anti-Fas antibody over a 6 hour period or U937 cells exposed to 10 
ng/ml TNFα for 48 h. Equal protein aliquots (20 µg) were separated on a 12 % (v/v) acrylamide SDS-PAGE 
gel prior to transfer to nitrocellulose membranes. The blots were probed with either, anti-caspase-8 antibody 
(2 µg/ ml) which recognises the pro-form (56 kDa) and the active-form (28 kDa) and anti-caspase-9 antibody 
(2 µg/ ml) which recognises the pro-form (46 kDa) and the active-form (34 kDa). Equal loading in each case 
was checked by copper stain for total protein or by probing for total ERK (1: 1000 dilution) The Western 
blots shown are representative of two separate experiments. 
4.2.2 TNFα treatment of SH-SY5Y cells 
Treatment with human TNFα caused no significant loss in cell viability of the cells over a 
72 h period (Figure 4. 9).  
 
Figure 4. 8 MTT reduction in SH-SY5Y cells following treatment with TNFα 
Cell viability was measured in SH-SY5Y cells over 72 hours, following the addition of 1, 5 and 10 ng/ml 
human TNFα. MTT reduction was determined and expressed as mean MTT reduction % control (where 
control is SFM + 0.1 [v/v] BSA carrier) ± S.D. Replicates in assay=12 and n=2. 
SH-SY5Y cells exposed to TNFα appeared viable in cell culture and caspase-3 activity in 
SH-SY5Y cells remained unchanged over a 96 h period (Figure 4. 9).  
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Figure 4. 9 TNFα does not induce caspase-3 mediated apoptosis in SH-SY5Y cells 
SH-SY5Y cells were exposed to 10 ng/ml TNFα for 24 h. Caspase-3 activation was measured using Acetyl-
Asp-Glu-Val-Asp-7-Amidomethylcoumarin as substrate and expressed as mean change FU/min/µg protein ± 
S.D. All data represent triplicate values from two independent experiments (n=2).  
4.2.3 Rotenone 
SH-SY5Y cells were exposed to a range of rotenone concentration over a 48 h time course 
and assessed for MTT reduction as an indicator of cell viability. Rotenone reduced MTT 
viability in a concentration- and time-dependent manner (Figure 4. 10A). Rotenone 
concentrations of 0.5 µM reduced cell viability by around 70% of untreated control levels 
by 48 h. SH-SY5Y cells were exposed to low concentration (0.5 µM) rotenone over a 96 h 
period and MTT reduction measured several times (Figure 4. 10B). 0.5 µM rotenone 
significantly reduced cell viability measured by MTT reduction throughout the 96 h time 
course. 
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Figure 4. 10 MTT reduction following rotenone exposure in SH-SY5Y cells 
(A) Cell viability was measured in SH-SY5Y cells over 48 hours, following the addition of 0.5, 5, 50 and 100 
µM rotenoen. MTT reduction was determined and expressed as mean MTT reduction % untreated control. 
Replicates in assay=12 and n=1. (B) Cell viability was measured in SH-SY5Y cells over 96 hours, following 
the addition of 0.5 µM rotenone. MTT reduction was determined and expressed as mean MTT reduction % 
control ± S.D. Replicates in assay=12 and n=7. MTT reduction in untreated cells was statistically compared 
to MTT reduction in 0.5 µM rotenone treated cells over time using two way ANNOVA, where the effect of 
0.5 µM rotenone on SH-SY5Y cells over the time course was significant at a confidence level of p=<0.001.  
Cell morphology studies gave an insight into the time course of rotenone toxicity. Figure 4. 
11 shows that following 48 h exposure to 0.5 µM rotenone, SH-SY5Y cells appear similar 
to untreated cells, with the exception of some floating cells (possibly apoptotic cells). Cells 
seem to then become extremely apoptotic very quickly peaking between 24-72 h on 
average. Caspase-3 is activated and peaks after 24 h rotenone treatment, with caspase-3 
lower at 48 h than at 24 h. At 48 h, the cells appear to either be extremely apoptotic. 
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Figure 4. 11 Effect of rotenone on cell morphology and caspase-3 activity 
(A) SH-SY5Y clones observed by phase contrast microscopy following 0.5 µM rotenone treatment over a 
48h period. Cells were visualised using a Nikon eclipse TS100 microscope. Photomicrographs (× 40 
objectives, taken on Nikon DN100 digital camera). Scale bar represents 20 µM. (B) Caspase-3 activity 
measured using Acetyl-Asp-Glu-Val-Asp-7-Amidomethylcoumarin as substrate in SH-SY5Y cells following 
0.5 µM rotenone treatment over a 48h period and expressed as ∆FU/min/µg protein ±S.D. Data represents 
values from four independent experiments over, where each extract was assayed in triplicate. Statistical 
analysis was performed using the Student’s t-test to compare caspase-3 activity following rotenone treatment 
to untreated cells for each time point, where n=4 and ***=p=<0.001. 
MAO catalytic activity is increased following rotenone treatment, peaking after 24 h at 
around 2 fold of control level (Figure 4. 12). 
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Figure 4. 12 Effect of rotenone on MAO activity 
Following addition of 0.5 µM rotenone, MAO activity was measured in SH-SY5Y via a radiometric method, 
using 14C-Tyramine as a substrate. MAO catalytic activity was expressed as pmoles/min/mg protein. Data 
represent triplicate values from two independent experiments (n=2) and are expressed as mean ± S.D. 
SH-SY5Y cells exposed to rotenone show subtle increases in ROS production. The cells 
were exposed to 0.5, 5 and 50 µM rotenone, but increasing the concentration of rotenone 
by 100 fold had no further effect on ROS levels.  
 
Figure 4. 13 Effect of rotenone on ROS levels 
Cells were exposed to 0.5, 5 and 50 µM rotenone for 8 h and 1µM STS as a positive control. DCDHF 
fluorescence was visualised using a CLSM Leica microscope. Photomicrographs are shown are laser power 
matched and are representative of 2 independent experiments. Scale bar represents 100 µm 
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4.2.4 Serum withdrawal 
SH-SY5Y cells deprived of serum for 24 h show different morphologies to untreated cells. 
The cells become extended, elongated and develop neurite outgrowths typical of cellular 
differentiation. Some cells appear apoptotic in the population after 24 h serum withdrawal 
(Figure 4. 14). Following 48 h serum withdrawal half of the cell population shows 
apoptotic morphologies and this effect continues in a time dependent manner (Figure 4. 
14).  
 
Figure 4. 14 Apoptotic morphologies of SH-SY5Y cells following serum withdrawal 
SH-SY5Y cells were deprived of serum over a 96 h period. Morphologies were visualised using a Nikon 
eclipse TS100 microscope. Photomicrographs (× 40 objectives, taken on Nikon DN100 digital camera) are 
shown at 0, 24, 48, 72 and 96 h post-treatment and are representative of 3 independent experiments. Scale bar 
represents 20 µm. 
Caspase-3 activity is significantly increased after 24 h serum deprivation (by ~two fold 
untreated control level). Caspase-3 activity remains increased until 72 and then begins to 
fall (Figure 4. 15).  
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Figure 4. 15 Serum withdrawal induced caspase-3 mediated apoptosis in SH-SY5Y cells 
SH-SY5Y cells were deprived of serum for a 96 h period. Caspase-3 activation was measured using Acetyl-
Asp-Glu-Val-Asp-7-Amidomethylcoumarin as substrate and expressed as mean change FU/min/µg protein ± 
S.D. All data represent triplicate values from five independent experiments (n=5, except at 48 h, where n=3). 
Statistical analysis of serum deprived cells compared to untreated controls was carried out using the 
Student’s t-test, where **p=<0.01. 
4.2.4.1 Relevance of MAO in serum withdrawal-induced apoptosis 
MAO catalytic activity increases in a time dependent manner following serum withdrawal 
(Figure 4. 16) over a 96 h period (~2 fold untreated control). Expression of MAO-A 
mRNA is also increased ~two fold at 24 h and ~3 fold at 72 h and then decreases slightly 
by 96 h of serum deprivation (Figure 4. 17). 




Figure 4. 16 Serum withdrawal caused increased MAO activity 
Following deprivation of serum over a 96 h period, MAO activity was measured in SH-SY5Y via a 
radiometric method, using 14C-Tyramine as a substrate. MAO catalytic activity was expressed as 
pmoles/min/mg protein. Data represent triplicate values from three independent experiments (n=3) and are 
expressed as mean ± S.D. Serum deprived samples were statistically compared to untreated controls at time 
zero using the Student’s t-test where * = p<0.05 and *** = p<0.001. 
 
Figure 4. 17 Serum withdrawal caused increased MAO-A mRNA expression 
MAO-A mRNA expression was measured by qRT-PCR following serum withdrawal over a 96 h period. Data 
represent duplicate values from three independent experiments (n=3). Values are expressed as molecules 
MAO-A mRNA / 1000 molecules GAPDH mRNA ± S.D. Statistical analysis of serum deprived samples 
compared to untreated controls was performed using the Student’s t-test, where * =  p<0.05 and ** = p<0.01.  
Finally, MAO-A protein levels are also elevated during serum withdrawal-induced 
apoptosis (Figure 4. 18). Dot blots revealed a time dependent increase in MAO-A protein 
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levels over the 96 h time course, peaking at 96 h (by more than 2 fold untreated control 
levels).  
 
Figure 4. 18 Serum withdrawal caused increased MAO-A protein levels 
(A) Representative dot blot of MAO-A protein following serum withdrawal. Equal protein homogenates were 
loaded on to a nitrocellulose membrane and probed with a MAO-A specific antibody. Mitochondrial 
membranes from human placenta (1 µg) are the positive control. (B) Quantification of dot blots. Blots were 
digitised and densitometry was performed to quantify relative MAO-A protein levels in all blots. These data 
represents values from three separate experiments (n=3) and expressed as mean arbitrary units (a.u.) ± S. D. 
Statistical analysis of treated cells in comparison to untreated controls was carried out using the Student’s t 
test, where * = p<0.05 and ** = p<0.01. 
4.2.4.2 Relevance of MAO-A in serum-withdrawal-induced apoptosis 
The effect of MAO-A inhibition on changes in cell morphology, cell viability and 
apoptosis were assessed to determine the relevance of MAO-A in serum withdrawal-
induced apoptosis. Cells deprived of serum in the presence of either tranylcypromine 
(TCP) or clorgyline appear less apoptotic (Figure 4. 19).  
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Figure 4. 19 The effect of MAO inhibitors on the apoptotic morphology of SH-SY5Y cells following 
serum withdrawal 
The effect of MAO inhibitors tranylcypromine (TCP) and clorgyline on the apoptotic morphology of SH-
SY5Y cells following serum withdrawal. Control SH-SY5Y cells (A) were exposed to serum withdrawal (B) 
and were treated concomitantly with 1 µM tranylcypromine (C) or 1µM clorgyline (D). Cells were visualised 
using a Nikon eclipse TS100 microscope. Photomicrographs (× 40 objectives, taken on Nikon DN100 digital 
camera) are shown at 48 hours post-treatment and are representative of 3 independent experiments. Scale 
bars represent 30 µm. Black arrows indicate typical morphology of apoptotic cells (shrunken, rounded, shiny, 
condensed and surface blebs), whilst white arrows show examples of normal SH-SY5Y cell morphology 
(elongated and flattened with axon like outgrowths). 
Serum withdrawal causes a significant loss of cell viability measured by MTT reduction 
over a 96 h time course, but concomitant treatment with TCP or clorgyline had no effect on 
MTT reduction throughout the 96 h period (Figure 4. 20A). On the other hand, loss of cell 
viability measured by trypan blue viable cell count was induced by serum withdrawal after 
72 h and concomitant treatment with TCP and clorgyline significantly protected from loss 
of cell viability (Figure 4. 20B). 
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Figure 4. 20 Effect of MAO inhibition on cell viability following serum withdrawal 
(A) Cell proliferation (MTT reduction) was measured in SH-SY5Y cells over a 96 h period, following serum 
deprivation or in serum deprived cells concomitantly treated with 1 µM clorgyline (+clor), 1µM 
tranylcypromine (+TCP). MTT reduction was determined and expressed as mean MTT reduction % control 
(where control is cells in growth medium containing serum) ± S.D. Replicates in assay=12 and n=4. MTT 
reduction in serum deprived cells was statistically compared to untreated controls using the Student’s t-test, 
where * = p<0.05, ** = p<0.01 and *** = p<0.001. Serum deprived MTT reduction was statistically 
compared to MTT reduction in serum deprived cells + Clor and + TCP, however there was no significant 
difference (p<0.05). (B) Viable cells were seeded at equal density prior to treatment. Cell number in control 
cells, following serum withdrawal and in the presence and absence of clorgyline and TCP were counted at a 
72 hour end point using trypan blue stain. Cell number was determined and expressed as mean cell number ± 
S.D. Cell counts were performed in duplicate and n=3. Viable cell number following serum deprivation was 
statistically compared to untreated cell numbers using the Student’s t-test, where ** = p<0.01. Cell number 
following serum deprivation was statistically compared to cell number following serum + Clor and + TCP, 
where ** = p<0.01. 
Serum withdrawal induced caspase-3 activation was significantly reduced by TCP but not 
clorgyline (Figure 4. 21) following 48 h serum deprivation (Figure 4. 21).  
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Figure 4. 21 The effect of MAO inhibition on serum withdrawal-induced caspase-3 activation 
SH-SY5Y cells were deprived of serum for a 48 h period in the presence and absence of MAO inhibitors. 
Caspase-3 activation was measured using Acetyl-Asp-Glu-Val-Asp-7-Amidomethylcoumarin as substrate 
and expressed as mean change FU/min/µg protein ± S.D. All data represent triplicate values from three 
independent experiments (n=3). Statistical analysis of serum deprived cells compared to serum deprived cells 
in the presence of MAO inhibitors was carried out using the Student’s t-test, where *p=<0.05. 
DNA fragmentation in cells deprived of serum for 72 h was assessed with or without the 
presence of the MAO inhibitors. Extensive DNA fragmentation was observed in SH-SY5Y 
cells deprived of serum. Fragmentation of DNA was significantly reduced in the presence 
of clorgyline and even more so (almost back to control status) in the presence of TCP 
(Figure 4. 22).  
 
Figure 4. 22 The effect of MAO inhibition on serum withdrawal-induced DNA fragmentation 
Serum was withdrawn for 72 h in the presence or absence of MAO inhibitors clorgyline (+Clor) or 
tranylcypromine (+TCP), DNA extracted and DNA fragmentation assessed by agarose gel electrophoresis. 
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4.2.4.3 Mechanism of MAO-A involvement in serum withdrawal-induced apoptosis 
To investigate the mechanism of MAO-A involvement in serum withdrawal-induced 
apoptosis, caspase signalling pathways, MAPK signalling pathways and ROS production 
were considered. 
Serum withdrawal caused cleavage (activation) of caspase-9 measured by reduced proform 
levels and increased active form levels (Figure 4. 23). Following deprivation for 96 h 
caspase-9 is substantially cleaved to its active form. Concomitant treatment with clorgyline 
delayed and reduced activation of caspase-9 (Figure 4. 23A). Quantification of caspase-9 
activation following serum withdrawal is illustrated in Figure 4. 23B.  
 
Figure 4. 23 Effect of MAO inhibition on caspase-9 activation induced by serum withdrawal 
(A) Activation of caspase-9 (pro-form/active form) was assessed in extracts of SH-SY5Y cells deprived of 
serum in the presence or absence of 1 µM clorgyline over a 96 h period. Equal protein aliquots (20 µg) were 
separated on a 12 % (v/v) acrylamide SDS-PAGE gel prior to transfer to nitrocellulose filters. Western blots 
were probed with anti-caspase-9 antibody (2 µg/ml). (B) Western blots were digitised and densitometry was 
performed to quantify relative caspase-9 proform and active protein levels. These data represents values from 
two separate experiments (n=2) and expressed as mean caspase-9 activity (by dividing the active C9 band 
intensity by the proform C9 band intensity) ± standard error. 
Caspase-8 proform levels remained unchanged following serum withdrawal in SH-SY5Y 
cells and the caspase-8 active form was not detected (data not shown). Numerous attempts 
were made to detect caspase-8 activation following serum withdrawal (and all other 
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treatments) using a fluorescent substrate-based caspase-8 activity kit from EMD 
Biosciences, New Jersey, U.S.A, however the kit was not sensitive enough to detect 
caspase-8 activation in any samples including positive controls provided by the company.  
SH-SY5Y cells deprived of serum for 72 h show subtle increases in ROS production 
(Figure 4. 24). Concomitant treatment with clorgyline slightly reduced ROS production 
caused by serum withdrawal (Figure 4. 24). 
 
Figure 4. 24 Serum withdrawal induces subtle elevation of ROS 
Cells were deprived of serum for 24 h (SFM) and in the presence of 1 µM clorgyline (SFM+Clor). DCDHF 
fluorescence was visualised using a CLSM Leica microscope. Photomicrographs are shown are laser power 
matched and are representative of 3 independent experiments. Scale bar represents 100 µm.  
Serum withdrawal induces changes in MAPK signalling pathways detected by antibodies 
directed against the phosphorylated (activated) MAPK proteins ERK, JNK and p38. 
Following serum deprivation levels of phosphorylated (phospho) ERK are initially 
decreased, but levels rise and fall somewhat throughout the time course (Figure 4. 25A). 
Quantification of data from independent experiments indicates that the ERK response is 
generally reduced following serum withdrawal (Figure 4. 25B). JNK is activated 
immediately upon withdrawal of serum and remains active throughout the time course, 
peaking approximately at~48-72 h according to mean quantified data (Figure 4. 25B). 
Figure 4. 25 shows that MAPK p38 is activated strongly following serum withdrawal, 
(peaking between 24-48 h according to quantified data). 
In preliminary experiments (shown as representative blot in Figure 4. 25A), the MAO 
inhibitors clorgyline and TCP had no effect on phosphor ERK, JNK or p38 levels at 24 h. 




Figure 4. 25 Effect of serum withdrawal on MAPK phosphorylation 
(A) Equal protein aliquots (80 µg) of cells extracts from SH-SY5Y cells deprived of serum over a 96 h period 
or serum deprived cells in the presence or absence of 1 µM clorgyline for a 24 h period were separated on a 
12 % (v/v) acrylamide SDS-PAGE gel prior to transfer to nitrocellulose membranes. Blots were probed with 
antibodies directed to pERK (1:1000 dilution), pJNK (1:500 dilution) and pP38 (1:1000). Equal loading was 
checked by probing for total ERK (1:1000 dilution) or total JNK (1:750 dilution). Blots shown are 
representative of three separate experiments. (B) Western blots were digitised and densitometry was 
performed to quantify levels of pERK, pJNK and pP38. These data represents values from three separate 
experiments (n=3) and expressed as mean corrected band intensity ± S. D. 
Inhibitors of ERK, JNK and p38 MAP kinases were employed to investigate their 
involvement in MAO-mediated apoptosis induced by serum withdrawal. Inhibition of 
specific phosphorylated MAPK proteins by the inhibitors was assessed by western blotting. 
The ERK inhibitor PD98059 reduced levels of phosphorylated ERK in both untreated SH-
SY5Y cells and following treatment with STS (Figure 4. 26 top panel). The JNK inhibitor 
Cep reduced phosphorylated JNK levels in untreated cells and following activation of JNK 
by STS (Figure 4. 26 middle panel). Phosphorylated p38 is detectable only following 
activation by stressors. STS treatment caused activation of p38 at 1 and 3 h. The p38 
inhibitor SB202190 completely reduced phosphorylated p38 levels in STS treated cells 
(Figure 4. 26 bottom panel). 
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Figure 4. 26 Effect of MAPK inhibitors on levels of phosphorylated MAPK proteins 
Equal protein aliquots (80 µg) of cells extracts from SH-SY5Y cells treated with vehicle control, 20 µM ERK 
inhibitor PD98059 (PD), 1 µM JNK inhibitor Cep, 10 µM P38 inhibitor SB202190 (SB) over a 3 h time 
period, 1 µM STS, 1 µM STS + 20 µM PD98059, 1 µM STS + 1 µM Cep or 1 µM STS + 10 µM SB202190 
over a 3 h time period were separated on a 12 % (v/v) acrylamide SDS-PAGE gel prior to transfer to 
nitrocellulose membranes. Equal loading was checked using copper stain for total protein (data not shown). 
Blots were probed with antibodies directed to pERK (1:1000 dilution), pJNK (1:500 dilution) and pP38 
(1:1000). Representative blots from three separate experiments are shown. 
MAO catalytic activity and mRNA expression are consistently increased in response to 
serum withdrawal in SH-SY5Y cells (Figure 4. 27A and B). After 96 h serum deprivation, 
MAO activity is increased ~2 fold compared to control cells. MAO activity was further 
increased in serum deprived cells concomitantly treated with the ERK inhibitor PD98059, 
although the increase was not statistically significant. Increased MAO activity induced by 
serum deprivation was reduced in the presence of the JNK inhibitor Cep (by ~33% of SFM 
alone) although this reduction was not statistically significant. Treatment of serum 
deprived cells with the p38 inhibitor SB202190, on the other hand, significantly reduced 
MAO activity to below control levels (Figure 4. 27A). 
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Figure 4. 27 Effect of MAPK inhibitors on MAO Activity and mRNA expression 
(A) Following deprivation of serum for 96 h end point (peak MAO catalytic activity following serum 
withdrawal) in the presence or absence of either 20 µM PD98059, 1 µM Cep or 10 µM SB202190, MAO 
activity was measured in SH-SY5Y via a radiometric method, using 14C-Tyramine as a substrate. MAO 
catalytic activity was expressed as pmoles/min/mg protein. Data represent triplicate values from three 
independent experiments (n=3) and are expressed as mean ± S.D. Serum deprived cells were statistically 
compared to control cells at 72 h using the Student’s t-test, where * = p<0.05. Serum deprived samples were 
statistically compared to serum deprived samples in the presence of each MAPK inhibitor using the Student’s 
t-test where * = p<0.05. (B) MAO-A mRNA expression was measured by qRT-PCR following serum 
withdrawal over a 96 h period in the presence and absence of MAPK inhibitors at the same concentration 
detailed above. Data represent mean values from two separate real time determinations, from one 
independent experiment (n=1). Values are expressed as mean molecules MAO-A mRNA / 1000 molecules 
GAPDH mRNA ± SEM. 
ERK inhibition had little effect on serum withdrawal-induced increased MAO-A mRNA 
levels over a 96 h time course (Figure 4. 27B). Conversely, JNK and p38 inhibition both 
greatly reduced MAO-A mRNA expression levels following serum withdrawal (Figure 4. 
27B) back to untreated control levels (in the case of SB202190) or below control levels (in 
the case of Cep).  
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4.3. DISCUSSION 
4.3.1 Death receptor-mediated apoptosis 
AAF failed to induce changes in cell viability or morphology or caspase-3 activity even at 
high concentrations. In contrast, rat C6 cells showed early signs of apoptotic morphologies 
when challenged with AAF and preliminary data indicates that caspase-3 was activated 
(unpublished observations, data not shown); both suggestive that AAF was active.  
Since apoptosis can occur independently of caspase-3 in SH-SY5Y cells (Racke et al. 
2002) and receptor mediated apoptosis can activate multiple caspases (Bratton et al. 2000), 
including the executioner caspase-7, activation of the upstream caspases-8 and -9 were 
monitored in cells exposed to AFF. Caspase-9 was not activated by AAF in SH-SY5Y 
cells and there was some evidence that caspase-8 is activated by Fas ligand after 4 and 8 
hours, since levels of the proform were reduced compared to control levels (Figure 4.7), 
but the active caspase-8 fragment was not detected.  
Detection of the caspase-8 active fragment in SH-SY5Y cells was not achieved with this 
antibody or other commercial antibodies following any apoptotic treatment. Therefore, 
U937 cells treated with TNFα were used as a positive control for the antibody; these cells 
are known to undergo apoptosis with TNFα (unpublished observations of Dr C. Ufer, 
Nottingham Trent University). In these cells, loss of caspase-8 proform was evident but 
again the active form of caspase-8 was not detected (Figure 4.7). Exposure of SH-SY5Y 
cells to TNFα had no effect on cell viability (Figure 4. 8) or caspase-3 activity (Figure 4. 
9). Detection of caspase-8 activation by a fluorescent substrate based assay was also 
attempted but the data were not reliable since results obtained with commercial standards 
were not convincing.  
In view of the data obtained it was clear that the extrinsic pathway was not activated in 
SH-SY5Y cells and the work was discontinued. Nonetheless, these data have given support 
to previous research that has proposed similar unresponsiveness to receptor-mediated 
inducers in SH-SY5Y cells (Hopkins-Donaldson et al. 2000, Desbarats et al. 2003, Miller 
et al. 2006). Considering the loss of caspase-8 proform detected by western blotting 
following AAF (Figure 4.7), the presence of caspase-8 expression (chapter 3) and 
expression of Fas receptor in SH-SY5Y cells (Russo et al. 2004), a schematic of the 
proposed caspase-8 situation is shown below.  
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Figure 4. 28 Possibilities for reduced caspase-8 function in SH-SY5Y cells 
Death receptors are activated following ligand binding and FADD and caspase-8 proform are recruited to 
form the death inducing signalling complex (DISC). Loss of proform indicates cleavage to the 28 kDa 
fragments. Recruitment or aggregation of multiple caspase-8 in close proximity somehow results in cross-
activation (Hengartner 2000), however the mechanism of caspase-8 activation remains unclear. 1. Activation 
may require unknown co-factors or proteases that are absent in SH-SY5Y cells, or events downstream of 
active caspase-8 in the apoptotic cascade are not functional. 2. Induced proximity is thought to be a 
sophisticated and tightly regulated mechanism, yet the mechanisms are still unknown. It is possible that this 
mechanism of caspase-8 activation is dysfunctional in SH-SY5Y cells. 3. Anti-apoptotic FLIP may inhibit 
caspase-8 function. Expression of FLIP is known to be regulated by ROS (Nitobe et al. 2003) and expression 
may be altered in SH-SY5Y cells because of malignancy. Finally, caspase-8L a novel inhibitory isoform of 
caspase-8 has been found in undifferentiated SH-SY5Y cells (Miller et al. 2006), which may act in a similar 
way to FLIP. 
4.3.2 Rotenone-mediated apoptosis 
4.3.2.1 Effects on cell viability and apoptosis 
Rotenone had a potent effect on SH-SY5Y cells. Cell viability following rotenone 
treatment was reduced in a time and dose dependent manner (Figure 4. 10A). The lowest 
concentration of rotenone used (0.5 µM) caused a significant loss of cell viability of 
approximately 25, 60 and 75 % after 24, 48 and 96 hours respectively (Figure 4. 10B). 
These data were complimented by the development of apoptotic cell morphologies 
following exposure to 0.5 µM rotenone for 48 h (Figure 4. 11A), together with a 2 fold 
increase in caspase-3 activity (Figure 4. 11B).  
Rotenone inhibits complex 1 of the ETC, and levels of ATP are likely to be strongly 
depleted. Apoptosis may only occur once ATP levels fall below a certain threshold, and 
this may explain the change in the cells’ appearance between 24 and 48 hours (Figure 4. 
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11A). However, if ATP levels drop very low, the cells are likely to die by necrosis. Recent 
work in SH-SY5Y cells has suggested that ROS production is more relevant than ATP 
depletion in rotenone toxicity (Watabe and Nakaki 2006). Other effector caspases, such as 
-7 and -12, may also be activated in rotenone-induced apoptosis. Indeed, rotenone has been 
shown to induce both the mitochondrial (caspase-9) and the ER-dependent (caspase-12) 
apoptotic pathways in SH-SY5Y cells (Kitamura et al. 2002, Newhouse et al. 2004). 
Caspase-3 is thought to only account for about half of the caspase activity responsible for 
rotenone induced apoptosis in SH-SY5Y cells (Newhouse et al. 2004).  
4.3.2.2 Role of MAO in rotenone-mediated apoptosis 
Significantly, MAO activity was also increased following rotenone treatment, at 
approximately the same time as caspase-3 (Figure 4. 12), and this was associated with a 
small increase in ROS levels (Figure 4. 13). Unfortunately due to time restraints, the 
molecular basis of the increase in MAO activity was not studied further but, it is now 
acknowledged that this observation may be very important since increased MAO activity 
in response to complex I inhibition has not previously been reported. Indeed a role for 
MAO in cell death induced by complex I inhibition is plausible since inhibition of complex 
I causes increased oxidative stress and ATP depletion, mitochondrial dysfunction and cell 
death (Abou-Sleiman et al. 2006). ROS levels detected by confocal microscopy in live 
cells were increased in rotenone treated cells (Figure 4. 13). MAO activity will in theory 
generate more ROS within the cell but MAO’s contribution to ROS levels was not assessed 
using MAO inhibition. The role of MAO in rotenone-induced apoptosis is further 
investigated in stable SH-SY5Y cells with reduced MAO-A (see chapter 6). 
4.3.3 Serum withdrawal-induced apoptosis 
Apoptotic morphologies and increased caspase-3 activity were evident in cell deprived of 
serum for 24 h, and following 48 h of serum withdrawal the cells were clearly apoptotic 
and caspase-3 activity had peaked. Caspase-9 was also activated, but maximum activation 
appeared to occur at 96 h. This was not expected since caspase-9 is upstream of caspase-3, 
indicating that apoptotic signalling following serum withdrawal is complex and may 
involve a diverse set of caspases and caspase interactions.  
The response to serum withdrawal is a slow process, occurring over 4-5 days, during which 
the majority of the cells remained attached to the monolayer. These and published data 
suggest that neuronal cells undergo a slow but highly regulated and complex response to 
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the withdrawal of growth signals. The initial response will probably involve direct 
activation of PI3K, Akt, cytochrome c release, activation of upstream caspases and 
caspase-3. 
Activation of caspase-3 alone is insufficient for apoptotic morphological changes in 
neuroblastoma cells (Racke et al. 2002) and therefore other systems, including up-
regulation pro-apoptotic proteins and activation of caspases-6 and -7 may be important in 
this model. This model has particular relevance to human pathology in ageing and 
neurodegeneration, where neurons are exposed to low-level stress over a long time period.  
4.3.3.1 Role of MAO in serum withdrawal-induced apoptosis 
MAO expression was increased during serum withdrawal at the mRNA (Figure 4. 17), 
protein (Figure 4. 18) and activity level (Figure 4. 16). Increased MAO-A mRNA levels 
were apparent after 24 h and reached a maximum at 72 h. Increases in MAO-A protein 
levels and MAO activity follow, both reaching their highest values after 96 h. These 
changes were preceeded by activation of caspase-3, suggesting that the MAO-A gene is 
down stream of caspase-3 activation.  
MAO-A inhibition failed to reduce caspase-3 levels or loss of cell viability measured by 
MTT; however it did reduce apoptotic morphologies and loss of cell numbers. These data 
disagree with the work of Ou et al (2006) who reported that clorgyline increased cell 
viability and reduced caspase-3 levels in SH-SY5Y cells subjected to serum withdrawal. 
MAO inhibition by clorgyline has previously been shown to reduce nucleosome 
fragmentation using in rat PC12 cells (DeZutter and Davis 2001). In the present work, 
DNA fragmentation induced by serum withdrawal in SH-SY5Y cells was reduced by 
clorgyline and more so by TCP (Figure 4. 22), indicating that MAO-A is involved in later 
phases of serum withdrawal-induced apoptosis (72 h onwards) and that cell death can 
progress to downstream processes such as DNA fragmentation independently of caspase-3. 
Clorgyline reduced caspase-9 activation throughout the serum withdrawal time course 
(Figure 4. 23), suggesting that MAO-A is likely to promote apoptotic signaling via 
caspase-9. 
4.3.3.1.1 Mechanism 
Levels of ROS are elevated in serum deprived SH-SY5Y cells and concomitant treatment 
with clorgyline reduced ROS to control levels (Figure 4. 24), signifying that ROS 
production by increased MAO-A activity may be involved in death signaling following 
Chapter 4                                                             The role of MAO-A in different models of neuronal apoptosis 
 124
serum withdrawal. Likely candidates for targets of elevated ROS produced by MAO in the 
cell include the diverse MAPK cascades. 
Following serum deprivation, levels of phosphorylated ERK MAPK are decreased (Figure 
4. 25). Active ERK is responsible for targeting transcription factors that will facilitate up-
regulation of proteins required for progression of the cell cycle (Figure 4. 3). Loss of 
growth factor binding causes decreased activation of Ras and therefore decreased 
phosphorylation of the MAPK signaling module that ultimately phosphorylated ERK. 
Reduced ERK activation causes growth arrest and increased phosphorylation of the stress-
activated MAPK proteins JNK and p38 (Figure 4. 25). Levels of phosphorylated JNK 
increase in a time dependent manner reaching maximal levels at 48-96 h (Figure 4. 25). 
Activation of p38 was also time dependent, but on average maximal levels were reached 
earlier at around 24 h (Figure 4. 25). These data suggest that as protective ERK levels 
deplete, MAPK signaling is tipped in favor of the stress response mediated by JNK and 
p38. Clorgyline has no effect on levels of active ERK, JNK or p38 MAPK at 24 h, 
suggesting that MAO-generated oxidative stress is not involved in activating MAPK 
signaling pathways at this point in the time course.  
On the contrary, MAPK signaling pathways are involved in up-regulating MAO-A 
expression following serum deprivation. Inhibition of JNK and p38 greatly reduced the 
elevated MAO activities induced by serum withdrawal, whereas ERK inhibition may have 
further increased MAO activity (Figure 4. 27). Similar effects were seen on elevated 
MAO-A mRNA expression during serum withdrawal. However, JNK inhibition was more 
effective than p38 at reducing MAO-A expression, with expression levels reduced below 
control level (Figure 4. 27). Inhibition of the JNK signaling pathway by Cep has previously 
been reported to preserve metabolism and growth of serum deprived rat neurons (Harris et 
al. 2002) and inhibitors of p38 MAPK have previously been reported to promote neuronal 
survival in serum deprived rat neurons in vitro (Horstmann et al. 1998). MAO-A has been 
showed to be the target of p38 signal transduction following serum deprivation in rat 
neurons (DeZutter and Davis 2001) and human neuroblastoma involving regulation by the 
transcription repressor R1 (Ou et al. 2006). The MAO-B gene has previously been show to 
be a target of MAPK signaling pathways following treatment with phorbol ester (PMA) in 
human hepatocytoma cells (Wong et al. 2002). MAO-B expression was increased 
following PMA exposure and the activation MAO-B involved a PKC, MAPK dependent 
pathway that acted through JNK specifically and the transcription factors c-jun and Egr-1 
(Figure 4. 27). Data in this chapter shows for the first time, that MAO-A is a target of both 
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JNK and p38 pro-apoptotic signaling pathways in human neuroblastoma cells, which is 
ROS and caspase-9 dependent. Data indicate that ROS generated by MAO are more 
involved in mitochondrial events than in activating MAPK, since clorgyline caused no 
changes in MAPK phosphorylation levels at 24 h. However, H2O2 generated by MAO in 
the cytosol may further enhance stress-signaling pathways but this event may occur later in 
the time course, when MAO activity is maximal (72-96 h).  
4.3.4 Conclusion 
MAO-A activity is increased in two selected models of apoptosis. MAO-A activity is 
increased in parallel to caspase-3 activation following complex I inhibition by rotenone. 
Rotenone will be discussed further in chapter 5 and 6. In serum withdrawal-induced 
apoptosis, MAO-A acts downstream of caspase-3. The role of MAO-A in serum 
withdrawal-induced apoptosis is shown in Figure 4. 29. Unlike STS-induced apoptosis, 
serum withdrawal is slower and allows the cell time to recruit pro-apoptotic proteins to 
enhance the death signals. The MAO-A gene is a target of both JNK and p38 MAPK 
pathways. The ensuing changes in oxidative levels generated by increased production of 
ROS by MAO-A may promote mitochondrial dysfunction, cytochrome-c release and 
activation of caspases. Together these data suggest that MAO is recruited by the cell to 
enhance apoptosis and depending on the nature of the stressor or inducer, MAO responds 
accordingly. Mechanisms by which MAO can be modulated to respond to cellular stress 
and/or survival signals may involve transcription factors, transcription and translation 
regulation at one end of the spectrum (slow or chronic responses) and post-translational 
modifications, enzyme maturation and regulation of enzyme rate as a rapid response. 
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Figure 4. 29 The role of MAO in serum withdrawal-induced apoptosis  
Constituents of the pathway elucidated in this study appear in magenta. Growth factor binding activates Ras 
and sends survival signals via the PI3K/Akt pathway and ERK MAPK pathway. Akt works by inhibiting Fas 
ligand expression, caspase-9 activation and Bad. ERK MAPK plays a major role in cell survival. ERK 
signals transcription factors such as ELK1 to up-regulate pro-survival and cell cycle genes. ERK is also 
known to inhibit apoptotic proteins such as caspase-9 by direct phosphorylation (Allan et al. 2003). Both 
PI3K/Akt and MAPK signalling pathways can tip in favour of death when survival factors are withdrawn or 
stress signals are elevated (Wang et al. 1998, Horbinski and Chu 2005). In the early phases, this may result in 
changes in Bcl-2 family proteins, cytochrome-c release and activation of caspase-9 followed by activation of 
caspases-3, 6, 7. At the same time JNK and p38 MAPK are activated following a cascade of phosphorylation 
triggered by Ras signalling events. JNK and p38 are known to target transcription factors such as c-jun and 
ATF-2 and promote up-regulation of pro-apoptotic genes (Yang et al. 2003), which following serum 
withdrawal includes up-regulation of MAO-A. Increased MAO-A expression results in increased H2O2 
production at the OMM. MAO-generated ROS in the cytosol could re-activate stress-activated MAPK 
signalling cascades in a dose-dependent manner (Guyton et al. 1996, Yoon et al. 2002). MAO produced ROS 
can directly damage IMM proteins (Cohen et al. 1997), causing loss of function and release of cytochrome-c, 
ROS and ATP, resulting in activation of upstream caspases and eventually executioner caspases, cleavage of 
substrates, DNA fragmentation and cell dismantling. Hence, MAO-A enhances apoptosis following 


















IN HUMAN NEUROBLASTOMA 
CELLS 
Chapter 5                                                                   Overexpression of MAO-A in human neuroblastoma cells 
 128
OVEREXPRESSION OF MAO-A IN HUMAN 
NEUROBLASTOMA CELLS 
5.1. INTRODUCTION 
5.1.1 Increased MAO levels in humans - physiological relevance 
Changes in MAO during the ageing process and in certain neurodegenerative disorders 
have been the focus of numerous publications. The majority of the work on humans has 
relied on post mortem brain samples or measurement of circulatory MAO-B in blood 
platelets, which has limited the collection of reliable data and resulted in some dispute over 
findings. Increased MAO-B activity has been linked to human ageing (Fowler et al. 1980b, 
Kornhuber et al. 1989, Sastre and Garcia-Sevilla 1993) and has been implicated in several 
neurodegenerative disorders, (reviewed by Strolin Benedetti and Dostert 1989). Indeed, 
increases in MAO-B expression have been observed in ageing mouse brain (Saura et al. 
1994a) and human brain (Fowler et al. 1980b, Sparks et al. 1991). These increases in 
MAO-B expression are partly due to a general increase in enzymatic levels per cell, but 
may also be a result of increased glial cell numbers in ageing (Halliwell 1992, Ekblom et 
al. 1993). MAO-B activity (Adolfsson et al. 1980, Oreland and Gottfries 1986, Bonuccelli 
et al. 1988, Sparks et al. 1991, Saura et al. 1994b) and MAO-B mRNA levels are elevated 
in AD (Emilsson 2002). MAO-B activity has been reported to be elevated in PD (Gerlach 
and Riederer 1993, Bongioanni et al. 1996, Danielczyk 1998), although some studies have 
revealed no change in MAO expression from platelets and plasma of patients with PD 
compared with healthy controls (Finch et al. 1995, Ahlskog et al. 1996). Increased MAO-
B expression has also been associated with Huntington’s disease (Mann et al. 1980) and 
Pick’s disease (Sparks et al. 1991). 
Increased levels of MAO-A isoform expression have only been reported in the temporal 
pole and nucleus basalis of Meynert (nbM) in ageing humans (Sparks et al. 1991), in the 
hypothalamus and frontal pole of those suffering from AD (Sparks et al. 1991) and in the 
hypothalamus of those suffering from PD (Sparks et al. 1991).  
Age-related increases in MAO levels result in increased oxidative stress that may act as a 
predisposing factor in the vulnerability of the brain to age-related neurodegenerative 
diseases such as PD (Westlund 1988, Cohen 1990, Kumar et al. 2003). Vulnerability of 
neurons to attack by free radicals is heightened by their low glutathione content, which in 
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the SNpc in PD is further reduced (Riederer et al. 1989). MAO-catalysed increased free 
radical production may contribute to age-related increase in the incidence of mitochondrial 
damage in the brain. Indeed MAO-generated oxidative stress has been linked with 
mitochondrial DNA mutation (Soong et al. 1992, Hauptmann et al. 1996), loss of 
mitochondrial respiratory capacity (Kumar et al. 2003) and disrupted mitochondrial 
electron flow (Cohen et al. 1997). 
5.1.2 Changes in MAO expression in in vitro cell culture systems 
MAO-B mRNA expression is increased following treatment of human hepatocytoma cells 
with phorbol 12-myristate 12-acetate (PMA), which was shown to be signalled via PKC, 
MAPK and regulated by the transcription factors c-Jun and Egr-1 (Wong et al. 2002). The 
following year the same working group showed that MAO-B expression was up-regulated 
during Caco-2 cell differentiation and the transcription factors Sp1 and Sp3 have been 
implicated (Wong et al. 2003).  
Increased MAO-A mRNA expression has also been observed in apoptosis induced by 
dexamethasone in human skeletal muscle cells (Manoli et al. 2005). MAO-A mRNA 
expression, protein levels and catalytic activity were increased during apoptosis induced by 
serum deprivation in rat pheochromocytoma cells (DeZutter and Davis 2001), which was 
shown to be regulated by the p38 MAPK pathway (DeZutter and Davis 2001). As noted in 
chapter 3, Ou and co-workers (2006) have recently shown that MAO-A mRNA expression 
and catalytic activity is increased in apoptotic human neuroblastoma cells deprived of 
serum and that the mechanism involved the p38 MAPK signalling pathway and the novel 
transcriptional repressor R1 (RAM2/CDCA7L/JPO2).  
5.1.3 Increased MAO expression following genetic manipulation 
Genetic manipulation of MAO expression in vivo has been limited to the creation of MAO 
knock out mice (Shih et al. 1999). Genetic elevation of MAO-B in vitro has been 
investigated previously by Kumar et al. (2003), who created an inducible rat 
pheochromocytoma (PC12) cell line where increased expression of MAO-B was similar to 
that observed during normal ageing. Kumar and colleagues showed that increased H2O2 
production via subtle elevations of MAO-B levels causes inhibition of the metabolic 
enzyme α-ketoglutarate dehydrogenase, decreased flux through mitochondrial complex I, 
loss of spare respiratory capacity and inability of dopaminergic cells to cope with stress 
(Kumar et al. 2003). 
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Yi and colleagues recombinantly overexpressed MAO-B in SH-SY5Y cells, which 
markedly increased levels of MAO-B protein and activity. Increased MAO-B did not affect 
the sensitivity of the cells to apoptosis induced by N-methyl-(R)salsolinol, suggesting that 
the MAO-B isoform was not involved in N-methyl-(R)salsolinol-induced apoptosis (Yi et 
al. 2006a).  
Methylation of the MAO-B promoter causes down-regulation/silencing of MAO-B gene 
expression (Wong et al. 2003). On the other hand, MAO-B mRNA expression and protein 
levels as well as catalytic activity were shown to be increased when SH-SY5Y, Sl2 and 
HepG2 cells were co-transfected with a transforming growth factor-β-inducible early gene 
(TIEG)2 expression vector. The latter study concluded that the MAO-B core promoter 
region contained a response element to TIEG2 (Ou et al. 2004). This group have more 
recently investigated the MAO-A isoform, knocking down levels of the novel 
transcriptional repressor R1 in human medullablastoma cells indirectly resulting in an 
increase in MAO-A activity and reduced cell proliferation (Ou et al. 2006). 
5.1.4 Rationale 
To date, no attempt has been made to directly overexpress MAO-A either in animals or in 
in vitro cell models and MAO-B has been the focus of the majority of in vivo studies. 
Therefore this chapter further explores the role of MAO in apoptotic cell death by 
overexpressing the MAO-A gene in SH-SY5Y cells. This would allow an assessment of 
whether increased MAO-A levels can lead to increased oxidative stress and apoptosis and 
render the cells more sensitive to toxic insult. Since our knowledge of MAO-A in 
neurodegeneration is limited, this section of work is of high importance.  
5.1.5 Aims of Chapter 
• To stably overexpress MAO-A in SH-SY5Y cells 
Human MAO-A was stably overexpressed in SH-SY5Y) cells by cloning human MAO-A 
cDNA into the expression vector (pcDNA3.1(-), Invitrogen, Karlsruhe, Germany). The 
expressed plasmid DNA was transfected into SH-SY5Y cells by electroporation. Stable 
SH-SY5Y clones were then selected by their resistance to blasticidin. 
• To characterise the MAO-A status of stably transfected SH-SY5Y cell clones 
Characterisation of the MAO status of the cells included determination of MAO-A mRNA 
expression levels, catalytic activity, protein levels and protein distribution. Comparisons 
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were made between MAO-A overexpressing cells, mock transfected control cells 
(pcDNA3.1(-) without MAO-A insert) and wild type cells.  
• To assess viability and general characteristics of the stably transfected cells 
The effects of overexpression of MAO-A on cell morphology, growth rate, cell 
proliferation, ROS production, caspase-3 activity and ATP levels were assessed by 
comparing MAO-A overexpressing cells with mock transfected and wild type cells. 
• To asses the sensitivity of MAO-A over expressing cells to apoptotic inducers 
Finally, the effects of MAO-A overexpression on the response to three different apoptotic 
inducers (staurosporine, serum withdrawal and rotenone) was monitored. Markers included 
caspase-3, MAPK activation, ROS production, cell proliferation and ATP levels.  
5.2. RESULTS 
5.2.1 Characterisation of SH-SY5Y cells overexpressing MAO-A 
5.2.1.1 Initial characterisation of MAO-A expression in stable overexpressing clones 
Transient transfections were initially undertaken to determine the appropriate time course 
of transfection and amount of DNA required (see appendix), which was found to be 1 µg 
DNA for 48 h. SH-SY5Y cells were stably transfected with the pcDNA3.1(-) vector 
lacking the MAO-A sequence, referred to as mock and those transfected with pcDNA3.1(-) 
containing the MAO-A cDNA sequence, referred to as MAO-A+. Stable clones were 
selected by their resistance to the antibiotic geneticin. A titration of G418 was performed 
to determine the lowest concentration required to kill wild type cells (see appendix), which 
was found to be 700 µg/ml. RNA was extracted for characterisation of MAO-A mRNA 
expression levels. Approximately 24 MAO-A+ clones were picked from 96-well culture 
plates and expanded but only 4 clones grew sufficiently to passage and for MAO-A mRNA 
analysis. Figure 5. 1A shows that those MAO-A+ clones assayed exhibited increased 
MAO-A mRNA expression compared to wild type and mock transfected SH-SY5Y cells. 
Mock transfection resulted in approximately a two fold increase in MAO-A mRNA 
expression compared to wild type cell clones. Increased expression of MAO-A mRNA in 
MAO-A+ SH-SY5Y clones ranges from ~63-10,000 fold increase, compared to wild type 
expression. SH-SY5Y cell clones were then expanded further and extracts taken for 
evaluation of MAO-A catalytic activity. Clone 2H7 growth was strongly impaired (see 
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Figure 5. 2) and was omitted from MAO activity assays. MAO activity in MAO-A+ cell 
clones differed from changes seen in mRNA expression (Figure 5. 1). Mock transfected 
cell clones had similar MAO activities compared to wild type SH-SY5Y cells, whilst 
MAO-A+ clones had increased MAO catalytic activities ranging between ~4-11 fold of 
wild type (Figure 5. 1). MAO-A+ clone 1A9 which showed the highest expression of 
MAO-A mRNA did not show the highest increase in catalytic activity. Conversely, MAO-
A+ clone 3I8, which had the lowest mRNA expression among all the over expressing 
MAO-A clones, showed the highest increase in catalytic activity (~11.4 fold of wild type). 
 
Figure 5. 1 MAO-A mRNA levels and catalytic activities are increased in MAO-A+ SH-SY5Y clones 
(A) MAO-A mRNA expression was measured by qRT-PCR in stable SH-SY5Y cell clones (within 1 month 
following clonal expansion). Data represent duplicate values from one set of cell extracts. (B) MAO catalytic 
activities were measured in stable SH-SY5Y cell clones in vitro via a radiometric method using 14C-
Tyramine as a substrate and are expressed as pmoles/min/mg total protein ± S.D. (C) MAO-A mRNA (top 
panel) and catalytic activity (bottom panel) data shown in figure 5.2A and 5.2B respectively, in a table 
format showing fold increase in mock and MAO-A+ stably transfected SH-SY5Y cell clones compared to 
wild type expression.  
5.2.1.2 Morphology of stable clones 
Mock transfected clones had wild type cell morphologies but some MAO-A+ clones (2H7 
and 3I8, taken 3 weeks following clonal expansion) appeared to have difficulty growing 
(Figure 5. 2). MAO-A+/2H7 and MAO-A+/3I8 cells showed typical apoptotic 
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Figure 5. 2) and was omitted from MAO activity assays. MAO activity in MAO-A+ cell 
clones differed from changes seen in mRNA expression (Figure 5. 1). Mock transfected 
cell clones had similar MAO activities compared to wild type SH-SY5Y cells, whilst 
MAO-A+ clones had increased MAO catalytic activities ranging between ~4-11 fold of 
wild type (Figure 5. 1). MAO-A+ clone 1A9 which showed the highest expression of 
MAO-A mRNA did not show the highest increase in catalytic activity. Conversely, MAO-
A+ clone 3I8, which had the lowest mRNA expression among all the over expressing 
MAO-A clones, showed the highest increase in catalytic activity (~11.4 fold of wild type). 
 
Figure 5. 1 MAO-A mRNA levels and catalytic activities are increased in MAO-A+ SH-SY5Y clones 
(A) MAO-A mRNA expression was measured by qRT-PCR in stable SH-SY5Y cell clones (within 1 month 
following clonal expansion). Data represent duplicate values from one set of cell extracts. (B) MAO catalytic 
activities were measured in stable SH-SY5Y cell clones in vitro via a radiometric method using 14C-
Tyramine as a substrate and are expressed as pmoles/min/mg total protein ± S.D. (C) MAO-A mRNA (top 
panel) and catalytic activity (bottom panel) data shown in figure 5.2A and 5.2B respectively, in a table 
format showing fold increase in mock and MAO-A+ stably transfected SH-SY5Y cell clones compared to 
wild type expression.  
5.2.1.2 Morphology of stable clones 
Mock transfected clones had wild type cell morphologies but some MAO-A+ clones (2H7 
and 3I8, taken 3 weeks following clonal expansion) appeared to have difficulty growing 
(Figure 5. 2). MAO-A+/2H7 and MAO-A+/3I8 cells showed typical apoptotic 
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morphologies, few cell connections and were smaller than wild type clones, whereas 
MAO-A+ clones 1A9 and 4B9 grew more easily and had morphologies similar to wild 
type cells. Therefore, MAO-A+ clone 1A9 was chosen to work with since it exhibited 
sufficient growth rate and had a 4.4 fold increase in MAO-A catalytic activity. Mock 
transfected clone 2D8 was randomly chosen as a control. 
 
Figure 5. 2 Cell morphologies of mock transfected and MAO-A+ SH-SY5Y stable clones 
Mock transfected and MAO-A+ stable SH-SY5Y clones observed by phase contrast microscopy(~3 weeks in 
culture following clonal expansion). Cells were visualised using a Nikon eclipse TS100 microscope. 
Photomicrographs (× 10 objectives, taken on Nikon DN100 digital camera). Scale bar represents 20 µM. 
5.2.2 Characterisation of newly cloned MAO-A+ (1A9, working clone) 
5.2.2.1 MAO-A protein-levels and localisation 
MAO-A protein in MAO-A+/1A9 cells compared to mock/2D8 cells, revealed by DAB 
staining (Figure 5. 3A) and confocal microscopy (Figure 5. 3B). Both methods reveal that 
MAO-A+/1A9 cells have significantly higher amounts of MAO-A protein compared to 
mock/2D8 cells.  
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Figure 5. 3 MAO-A protein levels in mock transfected and MAO-A+ SH-SY5Y cells 
(A) Immunohistochemistry – Mock/2D8 and MAO-A/1A9 cells (~9 months in continuous cell culture) were 
stained with MAO-A (6G11-E1) specific antibody and revealed using HRP-conjugated secondary antibody 
with 3, 3’-Diaminobenzidine (DAB) as substrate. Control sections incubated in the absence of MAO-specific 
antibodies but revealed under the same conditions did not reveal staining and are not shown. MAO specific 
immunoreactivity is represented by dark brown/red staining. The images shown are from a representative 
experiment. Scale bar represents 20 µm. (B) Confocal microscopy – Mock/2D8 and MAO-A+ cells (~9 
months in continuous cell culture) were exposed to MAO-A (6G11-E1) specific antibody and revealed using 
FITC-conjugated secondary antibody, which fluoresces green, visualised by a CLSM Leica microscope. 
Propidium iodide counterstained nuclei fluoresce red. Photomicrographs are representative of >6 independent 
experiments.  
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Figure 5. 4 MAO-A protein in MAO-A+/1A9 stable clones 
MAO-A+/1A9 cells (~ 8 months in continuous culture) were exposed to MAO-A (6G11-E1) specific 
antibody and revealed using FITC-conjugated secondary antibody (green fluorescence), visualised using a 
CLSM Leica microscope. Nuclei were counterstained with propidium iodide (red fluorescence). 
Photomicrographs are representative of >6 independent experiments. Scale is stated on photomicrograph 
(taken at × 63 objectives, with zoom function). 
Figure 5. 5 shows co-localisation of MAO-A protein in MAO-A+/1A9 cells with the inner 
mitochondrial membrane enzyme cytochrome c oxidase, further signifying that 
overexpressed MAO-A in SH-SY5Y cells continues to localise to the mitochondria. 
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Figure 5. 5 MAO-A in MAO-A+/1A9 cells is localised to mitochondria 
MAO-A+/1A9 cells (~ 9 months in continuous culture) were exposed to MAO-A (6G11-E1) specific 
antibody and cytochrome c oxidase specific antibody at the same time and MAO-A revealed using a FITC-
conjugated secondary antibody (green fluorescence) and cytochrome c oxidase revealed using a TRITC-
conjugated secondary antibody (red fluorescence). In the same experiment co-localisation of MAO-A and 
Cytochrome c oxidase is shown by the yellow colour from merging the two images together. The Top panels 
show ×63 magnification and the bottom panels show ×63 magnification with zoom.  
5.2.3 Characterisation of sub-cultured MAO-A+ stable SH-SY5Y cells (1A9 
working clone) 
5.2.3.1 Cell viability and growth 
Following ~9 months in culture, growth rates of mock/2D8 and MAO-A+/1A9 clones were 
determined by viable cell count. Mock transfected cells and wild type cells have doubling 
times of 20 and 21 hours respectively (Figure 5. 6B). MAO-A+/1A9 clone has difficulty 
growing and have a doubling time of 54 hours (~2.7 times longer than mock transfected or 
wild type cells.  
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Figure 5. 6 Growth and doubling times of wild type, mock/2D8 and MAO-A+/1A9 cells 
(A) Growth of wild type, mock/2D8 and MAO-A+/1A9 cells in culture, 9 months following initial 
expansion. Cell numbers were determined by viable cell counts from two independent cell populations and 
from four counts from the each sample. Data are expressed as mean cell number ± SD. Data plotted on a log 
scale Y axis. (B) Doubling times were calculated and expressed as mean doubling time (h). 
Figure 5. 7 illustrates the differences in cell proliferation/ metabolism between the three 
cell types. In wild type cells, MTT reduction increases over a 96 hour period. MTT 
reduction in Mock/2D8 is lower at 48 h, resulting in significantly lower MTT reduction 
over the time course. MTT reduction in MAO-A+/1A9 clones is significantly reduced 
compared to mock transfected controls (Figure 5. 7). Cell viability (MTT reduction) in 
MAO-A+/1A9 cells changes very little over 96 h, suggesting that cell viability is reduced 
in these cells already and/or these cells do not proliferate sufficiently to detect MTT 
reduction.  
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Figure 5. 7 MTT reduction in wild type, mock/2D8 and MAO-A+/1A9 cells 
MTT reduction was measured in wild type, mock/2D8 and MAO-A+/1A9 cells (8-9 months in continuous 
culture) over 96 hours and expressed as mean absorbance values at 570 nm ± S. D. Replicates in assay=12 
and n=5. MAO-A+ and mock/2D8 cell MTT reduction was statistically compared to wild type MTT 
reduction over time using two way ANNOVA test where *** p<0.001. Mock/2D8 MTT reduction over time 
was compared to MAO-A+/1A9 MTT reduction overtime using two way ANNOVA test, where *** 
p<0.001. 
ATP levels in the stable cell lines were measured using a luciferase based assay (Figure 5. 
8). ATP in mock/2D8 cells was significantly reduced (by approximately 50%, Figure 5. 8) 
compared to wild type levels. ATP in MAO-A+/1A9 clones was reduced further and 
compared to mock/2D8 levels, there was a significant reduction of approximately 66% 
(Figure 5. 8). 
 
Figure 5. 8 ATP levels in wild type, mock/2D8 and MAO-A+/1A9 cells 
ATP levels were measured in untreated wild type, mock/2D8 and MAO-A+/1A9 cells (~ 10 months in 
continuous culture). ATP levels were determined using a luciferase based assay, amount of ATP was 
determined using ATP standards and expressed as mean pmoles/µg total protein ± S. D. Replicates in 
assay=2 and n=9. MAO-A+/1A9 cell ATP levels were statistically compared to mock/2D8 cell ATP levels 
using the Student’s t-test where ** p<0.005. Mock/2D8 cell ATP levels were statistically compared to wild 
type cell ATP levels using the Student’s t-test where ** p<0.005. 
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5.2.3.2 Changes in morphology during long term culture 
MAO-A+/1A9 cells that have been continuously sub-cultured have abnormal 
morphologies and make very few cell connections. These cells do not grow in close 
proximity and few show extended neuronal morphologies or axonal outgrowths (Figure 5. 
9). They also show some curious morphological characteristics after long periods in culture 
(Figure 5. 9A and B). Cells of the mock/2D8 clone however continue to exhibit 
morphologies similar to wild type as shown in Figure 5. 9. 
 
Figure 5. 9 Changing cell morphologies of MAO-A+/1A9 SH-SY5Y cells after long term culture. 
(A) Left column shows Mock/2D8 SH-SY5Y cells and Right column shows MAO-A+/1A9 SH-SY5Y cells 
that have been in continuous subculture for ~ 10 months. Cells were visualised using a Nikon eclipse TS100 
microscope. Photomicrographs (× 10 and × 40 objectives, taken on Nikon DN100 digital camera). Scale bar 
represents 20 µM. (B) Enlarged photomicrographs of MAO-A+/1A9 cells, taken at × 40 objectives, taken on 
Nikon DN100 digital camera, showing cell surface whiskers. 
Figure 5. 10 shows morphologies of MAO-A+/1A9 cells that have been in continuous 
culture for 10 months (Figure 5. 10 panels E and F), or recovered from liquid nitrogen 
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stores and cultured for two weeks, termed ‘new batch’ (Figure 5. 10 panels A and B) and 
‘new batch’ cells that have been cultured for two weeks in the presence clorgyline (Figure 
5. 10 panels C and D). Cells cultured for >10 months appear sparse, apoptotic, do not have 
a flat neuronal phenotype, or make cell connections, and show extensive blebbing (Figure 
5. 10 panels E and F). New batch MAO-A+/1A9 cultured for a total of 6 weeks (4 weeks 
prior to cryopreservation and 2 weeks following resuscitation) show a typical flat and 
elongated neuronal phenotype and lack blebbing seen in long term culture. They make cell-
cell connections, divide and are less apoptotic (Figure 5. 10 panels A and B) The ‘new 
batch’ of MAO-A+/1A9 cultured in the presence of clorgyline had similar morphologies to 
the ‘new batch cells’ grown in growth medium except the population is denser ( Figure 5. 
10 panels C and D).  
 
Figure 5. 10 Changes in morphology during long term culture following cloning of MAO-A+/1A9 cells 
MAO-A+/1A9 were picked and expanded (I) for cryopreservation and then resuscitated and expanded in a 
T25 cm2 flask without clorgyline (panels A and B), or with clorgyline (panels C and D); or (II) continuously 
sub-cultured for 11 months (panels E and F), prior to taking photographs on a Nikon DN100 digital camera. 
Panels A, C and D are taken at × 10 and panels B, D and F at × 40 magnification. 
Antibodies directed against cytoskeleton proteins, (α-tubulin and β-actin) were used to 
further investigate the structure of MAO-A+/1A9 clone cytoskeleton in new batch MAO-
A+/1A9 cells (shown in Figure 5. 11) cultured for ~3 months. The distribution of α-tubulin 
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and β-actin is similar in wild type, mock/2D8 and MAO-A+/1A9 cells and there is no 
evidence of stress fibres that can be detected by β-actin staining. Some MAO-A+/1A9 cells 
appear apoptotic in their general shape and the cytoplasm appears shrunken and condensed 
compared to wild type and mock transfected controls, which is characteristic of apoptosis 
(Hengartner 2000).  
 
Figure 5. 11 Cytoskeletal proteins and GAPDH in wild type, mock/2D8 and MAO-A+/1A9 cells 
Mock/2D8 and MAO-A+/1A9 cells that have been in continuous culture for ~3 months were exposed to α-
tubulin, β-actin and GAPDH specific antibodies and revealed using a FITC-conjugated secondary antibody 
(which fluoresces green). Nuclei were counter-stained with propidium iodide (red). Images were taken at ×63 
magnification and scale bars are shown on each photomicrograph. Laser power was matched between 
different cell types for each protein of interest.  
Data in Figure 5. 11 confirm that blebs on the surface of MAO-A+/1A9 cells contain 
cytoskeletal proteins, indicating that blebs are a protrusion of the cytoplasm and are not 
inclusions. Figure 5. 11 also shows staining for GAPDH in mock/2D8 and MAO-A+/1A9 
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cells. Some GAPDH in MAO-A+/1A9 cells is present in the nucleus, suggesting a certain 
amount of translocation from the cytosol, a hallmark of apoptosis (Berry and Boulton 
2000).  
5.2.3.3 Changing characteristics of MAO-A+/1A9 cells during long term culture 
To assess basal levels of caspase-3 activity in MAO-A+/1A9 cells, caspase-3 activity of 
untreated cells was monitored over a culture period of 9 months (Figure 5. 12). At early 
time points, basal caspase-3 activity was higher than mock/2D8 and wild type cells (Figure 
5. 12). Caspase-3 activity then dramatically decreased to below wild type levels in both 
mock/2D8 and MAO-A+/1A9 cells after continuous culture for 9 months (Figure 5. 12).  
 
Figure 5. 12 Basal caspase-3 activities are reduced during long term culture of MAO-A+/1A9 cells 
Basal caspase-3 activity measured using Acetyl-Asp-Glu-Val-Asp-7-Amidomethylcoumarin as substrate in 
wild type, mock/2D8 and MAO-A+/1A9 cells measured over a 9 month culture period and expressed as 
∆FU/min/µg protein. Data represents values from single experiments over time where each extract was 
assayed in triplicate and intra-assay error shown. 
MAO-A protein levels detected by dot blotting are elevated by ~4 fold in MAO-A+/1A9 
cells compared to mock transfected and wild type controls (Figure 5. 13). Following 
continuous culture for ~25 weeks levels of MAO-A protein in MAO-A+/1A9 clones 
remains constant. 
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Figure 5. 13 MAO-A protein levels in MAO-A+/1A9 cells over a 6 month culture period 
(left panel) Dot blot of MAO-A protein levels in SH-SY5Y stable clones. Equal protein homogenates (3 µg) 
were loaded on to a nitrocellulose membrane (except positive control, 1 µg) and probed with a MAO-A 
specific antibody. Mitochondrial membranes from human placenta are the positive control and no primary 
antibody was the negative control (not shown). (Right panel) Quantification of dots. The dots were digitised 
and densitometry was performed to quantify relative MAO-A protein levels normalised to total protein levels 
(copper stain) and expressed as % wild type control. Time in culture of MAO-A+/1A9 cells is shown in 
brackets (number of weeks).  
5.2.3.4 Reactive oxygen species 
Figure 5. 14 shows that ROS production is much larger in MAO-A+/1A9 cells compared 
to mock/2D8 cells, which produced negligible amounts of ROS.  
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Figure 5. 14 Production of ROS is increased in MAO-A+/1A9 cells 
DCDHF fluorescence was monitored in live mock/2D8 cells (top panels) and MAO-A+/1A9 cells (bottom 
panels, ~9 months of continuous culture) and visualised using a CLSM Leica microscope. Two 
photomicrographs are shown from two independent experiments, labelled experiment (Exp’1) and (Exp’2) 
and are representative of at least 4 independent experiments. Scale bar represents 100 µm in experiment 1 
and 160 µm in experiment 2. 
5.2.3.5 Survival and stress proteins 
Levels of anti-apoptotic protein Bcl-2 were measured in untreated MAO-A+/1A9 cells 
(Figure 5. 15). Both western blotting analysis (Figure 5. 15A) and confocal microscopy 
(Figure 5. 15B) reveal loss of Bcl-2 in MAO-A+/1A9 cells compared to mock/2D8 
controls. Confocal microscopy was particularly useful at this stage (~8 months in culture), 
since the MAO-A+/1A9 cells were struggling to grow in large volume plasticware. The 
small wells used for microscopy and the need for fewer cells allowed the detection of 
specific proteins in these cells. 
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Figure 5. 15 Bcl-2 levels in mock/2D8 and MAO-A+/1A9 SH-SY5Y clones 
(A) Western blotting: Equal protein aliquots (20 µg) of cells extracts from untreated mock/2D8 and MAO-
A+/1A9 SH-SY5Y cells (~8 months in continuous culture) were separated on a 12 % (v/v) acrylamide SDS-
PAGE gel prior to transfer to nitrocellulose membranes. Blots were probed with antibody directed to cleaved 
Bcl-2 (1:750 dilution). Blots shown are from two independent experiments and representative of >4 
independent experiments (B) Confocal microscopy: Bcl-2 protein (shown by green fluorescence) levels were 
detected in fixed, untreated mock/2D8 and MAO-A+/1A9 SH-SY5Y cells. Cells were visualised using a 
CLSM Leica microscope. 
Antibodies directed against activated stress-associated MAPK proteins were used to probe 
mock/2D8 and MAO-A+/1A9 cells and visualised using confocal microscopy (Figure 5. 
16). The levels of both pJNK and the related transcription factor c-jun were increased in 
MAO-A+/1A9 cells. c-jun was detected predominantly in the nucleus of MAO-A+/1A9 
cells and active JNK was seen in only few mock/2D8 cells. pP38 could not be detected 
using immunofluorescence. 
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Figure 5. 16 Phosphorylated JNK and transcription factor c-jun in mock/2D8 and MAO-A+/1A9 cells 
c-jun and phosphorylated JNK levels were detected (both shown by green fluorescence) in fixed, untreated 
mock/2D8 and MAO-A+/1A9  SH-SY5Y cells (~8 months in continuous culture). Cells were visualised 
using a CLSM Leica microscope. Photomicrographs are representative of 3 separate experiments. 
5.2.4 Treatment of MAO-A+/1A9 SH-SY5Y stable clones with apoptotic 
inducers 
5.2.4.1 Cell viability 
Serum withdrawal significantly reduced MTT reduction by 72 h in both mock/2D8 and 
MAO-A+/1A9 clones (Figure 5. 17). In both cases the % reduction at 72 h was similar 
(54.8 % and 61.7 for the mocl/2D8 and MAO-A+/1A9 cells respectively, Table 5. 1). A 
significant reduction in MTT reduction was also evident in both clones following 72 h 
rotenone treatment (Figure 5. 17) but the effect of rotenone was significantly less in the 
MAO-A+/1A9 clone (Table 5. 1). 
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Figure 5. 17 Effect of apoptotic inducers on cell viability in wild type, mock transfected and over 
expressing MAO-A stable clones 
Cell viability was measured in (A) mock/2D8 and (B) MAO-A+/1A9 SH-SY5Y cells (~8 months in 
continuous culture) over 96 hours in the presence of normal growth medium (control), serum free medium 
following washing (-serum) and 0.5 µM rotenone (+ rotenone). MTT reduction was determined and 
expressed as mean absorbance values at 570 nm ± S. D. Replicates in assay=12 and n=5. Treated cell MTT 
reduction were statistically compared to untreated cell MTT reduction in mock transfected and MAO-
A+/1A9 cells using the Student’s t-test where * = p<0.05 and *** = p<0.001 for serum withdrawal and 
rotenone treatments. Treated cell MTT reduction were statistically compared to untreated cell MTT reduction 
over the 96 h time course in mock/2D8 and MAO-A+/1A9 cells using two way ANNOVA, where *** = 
p<0.001 (shown on key). 
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Table 5. 1 Effect of serum deprivation and rotenone treatment on MTT reduction 
Data from Figure 5. 17 at a 72 hour end point only including wild type values, expressed as mean MTT 
reduction (% untreated control) ± S.D. Replicates in assay=12 and n=5. MTT reduction (% untreated control) 
in wild type cells were statistically compared to MTT reduction (% untreated control) in mock transfected 
cells and MTT reduction (% untreated control) in MAO-A+/1A9 cells were statistically compared to MTT 
reduction (% untreated control) in mock transfected cells using the Student’s t-test where *** p<0.001. 
Levels of reactive oxygen species in MAO-A+/1A9 cells were much higher than in 
mock/2D8 controls (Figure 5. 18A and B, left panels). Serum withdrawal resulted in 
detectable increases in ROS production in mock/2D8 control cells (Figure 5. 18A), but not 
in MAO-A+/1A9 cells (Figure 5. 18A). Following challenge with STS, on the other hand, 
ROS levels were increased further in both mock/2D8 and MAO-A+/1A9 cells (Figure 5. 
18B). Clorgyline reduced ROS levels induced by serum withdrawal and STS in mock/2D8 
and MAO-A+/1A9 cells (Figure 5. 18).  
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Figure 5. 18 ROS production in mock/2D8 and MAO-A+/1A9 SH-SY5Y cells following STS and serum 
deprivation treatments 
DCDHF fluorescence was monitored in live mock/2D8 and MAO-A+/1A9 cells (~9 months in continuous 
culture) in (A) Growth medium (control), in serum free medium (no serum) and serum free medium with 1 
µM clorgyline (no serum + clor) for 72 h. (B) In SFM (control), SFM containing 1 µM STS (STS), SFM 
containing 1 µM STS and 1 µM clorgyline (STS + Clor) for 1.5 h. Cells were visualised using a CLSM Leica 
microscope, where laser power was matched. Scale bar represents 100 µm. 
5.3. DISCUSSION 
5.3.1 Development of a stable SH-SY5Y cell line over expressing MAO-A 
Human MAO-A cDNA was successfully cloned into the expression vector pcDNA3.1 (-), 
transformed into competent bacteria and transfected by electroporation into SH-SY5Y 
cells. Data were collected within the first month following the initial expansion of clones 
from single foci. Constitutive expression of MAO-A mRNA in wild type SH-SY5Y cells is 
~3 molecules/1000 molecules GAPDH. Mock transfected clones showed similar MAO-A 
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mRNA expression to wild type cells, whilst clones overexpressing MAO-A had 
dramatically increased (up to 10,000 fold) MAO-A mRNA expression (Figure 5. 1). MAO 
catalytic activity in mock transfected clones was the same as in wild type cells. MAO 
catalytic activity in MAO-A+ clones ranged between ~4-11 fold of wild type levels and did 
not necessarily follow the pattern of MAO-A mRNA expression in each MAO-A+ clone.  
Among overexpressing clones, the 3I8 MAO-A+ clone had relatively low MAO-A mRNA 
expression but high catalytic activity and grew slower than clones having lower catalytic 
activities (MAO-A+/1A9 and 4B9). This clone also showed apoptotic morphologies, 
including cell condensation and blebbing (Figure 5. 2). The initial assessment of SH-SY5Y 
clones overexpressing MAO-A suggested that increased MAO activity impairs viability, 
judged by cell morphology and observed growth rate. MAO-A+/1A9 was chosen as a 
working clone since in the initial weeks following expansion, it showed a ~4.4 fold 
increased MAO activity (also 4 fold increase in MAO-A protein level), appeared to 
proliferate and had a similar morphology to wild type and mock transfected control cells 
(Figure 5. 2). Mock transfected clone 2D8 was randomly chosen. 
MAO-A+/1A9 cells contain more MAO-A protein than mock transfected control or wild 
type cells, shown non-quantitatively by confocal microscopy and immunohistochemistry 
(Figure 5. 3) and quantitatively by dot blotting (Figure 5. 13, around 4-fold compared to 
mock control). High magnification confocal microscopy of MAO-A protein in MAO-
A+/1A9 cells revealed that MAO-A proteins are interspersed throughout the cell in distinct 
punctuated patches (Figure 5. 4), akin to mitochondrial staining in SH-SY5Y cells (for an 
example see Muqit et al. 2006). Indeed, MAO-A staining is almost completely co-localised 
with cytochrome c oxidase (Figure 5. 5), further indicating that overexpressed, intact 
MAO-A protein is inserted into the OMM.  
Very high MAO-A mRNA levels in MAO-A+ clones driven by the expression vector 
could be a result of multiple insertion of the vector. High levels of expression in general, 
may be controlled by the cell at a number of post-transcriptional steps. Firstly, processed 
mRNA may not all be transported to the intended cytoplasmic location (Czaplinski and 
Singer 2006). Turnover of mRNA can control gene expression. Sites for mRNA decay 
known as P bodies are up-regulated when cells are overloaded with RNA (Sheth and 
Parker 2003). Another control point is translation of mRNA, which may be controlled by a 
complex range of processes (Richter 2007). Stability and function of the translated protein 
will be further regulated via protein degredation pathways and post-translational 
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modifications, which may control inactivation, maturation and compartmentalisation of the 
enzyme. The physical space on the outer mitochondrial surface should also be considered, 
since insertion of MAO into the OMM is critical for catalytic activity (Zhuang et al. 1992). 
MAO activity may ultimately be limited by the number of mitochondria per cell and the 
space available on the mitochondrial membrane regardless of the amount of mRNA 
produced. For example, reducing levels of the MAO-A repressor R1, causes a 6-fold 
increase in MAO-A mRNA expression but only 35-50% increase in MAO catalytic activity 
(Ou et al. 2006).  
5.3.2 Consequences of MAO-A overexpression 
5.3.2.1 Increased MAO-A causes oxidative stress 
Measurement of reactive oxygen species in untreated mock/2D8 and MAO-A+/1A9 cells 
consistently revealed increased ROS in MAO-A+/1A9 cells (Figure 5. 14 and Figure 5. 
18). Increased ROS (via MAO catalysed H2O2 production) in MAO-A+/1A9 cells may 
affect G protein signalling (Nishida 2000), activation of MAPK survival/mitogenesis 
pathways (Vindis et al. 2000), stress signalling MAPK pathways (Crossthwaite et al. 2002, 
Yoon et al. 2002, Ruffels et al. 2003, Halliwell and Gutteridge 2007), oxidant signalling 
(Finkel 1998), modification of proteins (Finkel 2003) and cell death processes (Tan et al. 
1998). Indeed, overexpression of MAO-A resulted in increased levels of phosphorylated 
JNK and the transcription factor c-jun (Figure 5. 16) and decreased levels of anti-apoptotic 
Bcl-2 protein (Figure 5. 15).  
The viability and growth of MAO-A/1A9 cells was assessed using MTT reduction assays 
and trypan blue viable cell counts. Both wild type and mock transfected SH-SY5Y cells 
proliferate in a similar manner (Figure 5. 6A) and have a doubling time of ~21 hours 
(Figure 5. 6B). Proliferation of MAO-A+/1A9 cells is greatly reduced (Figure 5. 7) and 
their doubling time is more than twice as long at ~54 hours (Figure 5. 6). MTT data 
showed the same general trends (Figure 5. 7), but MTT reduction in MAO-A+/1A9 cells 
was very low, indicating low metabolism. These data demonstrate that elevated MAO-A 
expression has a negative effect on cell survival, proliferation and metabolism. Reduced 
proliferation in MAO-A+/1A9 can be mainly attributed to increased MAO-A, since stable 
transfection of the vector and the presence of geneticin did not significantly affect 
proliferation of the mock transfected cells (Figure 5. 6). Increased MAO activity in MAO-
A+/1A9 cells resulted in increased ROS production (Figure 5. 14) via increased H2O2, 
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which could potentially disrupt H2O2 homeostasis and signalling within the cells. Indeed, 
inhibition of MAO-A activity in MAO-A+/1A9 cells by clorgyline resulted in increased 
cell numbers compared to control (Figure 5. 10). In neuronal cells, oxidative metabolism of 
biogenic amines by MAO is a major contributor to the cytosolic and mitochondrial steady 
state levels of H2O2  (Cadenas and Davies 2000). Low levels of H2O2 are mitogenic in 
several cell types in culture (Halliwell and Gutteridge 2007) and also in cancer cells (Gius 
and Splitz 2006). However, in vivo small increases in H2O2 concentrations (above 500 nM) 
causes growth arrest and even higher (above 50 µM) can induce apoptosis (Giorgio et al. 
2007, Figure 5. 19). 
 
Figure 5. 19 Cellular effect of H2O2 concentration (modified from Giorgio et al. 2007) 
Diagram showing the opposing effects of H2O2 concentration on the cell. The resting cell in vivo has a H2O2 
concentration of ~100 nM alongside high concentrations of glutathione and ascorbate antioxidants (Halliwell 
and Gutteridge 2007), inducing proliferation. When the cellular concentration of H2O2 exceeds 500 nM, 
oxidative damage levels rise, transition metal ions that catalyse free radical reactions are released, free 
radicals damage DNA resulting in activation of transcription factors and adaptive response (increased levels 
of protective systems, e.g. chaperones, antioxidant enzymes). Growth is arrested to allow repair of DNA 
damage (Halliwell and Gutteridge 2007). H2O2 concentrations above 50 µM induce more severe 
mitochondrial and DNA damage, ensuing mitochondrially-mediated and p53-mediated apoptotic events and 
often execution of apoptosis (Giorgio et al. 2007, Halliwell and Gutteridge 2007).  
5.3.2.2 Increased MAO-A reduces ATP levels and cell viability 
The role of ATP in cell death is paradoxical, since ATP also provides the energy needed 
for cell death to occur and is often increased during the early phases of apoptosis. Lack of 
ATP ultimately kills cells because there is insufficient ATP for the sodium or calcium 
pumps (Brown 2005), which results in loss of membrane potential, swelling and rupture of 
the cell. ATP depletion is a classic marker of necrotic cell death, however apoptosis can 
lead to necrosis (Brown 2005). In a vicious cycle of events, stressful or apoptotic stimuli 
and mitochondrial dysfunction can also trigger ATP depletion. ATP levels and optimal 
ROS production are required for optimal mitochondrial activity and depletion of ATP has 
been shown to coincide with increased ROS production (Keating 2008). ATP levels in 
mock/2D8 cells are significantly lower than in wild type cells (by approximately 50%, 
Figure 5. 8). These data suggest that after 10 months in continuous culture, the long-term 
effects of geneticin and/or off target effects of stable transfection with the control vector 
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has caused reduced ATP. Nonetheless, ATP levels in MAO-A+/1A9 cells were 
significantly lower than mock/2D8 cells (around 66% less ATP, Figure 5. 8). This 
substantial loss of ATP in MAO-A+/1A9 cells (Figure 5. 8), implies that the electron 
transport chain/respiration is severely compromised by changes in H2O2 production. ATP 
depletion and increased ROS production has been shown to de-regulate exocytosis 
(Keating 2008). Impaired mitochondrial function and impaired regulation of exocytosis 
caused by or as a result of changes in ROS and ATP are implicated as underlying 
contributors to the initial stages of some human neurodegenerative disorders, including PD 
(Keating 2008). The present data support the hypothesis that MAO may be involved in 
these disorders. 
5.3.2.3 Increased MAO-A activity causes changes in cell morphology and growth 
Long term culture (~6 months) of MAO-A+/1A9 cells induced a state of growth arrest, 
associated with cell shrinkage and blebbing (Figure 5. 9). At this late stage, MAO-A+/1A9 
cells became difficult to sub-culture, except when seeded in small culture areas such as 
chamber slides (for an example see Figure 5. 6).  
Finally, resuscitated MAO-A+/1A9 cells grew normally, being neuronal-like and healthy 
compared to cells that had been in long term culture (Figure 5. 10). A population of early 
MAO-A+/1A9 cells (6 weeks in culture) were grown in media containing the MAO 
inhibitor clorgyline. These cells proliferated more quickly and showed healthier neuronal-
like morphologies than the new batch cells without clorgyline or old MAO-A+/1A9 cells 
(Figure 5. 10). These data again indicate that chronic exposure to increased MAO activity 
is responsible for injury to the cell.  
Extensive cell blebbing (as seen in Figure 5. 9), is typical of apoptotic cell death. However, 
other morphological characteristics of apoptosis such as cell shrinking, rounding and 
chromatin condensation were not always apparent in aged MAO-A+/1A9 cells (Figure 5. 
9). Antibodies directed against two cytoskeletal proteins were used to investigate the 
general structure and cell surface structures of MAO-A+/1A9 cells. The organisation of α-
tubulin is similar in mock/2D8 and wild type SH-SY5Y cells (Figure 5. 11). Actin 
filaments are normally highly concentrated in the cell cortex, just beneath the plasma 
membrane (Alberts et al. 1994). Mock/2D8 and wild type SH-SY5Y cells show similar 
staining of β-actin, and actin was present in the blebs at the cell surface, indicating that the 
blebs are apoptotic, since the structures are a protrusion of the cytoplasm. 
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5.3.2.4 Increased MAO-A levels result in apoptosis or necrosis 
That MAO-A+/1A9 cells are apoptotic is further supported by GAPDH staining in their 
nuclei (Figure 5. 11). As previously discussed (see section 3.3), GAPDH translocates from 
the cytosol to the nucleus during apoptotic events, since GAPDH assists in regulating 
certain genes that will favour apoptosis (for a review see Berry and Boulton 2000).  
During early phases of cell culture, caspase-3 activity was elevated in MAO-A+/1A9 cells, 
but at later stages negligible levels of caspase-3 were detected. 
It is likely that during the early stages of culture following transfection, MAO-A+/1A9 
cells are subjected to a moderate increase in oxidative stress which activates/up-regulates 
antioxidant defences, DNA repair mechanisms and possibly induces stress/apoptotic 
pathways including further regulation of MAO itself (although MAO-A protein remains 
stable over a 6 month period, Figure 5. 13). As indicated earlier, older cultures appear to be 
in a state of growth arrest or senescence. Response to oxidative stress may be reversible; 
for a variable period the cell is in an altered redox state which does not lead to cell death 
(Halliwell and Gutteridge 2007). Events triggered by this state can persist and become 
permanent (Halliwell and Gutteridge 2007). Senescence, a permanent state of non-division 
has been reported in a continuous culture of human fibroblast cells treated with 100-300 
µM H2O2 (Chen 1998), however treatment with such high concentrations are not 
physiologically relevant or convincing. Senescence after long periods in cell culture can 
also in part be due to the oxidative stress of the culture process (Halliwell and Gutteridge 
2007). Severe oxidative damage often initiates apoptosis; however, in a highly oxidised 
state caspases are oxidised via their active site –SH groups and are inactive, leading to 
survival of badly damaged cells. Badly damaged cells that survive but are not able to 
recover are likely to die by necrosis. 
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Figure 5. 20 Proposed effect of MAO-A overexpression on SH-SY5Y cells in long term culture 
Diagram showing appearance of SH-SY5Y cells overexpressing MAO-A during long term culture. Bold text 
relates to known characteristics and italic text relates to unknown characteristics. Initially, MAO-A 
overexpression results in increased production of H2O2, increased reactive species and hence stressed or 
injured cells. Basal caspase levels are high and cells may either execute apoptosis or, depending on the extent 
of the stress, continue to proliferate, adapt to the oxidative environment and maintain neuronal phenotype. If 
oxidative damage rises, DNA and mitochondria are damaged, ATP is low, caspases are shut-down, telomeres 
shortened, growth is arrested and repair mechanisms are working extensively to rescue the cell. The cell may 
be partly rescued enough for the cell to commit suicide through apoptosis, since it is badly damaged; this is 
preferred and protects integrity. However, the cell may eventually be damaged irreversibly, may not be able 
to undergo apoptosis, dies by necrosis, disintegrating into the surroundings.  
5.3.3 Response of MAO-A+ SH-SY5Y cells to stress 
Since MAO-A+/1A9 cells were severely damaged during cell culture in experiments 
involving further stressors were less useful than expected. Caspase levels were diminished 
in damaged cells and measurement of apoptosis was limited. MTT reduction assays were 
attempted following challenge with a subtle stressor (serum deprivation) and a 
mitochondrial toxin (rotenone). However, as discussed earlier MTT reduction assays are 
not very sensitive and are only a measure of cellular metabolism. Long term cultured 
MAO-A+/1A9 cells reduced MTT at extremely low levels (similar to rotenone treated 
cells). The fact that serum withdrawal affected MTT reduction to a similar extent in MAO-
A+/1A9 and mock/2D8 cells does not suggest different sensitivity in the MAO-A+/1A9 
cells. Indeed the reduced effect of rotenone on the MAO-A+/1A9 cells indicates that the 
electron transport chain is already impaired in these cells, supported by their very low ATP 
levels (Figure 5. 8). However, it is possible that if MAO-A+ cells in the early stages of 
culture had been tested, the cells may have been more sensitive to other stressors. STS 
Chapter 5                                                                   Overexpression of MAO-A in human neuroblastoma cells 
 156
treatment appeared to result in a further increase in ROS in MAO-A+/1A9 cells, again 
suggesting that MAO-A may be up-regulated in response to oxidative stress.  
5.3.4 Conclusion 
Increased MAO-A expression in human neuroblastoma cells by genetic manipulation has 
confirmed a role for increased MAO in promoting cell death. A 4-fold increase in MAO-A 
activity caused oxidative stress and compromised mitochondrial function, which over time 
results in cell death by apoptosis or necrosis. An overview of the biochemical changes are 
shown in Figure 5. 21. MAO may fine tune or modulate the cells’ response to different 
stressors. Mitochondria-generated ROS is thought to control lifespan/ageing (Giorgio et al. 
2007) and may be involved in this process.  
 
Figure 5. 21 Overview of biochemical changes in SH-SY5Y cells overexpressing MAO-A 
Increased expression of MAO-A mRNA driven by expression vector results in ~4 times more MAO-A 
protein (shown as red circles) and more than 4-6 times catalytic activity. Increased MAO activity causes 
oxidative stress because of increased production of H2O2 during MAO catalysis and therefore increased 
levels of ROS. The increased oxidative environment favours GAPDH translocation to the nucleus, activation 
of stress-signalling pathways, decreased Bcl-2 levels, activation (low-moderate oxidative stress) or inhibition 
(high level oxidative stress) of caspase-3, and ATP depletion. MAO-generated oxidative stress damages 
mitochondria, mitochondrial dysfunction further compromises cell viability and eventually the cell dies by 
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THE EFFECT OF KNOCKDOWN OF MAO-A EXPRESSION 
IN NEUROBLASTOMA CELLS 
6.1. INTRODUCTION 
6.1.1 Reduced MAO in humans-physiological relevance 
Reduced MAO expression has been reported in a wide range of human conditions, but as 
discussed in section 5.11, limited measurement of MAO levels in humans has lead to some 
debate over the findings. However, the existence of rare mutations in MAO genes in 
humans and work on MAO knockout mice has confirmed that marked deficiency of MAO 
activity is compatible with life. 
6.1.1.1 Norrie disease and Brunner syndrome 
Norrie disease is rare X-chromosome linked recessive disorder of unknown pathogenesis 
(Norrie 1927, Sims et al. 1989b). The disorder is characterised by retinal dysplasia and 
consequent congenital blindness (Sims et al. 1989b). About half the patients also manifest 
CNS dysfunction, mental retardation and certain psychiatric symptoms (Sims et al. 1989b, 
Chen et al. 1995). Patients with an atypical form of the disease were discovered to have 
submicroscopic chromosomal deletions and MAO deficiency. This MAO deficiency state 
has been described in families, with features of altered amine levels, low intelligence and 
difficulty in impulse control (Chen et al. 1995), delayed sexual maturation, altered 
peripheral autonomic function, sleep disorders and seizures (Sims et al. 1989a). The Norrie 
disease gene (NDP) and MAO genes are tandemly arranged in the p11.4-p11.3 region of 
the human X chromosome in the order MAO-A-MAO-B-NDP (Chen et al. 1995). Two 
individuals with Norrie disease were found to lack the genes encoding MAO-A and –B. 
This was associated with a 90% reduction in urinary metabolites of the MAO-A substrate 
NA, a 100-fold increase in the MAO-B substrate PEA and no change in the metabolites of 
DA and 5-HT. Plasma amine oxidase activity however was found to be normal (Murphy et 
al. 2005). 
Brunner syndrome is an X chromosome-linked form of mild mental retardation which was 
first identified in males from large Dutch family showing abnormal, aggressive and violent 
behaviour. Studies on five males with Brunner syndrome showed that they had complete 
and selective deficiency of MAO-A catalytic activity and a point mutation in the eighth 
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exon of the MAO-A structural gene, which changed a glutamine residue to a termination 
codon (Brunner et al. 1993).  
Human condition MAO Isoform Measured in Author Year 
Alcoholism MAO-B platelets Sullivan et al  2000 
Type A personality MAO-B platelets Smith, A. F 1994 
Pre-eclampsia MAO-A placenta Sivasubramaniam et 
al 2002 
Female bulimia nervosa MAO-B platelets Carrasco et al 2000 
Female anorexia 
nervosa 
MAO-B platelets Diaz Marsa et al 2000 
Pre-menstrual 






Fowler et al 1996 and 2003 
Sensation seeking MAO-B platelets Murphy et al 1977 
Aggression/ violence MAO-A genetic 
assessment  Caspi et al 2002 
Aggression/ violence MAO-A genetic 
assessment  Brunner et al  1993 
Aggression/ violence MAO-A 
and -B 
genetic 
assessment  Sims et al 1989 
 
Table 6. 1 Examples of some human conditions where MAO is reduced 
The effect of decreased MAO activity on humans, showing condition, MAO isoform, method of study and 
reference to relevant publication.  
6.1.1.2 Behaviour and addiction 
Reduced MAO expression was reported in the blood platelets of schizophrenic patients 
(Murphy and Wyatt 1972). Although reduced MAO activity has been suggested to be a 
genetic marker for schizophrenia and many studies following Murphy and Wyatt’s work 
have demonstrated reduced MAO expression (reviewed by Sandler et al. 1981), these 
studies have been complicated by effects of drug therapy and therefore remain 
controversial today. Decreased MAO activity has also been heavily associated with 
aggression and impulsive behaviour (review by Sandler et al. 1981, Oreland 1993, Shih et 
al. 1999).  
Decreased MAO activity has been linked to alcoholism, and evidence suggests that 
decreased MAO in alcoholics is a trait rather than an artefact of ethanol consumption or 
withdrawal (Sandler et al. 1981, Sullivan et al. 1990). Interestingly, cigarette smoke 
inhibits MAO-A activity (Fowler et al. 1996) and low levels of MAO-B expression have 
been found in the peripheral organs of smokers (Fowler et al. 2003). Smokers have lower 
MAO activity in blood platelets and lowered incidence of Parkinson’s disease (Oreland et 
al. 1981, Castagnoli and Murugesan 2003).  
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6.1.2 Reduced MAO in in vitro culture systems 
6.1.2.1 Reduction of MAO with inhibitors 
MAO inhibitors have been shown to protect against MPTP toxicity (Heikkila 1988). 
Propargylamine MAO inhibitors can prevent cell death in human neuroblastoma cells 
induced by various insults including MPP+ treatment, oxidative stressors and withdrawal of 
trophic factors (Naoi and Maruyama 2001, Akao et al. 2002, Maruyama et al. 2002). 
Inhibition of MAO-A by clorgyline can prevent apoptosis in human melanoma cells 
(Malorni et al. 1998), human neuroblastoma (Ou et al. 2006), mouse neuroblastoma (De 
Girolamo 2001) and rat pheochromocytoma cells (DeZutter and Davis 2001). MAO 
inhibitors prevent suppression of the mitochondrial electron transport chain caused by 
monoamine metabolism in rat brain mitochondria (Cohen et al. 1997). Hydroxyl radicals 
induced in rat mitochondria following ascorbate and Fe2+ treatment significantly and 
irreversibly inhibited both MAO-A and MAO-B activities (Soto-Otero et al. 2001), 
suggesting that overproduction of hydroxyl radicals can be regulated by MAO inhibition.  
6.1.2.2 Reduction of MAO expression 
A recent publication has shown that MAO expression is suppressed by the action of wild 
type Parkin (Jiang et al. 2006). Wild type Parkin has a protein-ubiquitin E3 ligase activity 
that targets protein substrates for proteolysis by the 26S proteasome. Mutations in Parkin 
are linked to early-onset PD and the absence of functional Parkin is thought to underlie the 
degeneration of DA neurons in PD (for review see McNaught et al. 2001, Dawson and 
Dawson 2003). Following work by Jiang and collegues Parkin was shown to have the 
additional neuroprotective role by acting to suppress the expression of MAO mRNA, 
rather than controlling MAO protein degradation. Stable overexpression of Parkin in SH-
SY5Y cells markedly reduced mRNA expression, protein and activities of both MAO-A 
and MAO-B (Jiang et al. 2006).  
The Ca2+-binding protein (calbindin-D28K) is greatly reduced in AD brain (Cao et al. 
2007). Whilst overexpression of calbindin-D28K in a mouse hippocampal cell line causes 
a significant reduction in MAO-A expression (Cao et al. 2007). These data suggest that 
increases in intracellular calcium availability could contribute to a MAO-A-mediated 
mechanism involving oxidative stress in AD.  
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6.1.3 MAO knockdown by genetic manipulation 
6.1.3.1 MAO knockdown in vitro 
To date, reduction of MAO expression directly using genetic techniques in vitro has only 
been achieved by Yi and co-workers in SH-SY5Y cells (Yi et al. 2006a). The endogenous 
dopaminergic neurotoxin, N-methyl(R)salsolinol induces apoptotic cell death in the SNpc 
of rats (Naoi et al. 1996) and SH-SY5Y cells (Maruyama et al. 1997). Yi’s group used 
RNA interference (specifically siRNA) to knockdown MAO-A in SH-SY5Y cells and 
showed that MAO-A was a target of N-methyl(R) salsolinol. The MAO-A isoform was 
suggested to play a role in binding neurotoxins and MAO-A knockdown in this study 
resulted in significantly reduced binding of N- methyl(R) salsolinol. Interestingly, 
Salsolinol belongs to a group of compounds known as tetrahydroisoquinolines, potential 
neurotoxins that exist naturally in the body and may regulate pituitary function (for a 
review see Toth et al. 2002). 
6.1.3.2 MAO-A and MAO-B deficient mice 
An isolated line of transgenic mice in which a transgene integration caused a deletion in 
the gene encoding MAO-A provided the first animal model of MAO deficiency (Cases et 
al. 1995). Levels of 5-HT in MAO-A deficient pup brains were increased by nine fold and 
levels of norepinephrine were increased two fold in both pup and adult brains. MAO-A 
deficient mice are viable but have behavioural abnormalities as pups. These include 
trembling, fearfulness and difficulty in righting (autonomic reflexes), which were reversed 
by a 5-HT synthesis inhibitor, suggesting that behavioural changes are due to elevated 5-
HT rather than a direct cause of MAO-A inhibition. Male adults developed enhanced 
aggression (Cases et al. 1995). Increased aggressive behaviour in MAO-A knockout mice 
is consistent with abnormal aggression reported in men from a Dutch family with complete 
MAO-A deficiency (Brunner et al. 1993), suggesting that elevated levels of 5-HT may be 
important in enhanced emotional learning that adult MAO-A knockout mice exhibit (Kim 
et al. 1997). MAO-B deficient mice were bred using homologous recombination by 
Grimsby and colleagues (Grimsby et al. 1997), where only the levels of PEA monoamines 
were increased. In 2004, a line of MAO-A/MAO-B knockout mice were isolated and bred 
from a litter of MAO-B knockout mice that spontaneously developed a point mutation in 
exon 8 of the MAO-A gene (Chen et al. 2004). Double knockout mice had reduced body 
weight, anxiety-like behaviour and greatly increased levels of monoamines. Brain levels of 
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5-HT, NA, DA and PEA were increased and 5-HT metabolites decreased compared to 
MAO-A or MAO-B single knockout mice (Chen et al. 2004). Differences between MAO 
double knockout mice and single knockout mice suggest that varying monoamine levels 
result in unique biochemical and behavioural phenotypes. More recently, Newman’s group 
have shown that mother-reared male rhesus monkeys with a low MAO-A activity 
polymorphism were highly aggressive (Newman et al. 2005). 
6.1.4 miRNA technology 
RNAi interference (RNAi) is a naturally occurring cellular mechanism that induces post-
transcriptional gene silencing (Gilmore et al. 2004). RNAi technology has had a 
revolutionary impact on molecular biology since its discovery in 1998 by Fire and 
colleagues who were working on gene silencing in C. elegans (Dykxhoorn et al. 2003). 
In mammalian cells, RNAi is generally induced by one of two techniques. One approach 
relies on transfection of cells with a small interfering RNA (siRNA) which in brief, mimic 
the structure of microRNA (miRNA) duplex intermediates formed during the processing of 
endogenous miRNA transcripts. Although siRNA technology is simple and effective, 
synthetic siRNAs can be expensive and the effects are often transient (Cullen 2006). The 
alterative approach relies on the transcription by RNA polymerase III of short hairpin 
RNAs (shRNAs) which mimic the pre-miRNA hairpins that result from the processing of 
endogenous primary miRNA (Cullen 2006). For the down-regulation of MAO-A in this 
chapter of work, miRNAs targeted to MAO-A were expressed in SH-SY5Y cells, using the 
BLOCK-iT Pol II miR RNAi expression vector kit (Invitrogen, Karlsruhe, Germany). 
Unlike shRNAs, miRNAs are found embedded in long primary transcripts (pri-miRNAs), 
containing a hairpin structure and driven by RNA polymerase II (Lee et al. 2004). 
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Figure 6. 1 An overview of miRNA gene silencing 
Transcription-miRNAs are initially expressed as part of transcripts termed primary miRNAs (pri-miRNAs). 
They are transcribed by RNA polymerase II and include 5’ caps and 3’ poly(A) tails. The miRNA portion 
forms a hairpin loop with signals for dsRNA-specific nuclease cleavage. Hairpin release-The dsRNA-
specific ribonuclease Drosha digests the pri-miRNA in the nucleus to release hairpin, precursor miRNA (pre-
miRNA). Drosha also generates either the 5’ or 3’ end of the mature miRNA, depending on which strand is 
selected by the RNA induced silencing complex (RISC). Export-Pre-miRNAs are exported from the nucleus 
to the cytoplasm. Dicer processing-Dicer is a member of the RNase III superfamily of nucleases. Dicer 
cleaves pre-miRNA approximately 19 bp from the Drosha cut site. The resulting dsRNA has 1-4 nt 3’ 
overhangs at either end. Only one of the two strands in the mature miRNA (some mature miRNAs derive 
from the leading strand and some derive from the lagging strand) is selected by RISC. Strand selection by 
RISC-Single stranded mature miRNA associates with the RISC complex to be able to control translation of 
target mRNAs. Most mRNAs contain multiple miRNA binding sites and many miRNAs usually act together 
to produce responsive miRNA-induced translational repression. The red asterisk * marks the journey of 
miRNA. Diagram and information from the Ambion Inc miRNA resource pages 
(www.ambion.com/techlib/resources/miRNA) accessed on 12th September, 2007 and the BLOCK-iT Pol II 
miR RNAi expression vector kit (Invitrogen, Karlsruhe, Germany) user manual (Catalogue number K4935-
00 Version C, September 26, 2006).  
6.1.5 Rationale 
The main reasons for this chapter of work were: -  
 (1) to provide support to work in chapter 3 and chapter 4, where reduction of MAO 
activity was achieved using chemical inhibitors. However, down-regulation of MAO 
expression using miRNA technology has its disadvantages. These include off-target effects 
(reviewed by Pulverer et al. 2003, Cullen 2006) and increased stress induced by the 
transfection process. These effects can be monitored by using the correct basic, negative 
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miRNA, and quantitative controls and also by using multiple, well-designed miRNA 
sequences for the cloning.  
 (2) To compliment the work in chapter 5, where MAO-A was overexpressed, 
resulting in significant and detrimental changes to SH-SY5Y cells. This chapter will 
address whether reduced MAO activity has an effect on SH-SY5Y cell growth and 
sensitivity to apoptotic inducers. 
6.1.6 Aims of Chapter 
• To reduce MAO-A expression in a stable SH-SY5Y cell line using miRNA 
SH-SY5Y cells were transfected with the Pol II miRNA (pcDNA6.2-GW/miR) containing 
an insert coding for pre-miRNA sequences that facilitate the targeting of MAO-A mRNA 
by RNAi (referred to as MAO-A knockdown or MAO-A-). SH-SY5Y cells were also 
stably transfected with the Pol II miRNAi (pcDNA6.2-GW/miR-neg) expression vector 
lacking MAO-A sequence but containing an insert that can form a hairpin structure and is 
processed into mature miRNA but does not to target any known vertebrate gene (referred 
to as negative miRNA control or Neg) to monitor off-target effects. 
• To determine the MAO status in MAO-A stable knockdowns 
MAO-A-/miRNA stable SH-SY5Y clones and controls were assessed for MAO mRNA 
levels and catalytic activity and a suitable stable clone with reduced MAO-A levels and a 
control chosen for further work. MAO protein levels in working clones was be determined 
by immunohistochemistry, confocal microscopy and dot blotting using a MAO-A specific 
monoclonal antibody, as before. 
• To characterise changes in MAO-A stable knockdown clones 
Once suitable clones had been chosen, SH-SY5Y cells with reduced MAO activity were 
characterised firstly for their growth, viability and morphology. ROS production using 
DCDHF/confocal microscopy was also detected in untreated cells. 
• To study the effect of MAO-A knockdown in SH-SY5Y cells in three different 
models of apoptosis 
Three different treatments comprising three different models previously used in this thesis, 
including STS, rotenone and serum withdrawal were used. Respectively, the three inducers 
represent three different types of stressor, one being a potent caspase-3 activator, one being 
a mitochondrial toxin and finally a subtle, slow activating stressor. Following treatments, 
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MAO-A- stable clones were assessed for changes in cell viability (MTT reduction), ATP 
levels and caspase-3 activity compared to both wild type SH-SY5Y cells and negative 
miRNA control clones.  
6.2.  RESULTS 
6.2.1 Characterisation of MAO-A knockdown SH-SY5Y cells 
Cells containing the miRNA vector are resistant to the antibiotic blasticidin. Stably 
transfected cells were grown in the presence of 6 µg/ml blasticidin (the predetermined 
concentration sufficient to kill wild type cells). 
6.2.1.1 Initial characterisation of MAO-A expression in stable knockdown clones 
Cell clones were expanded in the presence of the antibiotic blasticidin and RNA was 
extracted to determine the effects on MAO-A mRNA levels. Figure 6. 2A shows that 
MAO-A- SH-SY5Y clones exhibit decreased MAO-A mRNA expression compared to 
wild type and negative miRNA control SH-SY5Y cells. Transfection with the negative 
miRNA vector (Neg/2G11 clone) resulted in approximately a 60% increase in MAO-A 
mRNA expression compared to wild type expression. Knockdown of MAO-A mRNA 
expression in MAO-A- SH-SY5Y clones ranges from ~45-62 % knockdown, compared to 
wild type expression. These SH-SY5Y clones and other MAO-A- clones were then 
expanded further and extracts taken for evaluation of MAO-A catalytic activity. Negative 
miRNA transfected cell clones had MAO activity levels ranging between 8-20 
pmoles/min/mg, with clone 2G11 having approximately 30% more MAO activity than 
wild type SH-SY5Y cells. All MAO-A- clones had significantly decreased MAO catalytic 
activities, (except clone 6F10) ranging between approximately 20-60 % knockdown of 
activity compared to the wild type (Figure 6. 2B). Four MAO-A- clones-10D8, 4F1, 5E2 
and 5C8, showing MAO activity knockdown of 53%, 40%, 60% and 63% respectively-and 
four negative miRNA clones were chosen for further expansion. 
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Figure 6. 2 MAO-A mRNA and catalytic levels are decreased in MAO-A- SH-SY5Y clones 
(A) MAO-A mRNA expression was measured by qRT-PCR in stable SH-SY5Y cell clones and expressed as 
mean MAO-A qRT-PCR (% wild type) ± S.D, where n=3 for wild type, neg/2G11 and MAO-A-/10D8 but 
n=2 for MAO-A-/4F1 and MAO-A-/3C8. MAO mRNA level in MAO-A-/10D8 was statistically compared to 
wild type mRNA levels using the Student’s t-test where **p=<0.005. (B) MAO catalytic activities were 
measured in stable SH-SY5Y cell clones in vitro via a radiometric method using 14C-Tyramine as a substrate 
and are expressed as pmoles/min/mg total protein ± S.D, where n=4. MAO catalytic activity in MAO-A- 
clones was statistically compared to wild type activity using the Student’s t-test where **p=<0.005 and 
***p=<0.001.  
6.2.1.2 Morphology of MAO-A knockdown SH-SY5Y stable clones 
Figure 6. 3 shows negative miRNA and MAO-A- SH-SY5Y cell morphologies. Both 
negative control clones and MAO-A knockdown clones show similar morphologies to wild 
type cells following expansion from 96-well plates to 25 cm2 flasks. MAO-A- clone 10D8 
was chosen to work with since it exhibited sufficient growth rate and consistently had 
~50% knockdown of both MAO-A mRNA and catalytic activity. SH-SY5Y clone 
neg/2G11 was randomly chosen as the negative miRNA control.  
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Figure 6. 3 Morphology of stable miRNA SH-SY5Y clones 
Negative miRNA control transfected and MAO-A- miRNA stable SH-SY5Y clones observed by phase 
contrast microscopy. Cells were visualised using a Nikon eclipse TS100 microscope. Photomicrographs (× 
20 and × 40 objectives, taken on Nikon DN100 digital camera). Scale bar represents 20 µM. 
6.2.2 Characterisation of working MAO-A knockdown clone 10D8 
6.2.2.1 MAO-A protein levels 
MAO-A protein levels in MAO-A-/10D8 cells were observed by immunohistochemistry 
(Figure 6. 4A), confocal microscopy (Figure 6. 4B) and dot blotting (Figure 6. 5) using the 
specific MAO-A monoclonal antibody 6G11-E1. MAO-A protein detected using DAB as a 
substrate (shown by red/brown staining) is visibly reduced in MAO-A-/10D8 cells 
compared to controls. MAO-A protein detected by confocal microscopy in control SH-
SY5Y cells gives a weak signal (see Figure 6. 4B top left panel), however, when MAO-A 
is overexpressed (Figure 6. 4B top right panel), the signal and resolution is stronger. 
Whilst in MAO-A-/10D8 cells the signal is even weaker (Figure 6. 4B bottom panels). 
Chapter 6                                                        The effect of MAO-A knockdown in human neuroblastoma cells 
 168
 
Figure 6. 4 MAO-A protein levels in MAO-A knockdown clone 10D8 
(A) Immunohistochemistry – Negative miRNA control/2G11 and MAO-A-/10D8 clones were stained with 
MAO-A (6G11-E1) specific antibody and revealed using HRP-conjugated secondary antibody with 3, 3’-
Diaminobenzidine (DAB) as substrate. Control sections incubated in the absence of MAO-specific antibodies 
but revealed under the same conditions did not reveal staining and are not shown. MAO specific 
immunoreactivity is represented by dark brown/red staining. The images shown are from a representative 
experiment. Scale bar represents 20 µm. (B) Confocal microscopy – Wild type, MAO-A+/1A9 (positive 
control), negative miRNA control/2G11 and MAO-A-/10D8 clones were exposed to MAO-A (6G11-E1) 
specific antibody and revealed using FITC-conjugated secondary antibody, which fluoresces green, 
visualised by a CLSM Leica microscope. Laser power is matched and all images are from the same 
experiment. Photomicrographs are representative of 2 independent experiments. 
Figure 6. 5 shows a representative dot blot and quantification of MAO-A protein detected 
by MAO-A specific antibody in MAO-A-/10D8 clones. Dot blot (Figure 6. 5A) showing 
less MAO-A protein in MAO-A-/10D8 cells compared to negative miRNA control cells, 
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which is approximately half the amount of protein present in both the negative control 
clone 2G11 and wild type cells (Figure 6. 5B).  
 
Figure 6. 5 MAO-A protein detected by dot blotting in MAO-A knockdown SH-SY5Y and controls 
(A) Dot blot of MAO-A protein levels in Neg/2G11 and MAO-A-/10D8 SH-SY5Y stable clones. Equal 
protein homogenates (3 µg) were loaded on to a nitrocellulose membrane (except positive control, 1 µg) and 
probed with a MAO-A specific antibody. Mitochondrial membranes from human placenta are the positive 
control and no primary antibody was the negative control (not shown). (B) Quantification of dots. The dots 
were digitised and densitometry was performed to quantify relative MAO-A protein levels normalised to total 
protein levels (copper stain) and expressed as normalised MAO-A protein in arbitrary units (a.u). 
6.2.2.2 Cell growth and viability 
Growth rates of Neg/2G11 and MAO-A-/10D8 clones were determined by viable cell 
counts and compared to the growth rate of wild type SH-SY5Y cells. Figure 6. 6A shows 
that Neg/2G11 cells grow slower than wild type cells and have a doubling time of ~31 
hours, which is 10 hours longer than wild type doubling time (22 hours, Figure 6. 6B), 
supporting data in chapter 5. Two MAO-A- clones were assessed, MAO-A-/4F1 and 
MAO-A-/10D8. MAO-A-/4F1 grew at the same rate as wild type SH-SY5Y and had a 
similar doubling time. Compared to negative control, growth rates were faster in both 
MAO-A+ clones (Figure 6. 6B). 
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Figure 6. 6 Growth and doubling times of wild type, negative miRNA control and MAO-A- clones 
(A) Growth of wild type, Neg/2G11 and MAO-A-/4f1 and 10D8 cells. Cell numbers were determined by 
viable cell counts from two independent cell populations and from four counts from the each sample. Data 
are expressed as mean cell number ± SD. Data was plotted on a log scale Y axis. (B) Doubling times were 
calculated (see section 2.) and expressed as approximate doubling time (h). 
Cell viability measured by MTT reduction (cell metabolism) in untreated MAO-A 
knockdown SH-SY5Y clones and controls revealed increased MTT reduction in both 
Neg/2G11 and MAO-A-/10D8 compared to wild type SH-SY5Y over a 72 h growth period 
(Figure 6. 7) and no difference between Neg/2G11 control and MAO-A knockdown 
clones. 
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Figure 6. 7 MTT reduction in MAO-A knockdown SH-SY5Y cells and controls 
MTT reduction was measured in wild type, Neg/2G11 and MAO-A-/10D8 cells over a 72 h culture period 
and expressed as mean absorbance values at 570 nm ± S. D. Replicates in assay=12 and n=9. MAO-A- and 
Neg/2G11 cell MTT reduction was statistically compared to wild type MTT reduction over time using two 
way ANNOVA test where ** p<0.005 and *** p<0.001. Neg/2G11 MTT reduction over time was compared 
to MAO-A-/10D8 MTT reduction overtime using two way ANNOVA, which was not significantly different 
at confidence value p=<0.05. 
2 Cell structure and GAPDH localisation 
To determine whether cell morphology and cytoskeleton is affected by MAO-A 
knockdown in SH-SY5Y cells, antibodies directed against the structural proteins α-tubulin 
and β-actin were revealed by confocal microscopy in MAO-A-/10D8 cells and neg/2G11 
and wild type controls. MAO-A knockdown did not change structural proteins or cell 
morphology, compared to both negative miRNA and wild type controls (Figure 6. 8).  
GAPDH translocates to the nucleus in SH-SY5Y cells overexpressing MAO-A in long 
term culture (Figure 5.12), whereas MAO-A-/10D8 SH-SY5Y clones have similar 
GAPDH distribution to Neg/2G11 control cells and no GAPDH in the nucleus (Figure 6. 
8).  
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Figure 6. 8 Cytoskeletal and GAPDH proteins in MAO-A knockdown SH-SY5Y cells and controls 
Wild type, negative miRNA and MAO-A-/10D8 clones were exposed to α-tubulin, β-actin and GAPDH 
specific antibodies and revealed using a FITC-conjugated secondary antibody (green). Nuclei were counter-
stained with propidium iodide (red). Images were taken at ×63 magnification and scale bars are shown on 
each photomicrograph. Laser power was matched between different cell types for each protein of interest.  
2 ROS 
ROS levels in untreated MAO-A-/10D8 cells are slightly reduced compared to negative 
control cells (Figure 6. 9).  
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Figure 6. 9 ROS levels in untreated MAO-A knockdown SH-SY5Y and negative miRNA control 
DCDHF fluorescence was monitored in live Neg/2G11 cells (left panel) and MAO-A-/10D8 cells (right 
panel) and visualised using a CLSM Leica microscope. Photomicrographs shown are representative of three 
independent experiments. Laser power matched. Scale bar represents 40 µm. 
6.2.3 Effect of MAO-A knockdown on apoptotic induction 
To determine the relevance of MAO-A in neuronal apoptosis, cell viability, ATP and 
caspase-3 assays were performed on MAO-A-/10D8 cells and their response to three 
different apoptotic inducers compared to control cells. Apoptotic cell death was induced by 
treatment with STS (previously characterised in chapter 3), rotenone (previously 
characterised in chapter 4) and serum withdrawal (previously characterised in chapter 4).  
Cell metabolism was determined by MTT reduction. Following STS treatment for 3 h cell 
viability was not significantly reduced in wild type cells (see chapter 3). Negative miRNA 
cells had insignificant MTT reduction compared to wild type cells and MAO-A-/10D8 
cells were unaffected by STS (Figure 6. 10A). Rotenone treatment for 48 h caused a ~40% 
reduction in cell viability in wild type cells, which was further and significantly reduced in 
negative miRNA control cells. Knockdown of MAO-A significantly reduced this loss in 
cell viability by approximately 25% (Figure 6. 10B). Serum withdrawal for a 72 h period 
resulted in approximately 30 % loss of cell viability in wild type cells, miRNA and MAO-
A knockdown cells (Figure 6. 10C).  
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Figure 6. 10 Effect of apoptotic inducers on cell viability of MAO-A knockdown SH-SY5Y and controls  
Cell viability was measured following (A) 1 µM STS treatment for 3 h , (B) 0.5 µM rotenone treatment for 
48 h and (C) serum withdrawal treatment for 72 h. MTT reduction was determined and expressed as % 
untreated control ± S. D. Replicates in assay=12 and n=4. % control untreated MTT reduction in wild type 
cells was statistically compared to MTT reduction in neg/2G11 and MAO-A-/10D8 cells using the Student’s 
t-test, where *=p<0.05. % untreated control MTT reduction in neg/2G11 cells was statistically compared to 
% untreated control MTT reduction in MAO-A-/10D8 cells using the Student’s t-test, where *=p<0.05. 
ATP levels in untreated wild type, MAO-A+/10D8 and negative control cells were similar 
at around 500 pmoles/µg total protein following STS treatment for 3 h, albeit the levels in 
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the knockdown and negative control cells were not significantly higher than wild type cells 
(data not shown).  
 
Figure 6. 11 Effect of apoptotic inducers on ATP levels in MAO-A knockdown SH-SY5Y and controls 
ATP was measured following (A) 1 µM STS treatment for 3 h, (B) 0.5 µM rotenone treatment for 48 h and 
(C) serum withdrawal treatment for 72 h. ATP levels were determined using a luciferase based assay, amount 
of ATP was determined using ATP standards and expressed as % untreated control ± S. D. Replicates in 
assay=12 and n=3. ATP levels in wild type cells were statistically compared to ATP levels in negative 
miRNA controls and ATP levels in negative miRNA control cells were statistically compared to ATP levels 
in MAO-A-/10D8 cells using the Student’s t-test, where *=p<0.05. 
Rotenone reduced ATP levels in wild type cells and negative controls by around 80% 
(Figure 6. 11B). In MAO-A-/10D8 cells, ATP levels were reduced by ~70 % by rotenone ; 
this smaller loss of ATP was significantly less than in the negative control cells (Figure 6. 
11B). Serum deprivation for 72 h caused increased ATP levels in wild type cells (more 
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than four fold untreated levels). Negative miRNA clones had reduced ATP levels 
following serum deprivation, but ATP levels in MAO-A knockdown were unchanged 
following serum deprivation (Figure 6. 11C). 
Basal caspase-3 levels were similar in wild type, negative controls and MAO-A+/10D8 
cells (Figure 6. 12). As previously described in chapter 3, 1 µM STS induces apoptotic 
morphologies within 1 h of treatment in wild type cells. Negative control cells responded 
similarly to wild type cells following STS exposure (Figure 6. 12A, and chapter 3.2). 
MAO-A knockdown protected SH-SY5Y cells from apoptotic morphologies caused by 
STS in the early phases of apoptosis (1h, Figure 6. 12A). This is complimented by reduced 
caspase-3 activation (albeit this was not statistically significant) following 1 hr STS 
treatment (Figure 6. 12B). However, after 3 h STS treatment (peak caspase-3 activity in 
wild type cells), morphologies and caspase-3 activity in control cells and MAO-A-/10D8 
cells are similar (Figure 6. 12C). 
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Figure 6. 12 Effect of STS treatment on caspase-3 activity and apoptotic morphology in MAO-A 
knockdowns 
(A) Neg/2G11 and MAO-A-/10D8 SH-SY5Y clones observed by phase contrast microscopy following 1 µM 
STS treatment over a 6h period. Cells were visualised using a Nikon eclipse TS100 microscope. 
Photomicrographs (× 40 objectives, taken on Nikon DN100 digital camera). Scale bar represents 20 µM. (B) 
Caspase-3 activity measured using Acetyl-Asp-Glu-Val-Asp-7-Amidomethylcoumarin as substrate in wild 
type, Neg/2G11 and MAO-A-/10D8 following 1 µM STS treatment over a 6h period and expressed as 
∆FU/min/µg protein S.D. Data represents values from four independent experiments over, where each extract 
was assayed in triplicate. (C) Data in B at 3 h end point, expressed as % untreated control. 
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Figure 6. 13 Effect of rotenone treatment on caspase-3 activity and apoptotic morphology in MAO-A 
knockdowns 
(A) Neg/2G11 and MAO-A-/10D8 SH-SY5Y clones observed by phase contrast microscopy following 0.5 
µM rotenone treatment over a 72h period. Cells were visualised using a Nikon eclipse TS100 microscope. 
Photomicrographs (× 40 objectives, taken on Nikon DN100 digital camera). Scale bar represents 20 µM. (B) 
Caspase-3 activity measured using Acetyl-Asp-Glu-Val-Asp-7-Amidomethylcoumarin as substrate in wild 
type, Neg/2G11 and MAO-A-/10D8 following 0.5 µM rotenone treatment over a 48h period and expressed as 
∆FU/min/µg protein ±S.D. Data represents values from four independent experiments over, where each 
extract was assayed in triplicate. Statistical analysis was performed using the two way ANNOVA test for 
variance between Neg/2G11 controls and MAO-A-/10D8 cells following rotenone treatment over the time 
course, where **=p=<0.005. (C) Data shown in B, at a 48 h end point and expressed at % untreated control. 
Caspase-3 levels in negative miRNA control cells were statistically compared to caspase-3 levels in MAO-A-
/10D8 cells using the Student’s t-test, where *=p<0.05. 
 
Rotenone causes a dramatic loss of cell viability and apoptotic morphology after 48 h 
treatment in wild type and negative miRNA control cells (Figure 6. 13A), linked with a 50 
% activation of caspase-3 (Figure 6. 13B). MAO-A knockdown reduces cell loss following 
Chapter 6                                                        The effect of MAO-A knockdown in human neuroblastoma cells 
 179
48 h rotenone treatment (Figure 6. 13A), but by 72 hrs cells are also floating and apoptotic 
(data not shown). Caspase-3 is not activated following 48 h rotenone treatment in MAO-A 
knockdown cells (Figure 6. 13C).  
 
Figure 6. 14 Effect of serum withdrawal on caspase-3 activity and apoptotic morphology in MAO-A 
knockdowns 
(A) Neg/2G11 and MAO-A-/10D8 SH-SY5Y clones observed by phase contrast microscopy following serum 
withdrawal over a 96h period. Cells were visualised using a Nikon eclipse TS100 microscope. 
Photomicrographs (× 40 objectives, taken on Nikon DN100 digital camera). Scale bar represents 20 µM. (B) 
Caspase-3 activity measured using Acetyl-Asp-Glu-Val-Asp-7-Amidomethylcoumarin as substrate in wild 
type, Neg/2G11 and MAO-A-/10D8 following serum withdrawal over a 96h period and expressed as 
∆FU/min/µg protein ±S.D. Data represents values from four independent experiments over, where each 
extract was assayed in triplicate. (C) Data shown in B, at a 48 h end point and expressed at % untreated 
control. Caspase-3 levels in negative miRNA control cells were statistically compared to caspase-3 levels in 
MAO-A-/10D8 cells using the Student’s t-test, where *=p<0.05. 
Serum withdrawal causes apoptotic morphologies in SH-SY5Y cells after 24 hrs of 
deprivation. However, MAO-A-/10D8 cells did not appear apoptotic until ~72-96 h 
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following serum deprivation (Figure 6. 14A). Caspase-3 activity in MAO-A+/10D8 cells 
remained unchanged at 72 h (Figure 6. 14C). 
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Table 6. 2 A summary of the effects of MAO-A knockdown in SH-SY5Y cells on their response to 
different apoptotic inducers 
6.3. DISCUSSION 
6.3.1 Stable MAO-A knockdown in SH-SY5Y cells 
Stable knockdown of MAO-A was successful. Nearly all the SH-SY5Y clones expanded 
for MAO assays had significantly reduced MAO-A activity. Maximum knockdown of 
MAO-A activity achievable from the clones picked was around 50% (Figure 6. 2B). 
Similarly, MAO-A mRNA expression levels were also reduced by 50% in three MAO-A 
knockdown clones assayed by qRT-PCR (Figure 6. 2A). Semi-quantitative measurement of 
MAO-A protein levels in the MAO-A knockdown clone 10D8 revealed a 50% reduction 
compared to controls (Figure 6. 5). These data were supported by immuno-histochemical / 
-fluorescent analysis of protein levels (Figure 6. 4A and B). 
Data from qRT-PCR and MAO activity assays indicated that transfection with the negative 
miRNA control vector caused small increases in MAO-A expression of around 20 % in the 
N2G11 clone (Figure 6. 2). This increase may result from the stress of the transfection 
procedure and/or the presence of the selection marker blasticidin. Nonetheless, the fact that 
sufficient knockdown of MAO-A was still achieved in the MAO-A/- clones indicates the 
efficiency of the method. 
Although RNAi technology is the most specific and effective technique known to induce 
loss of function in vitro (Constans 2005), 100 % knockdown is rarely achieved. Part of the 
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aim of this chapter was to support data in this thesis using MAO inhibitors. In situ, both 
MAO inhibitors clorgyline and TCP were able to reduce MAO activity by approximately 
90% in untreated cells (Figure 3.13), which is more effective than the 50% knockdown 
achieved here with miRNA technology. On the other hand, in the only known study where 
siRNA silencing of MAO-A has been reported, MAO activity was reduced by only 25% 
(Yi et al. 2006a).  
6.3.2 Characteristics of stable MAO-A knockdown clone 10D8 
MAO-A- stable clones had similar morphologies to wild type cells (Figure 6. 3) and grew 
at similar rates generally. However, Neg/2G11 cells grew at a slower rate than wild types 
cells (doubling times of 31 and 22 h respectively) and MAO-A-/10D8 cells had a faster 
growth rate than the negative control cells, having a doubling time of 18 h (Figure 6. 6). 
MTT reduction in both Neg/2G11 and MAO-A-/10D8 cells were significantly greater than 
in wild type cells over a 72 h period (Figure 6. 7), but there was no difference between the 
MAO-A-/10D8 and Neg/2G11 cells. Cytoskeletal staining remained unchanged for both α-
tubulin and β-actin proteins in MAO-A-/10D8. These data imply that reduced MAO-A has 
no effect on cell division or cell structure. 
In addition to its role in cell death mechanisms, MAO may also help to maintain steady 
state levels of ROS and therefore play a role in cell survival and proliferation. Further work 
is needed in this area to understand the mechanisms involved. Interestingly, ERK 
inhibition resulted in further increased MAO-A catalytic activity and MAO-A mRNA 
expression following serum withdrawal-induced MAO activation (Figure 4.27), implying 
that ERK MAPK may be involved in modulating MAO-A expression as part of cell 
survival mechanisms.  
According to Cadenas and Davies (2000) calculations, if MAO-A activity is reduced by 50 
% (as in the case of MAO-A-/10D8 cells), the steady state concentration of H2O2 formed 
from MAO will be approximately 4×10-7 M. In the resting cell, the effect of this reduction 
may not be apparent because of limitations of available detection methods. Indeed, ROS 
levels measured in MAO-A-/10D8 cells were only very slightly reduced compared to 
negative control cells (Figure 6. 9). 
Untreated MAO-A-/10D8 cells showed no evidence of GAPDH in nuclei (Figure 6. 8) and 
levels of both ATP (Figure 6. 11) and active caspase-3 (Figure 6. 12) were similar to 
control levels. These data further confirm that resting MAO-A-/10D8 cells are not 
apoptotic and loss of MAO-A function is not detrimental. These finding are consistent with 
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our knowledge of decreased MAO-A expression in vivo, where even complete deletion of 
MAO-A expression is not fatal. The remaining MAO-A in MAO-A-/10D8 cells is able to 
maintain functionality as far as deamination of amines and possibly production of ROS as 
a second messenger in survival.  
6.3.3 The effect of MAO-A knockdown in selected apoptotic models 
Three different apoptotic inducers previously characterised in this thesis were used to 
challenge MAO-A-/10D8 cells. The three inducers STS, rotenone and serum withdrawal 
represent three distinct types of cell death.  
6.3.3.1 STS 
STS causes rapid and strong induction of caspase-3 activity in wild type cells (Figure 3.10 
and Figure 6. 12) and depletes ATP levels in wild type cells, but has no significant effect 
on MTT reduction over 3 h (Chapter 3, Figure 3.15). MTT reduction in Neg/2G11 and 
MAO-A-/10D8 also remained unchanged following STS exposure for 3 h (Figure 6. 10). 
MTT is not a good measure of cell viability/proliferation in the STS model, since cells 
remain metabolically active throughout the short apoptotic time course. MAO-A 
knockdown had no significant effects on ATP levels at 3 h either. This might be explained 
by the nature of STS-induced cell death. At 3 h following STS treatment in wild type cells, 
caspase-3 levels are maximal and increased MAO activity occurs prior to caspase-3 
activation. Since up-regulation of the MAO-A gene was not apparent in the wild type STS 
model (Chapter 3); post-transcriptional events were thought to be important. Hence, 
remaining MAO-A enzyme/ MAO-A mRNA levels in MAO-A-/10D8 cells may still be 
sufficient for post-transcriptional modification and therefore increased catalytic activity 
following STS insult. Events that follow MAO’s early role here (such as ATP depletion) 
may be unaffected. Measurements of MAO activity in STS treated MAO-A-/10D8 cells 
should be undertaken to confirm this.  
Interestingly, MAO-A knockdown slows caspase-3 activation, since at 1 h caspase-3 
activity is reduced compared to control cells by around 30 % (Figure 6. 12B). This 
protection in the early phase is evident in cell morphologies following STS treatment 
(Figure 6. 12A). Reduction of MAO-A in MAO-A-/10D8 cells is relevant in the first hour 
since MAO acts upstream of apoptotic execution. However, a 50 % reduction of MAO 
may not be sufficient to override the apoptotic execution by this potent toxin. 
6.3.3.2 Serum withdrawal 
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Serum withdrawal induced loss of cell proliferation (measured by MTT reduction) in 
control cells, by around 35%. MAO-A knockdown did not affect this loss of cell 
viability/proliferation (Figure 6. 10). MAO-A acts late in the death processes induced by 
serum withdrawal in wild type cells, enhancing already activated apoptotic signals. In wild 
type cells (chapter 4), MAO inhibitors had no effect on MTT reduction during serum 
withdrawal; therefore it was likely that MAO-A knockdown had no effect on MTT 
reduction levels.  
Serum withdrawal causes a rise in ATP levels in wild type cells at 72 h (Figure 6. 11). 
Increased ATP reflects the cell’s need for energy at this time. Since serum withdrawal is a 
slow, highly regulated process, increased ATP in serum withdrawal may be viewed as a 
necessary event for the progression of apoptosis and may arise from release of 
mitochondrial ATP. It is interesting that, in Neg/2G11 cells ATP levels are significantly 
reduced after 72 h. It is possible that Neg/2G11 cells (having more MAO expression and 
being consistently more sensitive), have more rapidly progressed into apoptosis and 
therefore have reduced ATP levels. ATP levels in MAO-A-/10D8 cells do not change in 
response to serum withdrawal, but the levels are significantly higher than in the miRNA 
control cells. The role of ATP is complicated and a time course of ATP events is needed.  
Caspase-3 activity was not increased significantly in any cell type following serum 
withdrawal and therefore there was no difference in their response to serum deprivation. 
MAO inhibitors had no effect on caspase-3 activation during serum withdrawal; it is not 
surprising that MAO-A knockdown had no effect on caspase-3 activity during serum 
deprivation. Indeed, cell morphologies in Neg.2G11 and MAO-A-/10D8 cells were similar 
throughout the time course (Figure 6. 14A).  
The lack of effect of MAO-A knockdown in serum withdrawal-induced apoptosis is a 
indication of the different roles of MAO in different types of cell death. It is feasible that 
following serum deprivation in MAO-A-/10D8 cells, apoptosis occurs upstream of MAO-
A. For example other pro-apoptotic proteins may come into force. Another possibility is 
that MAO-A is up-regulated following serum withdrawal in MAO-A-/10D8 cells (as in 
wild type cells) and although MAO-A miRNA may continue to target existing MAO-A 
mRNA, the miRNA system may be counteracted by new MAO-A transcription or 
increased stabilisation of MAO-A mRNA. It is also worth mentioning that production of 
miRNA is quite slow and in transient transfection experiments, cells were left for at least 
48 h post-transfection for the miRNA process to have an effect. Serum withdrawal-induced 
apoptosis is also a slow process, however overexpression of MAO-A begins within the first 
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24 h. miRNA may be efficient at inhibiting normal MAO-A expression, but following 
apoptotic induction miRNA processes driven by the expression vector may result in less 
than efficiency in apoptotic MAO-A- cells compared to non-apoptotic MAO-A- cells. 
6.3.3.3 Rotenone 
Rotenone produces significant differences in ATP levels, MTT reduction, caspase-3 
activity and morphologies between MAO-A-/10D8 cells and their controls. Less reduction 
in cell viability and ATP levels in MAO-A-/10D8 cells indicate protection from rotenone-
induced apoptosis. The effects of rotenone in the neg/2G11 cells was greater than in wild 
type cells, suggesting that their increased sensitivity is due to the genetic manipulation, the 
presence of the selection marker and increased MAO-A expression. 
Rotenone treatment reduced ATP levels in control cells by around 80% after 48 h, 
revealing dysfunction of mitochondrial electron transport. MAO-A knockdown was able to 
significantly reduce this effect by around 40 % compared to negative miRNA control 
(Figure 6. 11). Caspase-3 activity was increased following rotenone exposure in wild type 
cells, however the activation was low (Figure 6. 13B). This supports the idea that caspase-
3 independent pathways are responsible for the majority of rotenone induced apoptotic 
signals (as discussed in chapter 4). Caspase-3 activity is increased to a larger extent in 
Neg/2G11, further supporting the idea that these cells are more sensitive to toxic insult. 
Knockdown of MAO-significantly reduced caspase-3 activation during rotenone-induced 
apoptosis, compared to the miRNA control (Figure 6. 13B). Neg/2G11 cells showed 
extensive apoptotic morphologies and cell death (indicated by floating cells) at 48 h 
whereas MAO-A-/10D8 cells at this stage continue to show normal SH-SY5Y phenotype 
and there are very few floating cells (Figure 6. 13A).  
One can conclude from these data that MAO is more relevant to cell death mechanisms 
that arise from mitochondrial dysfunction. Mitochondria can respond rapidly to cellular 
events by tuning their input and output of a wide range of important mediators involved in 
cell function (Pagliarini 2006).  
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Figure 6. 15 Hypothetical schematic of MAO’s ability to enhance rotenone-induced cell death 
MAO activity is increased via an unknown mechanism. Increased production of ROS can affect 
mitochondrial respiration (Cohen and Kesler 1999) and this is thought to involve damage to electron 
transport chain proteins by H2O2 (Cohen et al. 1997).  
6.3.4 Conclusion 
Taken together these data reflect the role of MAO in each apoptotic model. MAO may 
enhance cell death mechanisms in the same way, regardless of the trigger (see general 
discussion). However, data shown in this chapter indicates that the apoptotic inducer rather 
affects how MAO is recruited. MAO-A knockdown only significantly reduced cell death 
induced by the mitochondrial toxin rotenone, but not by serum withdrawal or STS. These 
findings imply that MAO is involved in modulating mitochondrial function and therefore 
MAO plays a more important role in rotenone-induced cell death than in serum withdrawal 
or STS-induced death. This may have particular relevance in conditions such as PD where 
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CONCLUSIONS AND FUTURE DIRECTIONS 
7.1. MAIN FINDINGS 
In this study, the role of MAO in neuronal cell death was investigated in three diverse 
apoptotic models in human neuronal cells namely STS, serum withdrawal and rotenone. 
Elucidating the relevance of MAO in cell death was made possible by the use of MAO 
inhibitors and the creation of two stable neuronal cell lines where MAO levels were stably 
overexpressed or knocked down. The results suggested that MAO-A is involved in 
regulating cell death processes and that the mechanism and extent to which it is involved 
depends on the type of cell death and the nature of the inducer. These findings indicate that 
MAO-A may play a dynamic role in the cell. Indeed, MAO may have a dual role within 
the cell; to deaminate amines but at the same time to act as a sensor for mitochondrial 
function and stress and respond according. The MAO response appears to involve a 
combination of the promotion of oxidative stress at the mitochondria, redox imbalance and 
activation of apoptotic signalling pathways via its production of H2O2. However, the 
mechanism by which MAO is recruited and activated can change depending on the type of 
cell death. This was supported by the fact that in three very diverse models of apoptosis, 
MAO-A activation occurred by different mechanisms.  
7.1.1 Role of MAO-A in STS and serum withdrawal models 
In a classical model of apoptosis induced by staurosporine, my data shows for the first time 
that MAO-A was involved in this type of cell death. This occurs via MAPK signalling 
pathways upstream of apoptotic execution, which appears to be a result of MAO-A-
dependent increase in ROS. However, the mechanism by which MAO-A activities are 
elevated is unknown, since up-regulation of the gene is not involved, although there is a 
transient increase in MAO-A protein levels. As discussed previously, post-transcriptional 
events account for a significant amount of expression regulation. Increased MAO-A in the 
STS model is likely to result from regulation of MAO-A RNA stability, catalytic 
environment or compartmentalisation of the enzyme. Increased MAO activity could also 
result from changes in the mitochondrial environment or a combination of these factors. 
Regulation of MAO catalytic activity may be influenced by the availability of substrates 
and co-factors and very recently Cao and colleagues (2007) showed that increased free 
calcium enhanced MAO-A catalytic activities via an unknown mechanism. Opening of the 
PTP following mitochondrial stress would certainly result in leakage of free calcium from 
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mitochondrial stores into the cytoplasm (Jacobson and Duchen 2002, Abou-Sleiman et al. 
2006). Indeed H2O2 produced by MAO in rat brain mitochondria affects Ca2+ efflux and 
glutathione levels, two important factors in mitochondrial function (Sandri et al. 1990). An 
intense calcium flux in close vicinity to MAO enzyme could possibly increase activity 
(Cao et al. 2007).  
In apoptosis induced by withdrawal of growth factors, the cell response was relatively slow 
but MAO-A gene expression, protein and activity levels were elevated after caspases were 
activated. These data suggest that the MAO- A gene is a target of stress-signalling 
pathways following serum withdrawal and that MAO generated oxidative stress impacts 
downstream of caspase-3 activities. It appears that the MAO-A gene is a target of the JNK 
and p38 MAPK signalling pathways in this model. This is the first time that JNK has been 
implicated in the expression regulation of MAO-A. The important role of the p38 
signalling pathway was also confirmed, which was in agreement with previous reports 
(DeZutter and Davis 2001, Ou et al. 2006). As a consequence of elevated MAO-activity, it 
is likely that increased ROS cause PTP opening, release of Cyt-c and apoptosome 
formation since caspase 9 was activated.  Inhibition of MAO consistently reduced caspase-
9 activation. Inhibition of MAO may suppress PTP opening because of reduced ROS 
levels, which in turn  reduces release of procaspase-9 stored within mitochondria 
(Krajewski et al. 1999).  
Complete inhibition of MAO activity with clorgyline and TCP was significantly protective 
in each model of apoptosis.  
7.1.2 Consequences of MAO-A overexpression  
Overexpression of MAO caused cell death characterised by reduced cell growth rates, 
depleted ATP and loss of cell viability. Increased MAO activity resulted in massively 
increased oxidative stress (ROS levels) and eventually cell death. Chronic exposure to 
increased MAO-A activity induced a state of senescence/growth arrest and eventually 
death by necrosis. These data are in agreement with studies showing that H2O2 has a dose 
dependent effect on the cell and confirm that MAO has a central role in redox signalling, 
mitochondrial function and cell death. The fact that protective proteins such as Parkin 
suppress MAO-A expression (Jiang et al. 2006) support the finding that high MAO activity 
is pro-apoptotic.  
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7.1.3 Consequences of MAO-A knockdown 
When levels of MAO activity were significantly reduced using inhibitory RNA 
technology, the cells were less sensitive to STS treatment in the early phases of apoptosis 
but not at peak caspase-3 activity. This supported the supposition that MAO is important in 
the initial phases of STS-induced apoptosis. MAO acts in the late phases of apoptosis in a 
serum withdrawal-apoptotic model and relies on up-regulation of pro-apoptotic genes, 
which may explain why MAO knockdown was not significantly protective. Increased gene 
expression in serum withdrawal may not be silenced by the miRNA efficiently for 
example.  
Most significantly, reduced MAO-A levels protected against cell death induced by the 
complex 1 inhibitor rotenone, suggesting that MAO has an important role in regulating 
mitochondrial function. Rotenone-induced apoptosis was associated with reduced ATP 
levels, apoptotic morphologies and reduced cell metabolism, indicative of mitochondrial 
dysfunction, involving increased MAO activity and elevated ROS levels. ROS production 
is more relevant than ATP depletion to apoptosis induced by electron transport inhibitors 
(Watabe and Nakaki 2006), which may explain why MAO has a more significant role here. 
Rotenone also induced increased MAO activity levels in wild type cells.  
7.1.4 Rotenone and mitochondrial regulation 
Previously Cohen and others have described the mechanisms by which H2O2 produced by 
MAO can have a direct effect on inner mitochondrial invents by modifying IMM proteins 
such as those of the ETC. MAO-generated ROS is also known to damage mtDNA 
(Hauptmann et al. 1996) and reduce electron transport flux (Kumar et al. 2003). The OMM 
location of MAO is extremely important and MAO is often described in the literature as 
being a major source of mitochondrial ROS. As noted earlier increased H2O2 at the 
mitochondria is particularly toxic, since mitochondria harbour pools of copper and iron 
which can catalyse the Fenton reaction to produce the extremely damaging hydroxyl 
radical (Cadenas and Davies 2000). Even reversible damage to complex I can cause 
increased production of the equally damaging superoxide radical (Taylor et al. 2003). 
Decreases in respiratory chain complex activities and elevated iron concentrations have 
been implicated in neurodegenerative disorders such as PD (Davey et al. 1998, Anderson 
2004). Mitochondrial damage mediated by MAO in rat brain caused deletions in mtDNA 
coding for ETC proteins, increased lipid peroxides and increased protein carbonyls which 
are suggestive of protein damage (Alves et al. 2007).  
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Since redox balance in the cell is tightly controlled it seems likely that MAO is also under 
the control of a set of signalling pathways. This is particularly true for other mitochondrial 
proteins that have recently been shown to be involved in protective signalling events that 
regulate mitochondrial function (Abou-Sleiman et al. 2006, Jiang et al. 2006). MAO 
expression has been shown to be under the control of a number of transcription factors and 
repressors that are inducible by diverse cellular signalling pathways, suggesting that MAO 
can be tightly controlled. Rotenone has been previously shown to mediate apoptosis via the 
activation of p38 and JNK MAPK in dopaminergic cells (Newhouse et al. 2004) and may 
be responsible for up-regulation of MAO-A activity following rotenone treatment in wild 
type cells.  
 
Figure 7. 1 Overview of role of MAO in mitochondrial dysfunction 
During STS-induced apoptosis (1) MAO activity, protein and MAO-generated ROS are involved in 
enhancing apoptosis. The mechanism involves ROS activated MAPK signalling that is likely to target 
nuclear transcription of pro-apoptotic proteins. However, the activation of MAO is not a result of increased 
gene expression but may result from post-transcriptional events and/ or increased free calcium released from 
mitochondrial stores (loss of Bcl-2 levels indicated PTP opening). Serum withdrawal induced apoptosis (2) 
induces increased expression of MAO-A via MAPK signalling pathways which results in increased ROS and 
is contributes to the ensuing apoptotic events. Rotenone (3) inhibits complex 1 and therefore caused 
increased oxidative stress, ATP depletion, increased MAO activity and apoptosis. Increased MAO activity by 
genetic manipulation (4) causes massive elevation of mitochondrial ROS, ATP depletion and loss of cell 
death via apoptosis or as a result of caspase-3 inactivation and growth arrest and eventually necrosis. MAO-
potentiated cell death is likely to involve reduced electron transport, PTP opening.  
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7.2. WIDER SIGNIFICANCE IN RELATION TO THE DEVELOPMENT 
AND TREATMENT OF PD 
Increased MAO activity results in increased oxidative stress and both increased MAO 
activity and oxidative stress are linked to neurodegenerative diseases. In ageing and in PD, 
antioxidant defences are lowered (Riederer and Youdim 1986, Anderson 2004). PD 
therapies such as L-DOPA slow dopamine catabolism and therefore cause increased DA 
turnover in neuronal cells. The resulting increase in MAO activity may generate more ROS 
that have significant effects on an already overwhelmed system and may even contribute 
towards the rapid progression of the disease in the later stages. Preliminary studies in this 
work have shown that in GSH depleted cells, levodopa/carbidopa (Sinemet) induces 
apoptosis in a dose dependent manner (see appendix). Often L-DOPA is given in 
conjunction with MAO-B inhibitors such as deprenyl and carbidopa which inhibits COMT, 
but intervention with MAO inhibitors is often late stage. These data suggest that earlier 
intervention with MAO inhibitors may be useful. Indeed, the therapeutic effects of MAO 
inhibitors in AD have been mainly attributed to their antioxidant properties and may be 
useful in other dementias. Youdim et al (Maruyama et al. 2002, Youdim et al. 2003) have 
proposed that propargylamine inhibitors are neuroprotective because they signal up-
regulation of Bcl-2 at the gene level involving the action of GAPDH translocation. Studies 
here were in disagreement with this proposal and suggest that the relationship of MAO 
with Bcl-2 maybe more complicated. Nevertheless, MAO inhibitors such as CGP3466 now 
in phase III trials for PD are thought to protect neurons by a mechanism that is not due to 
slowing of DA catabolism entirely. This has wider implications for the use of antioxidants 
as a preventative measure against ND but also as an alternative therapy. Indeed, in this 
work NAC prevented ROS production and protected against cell death to a similar extent 
to clorgyline and numerous publications have shown that antioxidants such as vitamin E 
and those found in green tea are neuroprotective (reviewed by Dunnett and Bjorklund 
1999).  
The JNK inhibitor Cep used in this study is now in phase II clinical trails for PD (Maroney 
et al. 2002). Data in this thesis has shown for the first time that JNK is important in 
regulating MAO-A expression during apoptosis and adds support for the use of JNK 
inhibitors for neuroprotection. Finally, the role of MAO as an enhancer of neuronal cell 
death raises questions about predisposition to ND with respect to both genetic and 
environmental factors. MAO activity levels in humans could potentially influence 
susceptibility to neurodegenerative diseases. Indeed, MAO levels are generally thought to 
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be elevated during ageing and smokers, who have reduced MAO activity are known to be 
less likely to develop PD (Castagnoli and Murugesan 2003). In addition, exposure to 
environmental pesticides that inhibit complex I have been linked with PD (Betarbet et al. 
2000). Elevated MAO in these cases may give rise to additional problems.  
Understanding of the mechanism by which neuronal cells die is also relevant in terms of 
our general understanding of ageing and disease. Changes in lifestyle and/ or preventative 
actions could reduce the need for late stage treatment and prolong quality of life. 
7.3. FUTURE DIRECTIONS 
A non-exhaustive list of possibilities for future directions is shown below. 
7.3.1 Expanding insights into relevance of MAO-A overexpression and 
knockdown 
Recombinant overexpression of MAO in SH-SY5Y cells caused cell death and culture of 
stable clones resulted in some experimental complications. In order to investigate the role 
of subtle elevation in MAO-A expression in a working model (I. e following challenge 
with apoptotic inducers), the creation of a stable cell line where elevation of MAO-A is 
inducible would be particularly valuable. A dox-inducible system may be considered for 
this purpose. The use of reversible MAO inhibitors such as TCP may also be useful for the 
culture of SH-SY5Y cells overexpressing MAO-A. An investigation into possible 
oxidative damage to ETC and other relevant proteins in MAO-A+ cells may also be of 
interest. 
MAO-A- stable clones have proven extremely useful and expansion of this work is 
important. Mechanistic studies would be useful to elucidate signalling pathways involved 
in these cells following treatment. A study of changes in MAO-A mRNA, protein and 
activity levels following apoptotic induction in MAO-A- cells would indicate whether 
miRNA mechanism are able to cope with changing gene expression during different 
models of apoptosis and may explain some of differences between the apoptotic models in 
terms of protection in these cells.  
7.3.2 The role of MAO-A in rotenone-induced cell death 
The complete mechanistic studies to determine a wider knowledge of the role of MAO-A 
in rotenone-induced cell death in wild type SH-SY5Y cells is needed. Increased catalytic 
activity in this model may be a result of increased gene expression and /or protein levels or 
none of these.This knowledge would be invaluable considering the significant role of 
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MAO in mediating rotenone-induced mitochondrial dysfunction. Determining the levels of 
ROS in the presence and absence of MAO inhibitors could indicate how important MAO-
produced ROS is in this model. Co-localisation studies involving ROS detection and 
mitochondrial markers would indicate sites of ROS production. On the same theme, 
mitochondrial function measures such as the selective mitochondrial stain JC-1, which 
changes colours depending on mitochondrial activity could give some interesting real time 
confocal footage in live cells in the presence and absence of signalling inhibitors.  
7.3.3 The relationship between MAO and other mitochondrial proteins 
To date the physical relationship between MAO and other mitochondrial proteins such as 
Bcl-2 at the mitochondrial surface have not been investigated. Overexpression of MAO-A 
resulted in decreased Bcl-2 levels. Whether or not this is due to apoptotic events or 
whether this is a result of OMM imbalance is not known but an interesting area for future 
research. It is possible that Bcl-2 family members or other OMM proteins interact with 
MAO to activate or suppress its activity and therefore regulate apoptosis. For example 
BH3-only proteins induce oligomerisation of certain Bcl-2 family protein via an unknown 
mechanism to regulate apoptosis (see chapter 1). It seems likely that as a membrane bound 
mitochondrial protein that MAO could also be involved here. 
It is also possible that the activities of complex 1 and electron transport have a functional 
relationship with MAO (see Cohen et al. 1997), where MAO responds to ETC 
functionality and the ETC responds to MAO activity accordingly. A starting point for 
protein interaction work could involve co-immunoprecipitation; pull down assays and 
other functional studies aided by genetic manipulation. Co-immunoprecipitation work 
should be approached with care since avoiding artefacts from the isolation and 
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Figure A1. 1 The concentration of moclobemide required to inhibit MAO in situ is toxic to SH-SY5Y 
cells 
(A) MTT reduction was measured in SH-SY5Y cells over 24 hours, following the addition of 1 nM, 10 nM, 
100 nM, 1 µM, 10 µM and 100 µM moclobemide. MTT reduction was determined and expressed as mean 
MTT reduction % untreated control. (B) MAO activity was measured in SH-SY5Y extracts in vitro following 
the addition of 1 nM, 10 nM, 100 nM, 1 µM, 10 µM and 100 µM moclobemide via a radiometric method, 
using 14C-Tyramine as a substrate. MAO catalytic activity was expressed as mean counts per minute (Cpm) ± 
S.D. Data represent triplicate values from three independent experiments (n=3). Untreated controls were 
statistically compared to treated cells at each concentration using the Student’s t-test where * = p<0.05. (C) 
MAO activity was measured in SH-SY5Y cells in situ following the addition of 1 mM moclobemide after 3 
h, via a radiometric method, using 14C-Tyramine as a substrate. MAO catalytic activity was expressed as 
mean counts per minute (Cpm) ± S.D.  




Figure A1. 2 Effect of clorgyline on proteasome activity during STS-induced apoptosis  
Proteasome activity (CLA) was measured in SH-SY5Y cells over 72 h, following the addition of 1 µM STS 
or 1 µM STS + 1 µM clorgyline. Proteasome activity was determined and expressed as mean proteasome 
activity (% untreated control) ± S.D. Data represent triplicate values from three independent experiments 
(n=3). Untreated controls were statistically compared to treated cells at each concentration using the 
Student’s t-test where *** = p<0.001. 
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Figure A1. 3 Effect of Sinemet and BSO on MAO catalytic activity 
MAO activity was measured in SH-SY5Y cells following the addition of 50 µM, 100 µM, 200 µM Sinemet 
preparation either in the presence or absence of 2 mM BSO and measured via a radiometric method, using 
14C-Tyramine as a substrate. MAO catalytic activity was expressed as mean counts per minute (Cpm) ± S.D. 
Data represent triplicate values from three independent experiments (n=3). Untreated controls were 
statistically compared to treated cells at each concentration using the Student’s t-test where ** = p<0.01 and 
***= p<0.001. 




Figure A1. 4 Determination of a working concentration of G418 sulphate (geneticin) and blasticidin for 
use in SH-SY5Y cells 
(A) The effect of 50, 100, 200, 400, 600 and 800 µg/ml G418 sulphate (geneticin) on SH-SY5Y cell 
morphology after 4 days treatment.  (B) The effect of 1, 2, 4, 6, 8, 10 and 20 mg/ml blasticidin on SH-SY5Y 
cell morphology after 4 days treatment Cells were visualised using a Nikon eclipse TS100 microscope. 
 
